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ABSTRACT 
Dendritic cells (DCs) are potent innate antigen presenting cells which are able to 
sense and engulf pathogens from sites of infection, which are then processed and 
presented to adaptive T lymphocytes in secondary lymphoid organs. Therefore, 
they are critical for the initiation and modulation of primary antigen-specific 
adaptive immune responses. They also play a critical role in the maintenance of T 
cell tolerance. T cells play vital roles in mediating both cellular and humoral-specific 
adaptive immune responses. There are various types of T cells present within the 
immune system including the cytotoxic CD8 T cells and T helper CD4 cells. CD4 T 
cells can be further subdivided into various subtypes examples of which include T 
helper 1 cells (Th1), Th2, Th17 and T regulatory cells. Each subset has its own 
distinctive function, transcriptional regulation and effector cytokine profile.  
It is established that appropriate DC and T cell immune function is highly dependent 
on their intracellular redox status. Cellular redox homeostasis is maintained 
through a balance between oxidising agents e.g. reactive oxygen species (ROS) and 
anti-oxidant or reducing agents e.g. glutathione (GSH). Excessive ROS production 
resulting in oxidative stress is extremely deleterious to the cell and if left 
unimpeded can result in cell necrosis, tissue damage and the onset of disease. As a 
result, mammalian cells have evolved an inducible adaptive defence system which 
provides protection against such oxidative or chemical insult. The functionality of 
this cellular defence system is principally governed by the activity of the redox-
sensitive transcription factor Nrf2. In response to oxidative stress, Nrf2 induces the 
transcription of a battery of cytoprotective and antioxidant genes involved in GSH 
synthesis, detoxification of xenobiotics and their reactive metabolites and the 
maintenance of cellular redox homeostasis. It is now emerging that Nrf2 plays a 
pivotal role in immunity. However, its precise role in DC and T cell function is 
unclear.  
Using immature bone marrow-derived DCs (iDCs) from Nrf2+/+ and Nrf2-/- mice, the 
work presented in this thesis demonstrates that Nrf2 deficiency in iDCs resulted in 
lowered GSH levels, enhanced iDCs co-stimulatory receptor expression, impaired 
endocytic and phagocytic capacity, and increased iDC-mediated antigen-specific 
CD8 T cell stimulatory capacity in response to both an antigenic and self-peptide. 
Furthermore, artificially lowering GSH levels in the iDCs did not recapitulate the 
Nrf2 deficient iDC phenotype. Moreover, Nrf2-/- DCs exhibited an enhanced capacity 
to present cell-associated peptide antigens to antigen-specific CD8 T cells, resulting 
in increased CD8 T cell effector function. Loss of Nrf2 in LPS-stimulated DCs results 
in a lowered Th1 cytokine profile. These results have implications for Nrf2 in DC-
mediated CD8 T-cell immunity, peripheral CD8 T cell tolerance and CD4 effector 
differentiation. 
The role of Nrf2 in T cell function is poorly understood. Using thymocytes, 
splenocytes and lymph-node derived T cells from Nrf2+/+ and Nrf2-/- mice, we 
demonstrate that loss of Nrf2 did not affect the development of CD4+CD25+ natural 
occurring Treg, mature CD4 and CD8 T cell populations within the thymus. 
ii 
 
Furthermore, Nrf2 deficiency did not alter the composition of CD4 and CD8 T cell 
populations within secondary lymphoid organs. It was observed that splenic Nrf2-/- 
naïve T cells exhibited enhanced ROS generation, accompanied by low level 
increases in T cell activation markers. However, the marginal augmentation of Nrf2-
/- naïve T cell activation status did not result in increased T cell receptor (TCR)-
triggered T cell proliferation. In contrast, Nrf2 deficient effector T cells exhibited 
enhanced TCR/CD3-triggered proliferation, associated with increased Th1 and 
decreased Th2 effector function. Importantly, we demonstrated that Nrf2-/- effector 
T cells secreted increased levels of IL-17A and IL-22, a signature cytokine profile 
indicative of the more recently identified Th17 cell lineage. This was also observed 
under Th17 polarising conditions, further suggesting that loss of Nrf2 predisposes 
effector Th17 development. The implications of the latter findings are significant 
given the pivotal role that Th17 cells play in the pathogenesis of a variety of 
autoimmune diseases including multiple sclerosis (MS) and Systemic lupus 
erythematosus (SLE).  
Nrf2 plays a critical role in the detoxification of xenobiotics in the liver, which as the 
primary drug-metabolising organ, is subjected to an array of xenobiotics and their 
respective metabolites. Individuals vary in their responses to xenobiotic exposure 
from adaptation to severe adverse drug reactions. However, it is unknown whether 
this human disparity in drug response is a consequence of inter-individual variation 
in the Nrf2 adaptive defence system to xenobiotic stress. In light of this, we aimed 
to firstly investigate whether variation in the Nrf2 adaptive system was present 
within individuals in response to a chemical inducer of Nrf2, CDDO-Me. To address 
this issue, basal and induced Nrf2 protein levels and downstream NQO1 expression 
were measured in activated human T cell blasts, in response to increasing 
concentrations of CDDO-Me. Examination of various donor-derived T cells, 
demonstrated that humans vary in their Nrf2 response to CDDO-Me, with respect 
to nuclear Nrf2 and NQO1 mRNA expression. Therefore we concluded that inter-
individual variation does exist in the human’s Nrf2 adaptive system in response to a 
known Nrf2 probe.  
Overall, the experimental results obtained in this PhD programme have provided 
detail on the role of Nrf2 in immune cells and highlights the potential for 
therapeutically targeting Nrf2 in immune-mediated disease. 
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1.0 INTRODUCTION 
1.1 The Immune System 
Multi-cellular animals are continuously threatened by a diverse range of pathogenic 
and innocuous bacteria, fungi, viruses and parasites. The immune system is geared 
towards recognising the potential pathogens to which it is exposed to and thus 
defend the host against infection. Furthermore, this system must be able to 
discriminate between the animal’s own cellular components (i.e. self) and that of 
an invading pathogen (i.e. non-self). Failure to do so gives rise to detrimental 
inappropriate immune responses which underpin the pathogenesis of autoimmune 
diseases such as diabetes and Multiple Sclerosis (MS).  
The immune system is typically divided into two parts, the innate and the adaptive. 
Each division of the immune system is made up of both cellular and humoral 
components. Although the innate and adaptive arms functionally complement one 
another, they differ significantly in their capacity to recognise and subsequently 
eradiate infectious pathogens. The following introduction gives an overview of the 
innate and adaptive immune system with a focus on dendritic cells and T 
lymphocytes. 
1.2 Innate immunity 
The innate immune system is comprised of physical cellular barriers (e.g. skin and 
mucosal epithelia), humoral components (e.g. complement system and anti-
microbial peptides), and innate immune cells that provide the initial, non-specific 
defence against invading pathogens. In general, innate immune cells including 
monocytes, macrophages, neutrophils, basophils, eosinophils, mast cells and 
conventional dendritic cells (cDCs) arise from common myeloid progenitors (CMPs) 
in the bone marrow. Other innate immune cells namely natural killer (NK) cells and 
particular subtypes of dendritic cells arise from bone marrow-derived common 
lymphoid progenitors (CLPs) (Beutler, 2004). The physiological and 
pathophysiological functions of the various types of innate immune cells are 
outlined in Table 1.1.  
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Cell type Function and features Pathophysiology Reference 
Basophil  Morphologically similar to 
mast cells 
 Activation via cross-linage of 
FcεRI with IgE resulting in 
degranulation  
 Provide anti-parasitic 
immunity: 
- Release granules 
containing histamine and 
proteases 
- Produce IL-4, IL-13 
Helminth 
infection, 
asthma, allergic 
rhinitis, atopic 
dermatitis 
(Stone et 
al., 2010) 
 
 
Dendritic  
cell (DC) 
 Most Potent APC 
 Initiate and modulate 
adaptive immune responses 
 Involved in anti-viral, anti-
parasitic, anti-bacterial, anti-
fungal and anti-tumour 
immunity 
 Maintenance of T cell 
tolerance 
SLE, systemic 
sclerosis, RA, 
asthma, 
psoriasis, atopic 
dermatitis, 
hypersensitivity 
reactions, 
measles, cancer, 
type 1 diabetes 
(Ueno et 
al., 2007; 
York, 
2011; 
Dorner, 
2012) 
Eosinophil  Activated by cross-linage of 
FcγRII with IgG resulting in 
degranulation 
  Provide anti-parasitic 
immunity: 
- Release cytolytic granule 
proteins  
- Produce IL-4, IL-5, IL-10, 
TNFα  
Helminth 
infection, allergic 
rhinitis, asthma, 
hyper-IgE 
syndrome, atopic 
dermatitis 
(Stone et 
al., 2010) 
Macrophage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Activated by PAMPs via TLR 
and opsonised bacteria  via 
FcR  
 Professional phagocyte and 
APC capacity 
 Involved in cellular 
homeostasis via ingestion of 
apoptotic cells 
 Involved in anti-bacterial 
immunity: 
- Engulfment of microbes 
and lysis via NOX-
respiratory burst 
mechanisms. 
- Produce IL-1β, TNFα, IL-
12, IL-6, IL-8 
Gaucher disease,  
Atherosclerosis, 
systemic 
sclerosis, SLE, 
sepsis 
(Morel et 
al., 1991; 
Naito, 
2008; 
York, 
2011; 
Dorner, 
2012) 
(Tzima et 
al., 2009) 
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Macrophage 
(continued) 
 Involved in anti-viral 
immunity: 
- Secrete IFNβ preventing 
intracellular viral 
replication 
Mast cell  Activated by cross-linage 
FcεRI with IgE resulting in 
degranulation 
  Involved in anti-parasitic 
immunity 
- Release granules 
containing histamine and 
proteases  
- Produce TNFα, IL-5, IL-3 
Helminth 
infection, 
anaphylaxis, 
allergic rhinitis, 
asthma, 
mastocytosis, 
systemic 
sclerosis, atopic 
dermatitis 
(Stone et 
al., 2010; 
York, 
2011) 
Monocyte  Precursor reserve pool for 
macrophages and DCs 
(under inflammatory 
conditions) 
 Professional phagocyte but  
low APC capacity as bona 
fide monocyte 
 Involved in cellular 
homeostasis via ingestion of 
apoptotic cells 
 Involved in anti-bacterial 
immunity: 
-  engulfment of microbes 
and killing via iNOS 
activity and ROS 
production 
- Produce TNFα, IL-1β, IL-
6, IL-10 
RA, 
Atherosclerosis, 
systemic 
sclerosis, Crohn’s 
disease, HIV, 
sepsis, asthma 
(Auffray 
et al., 
2009; 
York, 
2011) 
 
 
 
Natural 
Killer cell 
(NK)  
 
 
 
 
 
 
 
 
 
 
 
 Provide anti-tumour and 
anti-viral immunity:  
Target and lyse abnormal/ 
viral infected cells which 
have low/absent expression 
of self-MHCI cell surface 
molecules 
 Provide anti-bacterial 
immunity: 
Recognise and lyse antibody 
coated targets via FCR 
activation.  
 Lysis via release of cytolytic 
granules containing perforin 
and granzyme B 
systemic 
sclerosis, MS, RA, 
type 1 diabetes, 
cancer, 
leukaemia 
(Liang and 
Graham, 
2008; Wu 
and Van 
Kaer, 
2009; 
York, 
2011) 
 
5 
 
Neutrophil  Activated by PAMPs via TLR 
via and opsonised bacteria  
via FcR  
 Professional phagocyte and 
APC capacity 
 Involved in cellular 
homeostasis via ingestion of 
apoptotic cells 
 Involved in anti-bacterial 
immunity: 
- Engulfment of microbes 
and lysis via NOX 
respiratory burst 
mechanisms. 
- Produce IL-1β, TNFα, IL-
12, IL-6, IL-8 
CGD disease, 
myelokathexis 
syndrome 
(WHIM), SLE, 
sepsis 
 (Dale et 
al., 2008; 
Dorner, 
2012) 
 
 
 
Innate immune cells migrate via the blood stream and distribute throughout the 
body which helps in the rapid identification and efficient removal of potential 
infectious pathogens. These cells are activated upon recognition of conserved 
molecular components, known as pathogen-associated molecular patterns (PAMPs) 
(e.g. lipopolysaccharide (LPS) found in the bacterial cell wall of gram negative 
bacteria), via the expression of pathogen recognition receptors (PRRs) including 
Toll-like receptors (TLRs) (Beutler, 2004). These receptors are germline-encoded 
and recognise a limited number of molecules that are shared by numerous 
infectious agents. Engagement of PPRs result in a variety of immediate effector 
responses that endeavour to directly disable the harmful pathogen usually within 
the first 12 hours of infection (Murphy et al., 2012). A prime example is the 
activation of dectin-1, a member of the C-type lectin receptor (CLR) superfamily, 
Table 1.1 Innate immune cells and their roles in health and disease.  
APC: antigen presenting cell; CGD: Chronic granulomatous disease; FcR: Fc receptor which 
binds to Fc portion present in tail region of secreted immunoglobulin; HIV: Human 
immunodeficiency virus; IFNβ: interferon-β; Ig: Immunoglobulin or antibody secreted by 
activated B-cells IL-: interleukin; iNOS: inducible nitric oxide synthase; MHC: major 
histocompatibility complex; MS: Multiple sclerosis; NOX: nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase; PAMPs: pathogen-associated molecular patterns; RA: 
Rheumatoid arthritis; ROS: reactive oxygen species; SLE: Systemic lupus erythematosus; 
TLR: Toll-like receptor; TNFα: Tumor necrosis factor-α  
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that is present on phagocytic myeloid cells including neutrophils and macrophages 
(Geijtenbeek and Gringhuis, 2009). Dectin-1 binds to β-glucans present in fungal cell 
walls, certain bacteria and plants, resulting in the phagocytosis and proteolytic 
destruction of the pathogen (Lee and Kim, 2007). Activation of dectin-1 also triggers 
the release of proinflammatory cytokines e.g. IL-1β and chemokines e.g. CXCL8, 
which not only promote inflammation, but also instigate the recruitment of 
neutrophils and macrophages at the site of infection. This results in the 
amplification of the inflammatory response and effective removal of the pathogen 
(Murphy et al., 2012). Neutrophils, macrophages and in particular dendritic cells 
(DCs) are termed antigen presenting cells (APCs), which possess a unique ability to 
sense and engulf pathogens from sites of infection that are then processed and 
presented to adaptive immune cells in secondary lymphoid organs (Table 1.1). 
Proinflammatory cytokine release from innate immune cells, play a crucial role in 
priming APCs for efficient antigen presentation, APC-mediated adaptive immune 
cell activation and subsequent differentiation. This highlights the pivotal role of the 
innate immune system in complementing and modulating adaptive immune 
responses (Maldonado-Lopez et al., 1999; Tse et al., 2007; Abi Abdallah et al., 
2011).  
The innate immune system is not without its limitations. The PPRs are restricted to 
recognising only common microbial structural features and thus are limited in 
perceiving a narrow range of potential pathogenic insults. Furthermore, these 
receptors cannot provide antigen-specific protection to invading pathogens and 
thus fail to prevent re-infection (Beutler, 2004). In contrast to the innate arm of the 
immune system, the adaptive immune system specifically recognises and provides 
protective immunity against a diverse array of invading pathogens, but more 
importantly, it provides long lasting protection against re-infection due to its unique 
feature, immunological memory. Although adaptive immune responses are long 
lasting, they are delayed in their initiation. Therefore, the adaptive arm must work 
in concert with the rapid responses of the innate immune system to ensure both 
the immediate and long term protection against pathogenic invasion.  
1.3 Adaptive Immunity 
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The adaptive immune system is organized around B and T lymphocytes, which have 
the ability to recognise a myriad of invading pathogens and can mount a specific 
immune response. The great diversity in antigen specificity among lymphocytes is 
determined by the structure of the B and T cell receptors’ (BCR and TCR) antigen-
binding site, whose structural segments are a result of somatic recombination of 
antigen receptor genes, together with palindromic and random nucleotide addition 
during development. Naïve T cells and B cells reside in secondary lymphoid tissues 
such as the spleen, lymph nodes and Peyer’s patches, where they await contact 
with circulating DCs. The DCs migrate to lymphoid tissues and present captured 
antigens from the periphery to these adaptive immune cells. The recognition of 
antigens by the TCR/BCR leads to T/B cell clonal expansion and affinity maturation. 
Clonal expansion gives rise to a large pool of antigen-specific T or B cells, some of 
which remain dormant in the body after the infection has been resolved. This gives 
rise to immunological memory which permits a rapid response upon second 
exposure to the same antigen (Parkin and Cohen, 2001). 
B cells are critical mediators of humoral immunity owing to their distinctive capacity 
to produce antigen-specific antibodies (also known as immunoglobulins (Ig)). During 
B cell development in the bone marrow, a competent rearranged BCR is formed 
which is composed of an antigen-specific transmembrane Ig (Pieper et al., 2013). B 
cells migrate to follicular regions of peripheral lymphoid organs where they await 
recognition of their respective antigen. Generally, B cells require T cell help for 
competent B cell activation and differentiation. Once the B cell has become fully 
activated, it undergoes processes of somatic hypermutation and affinity 
maturation, resulting in the clonal expansion of high affinity antigen-specific, 
antibody-secreting plasma cells and memory cells (LeBien and Tedder, 2008). In 
parallel, cytokines secreted from the T helper cells induce Ig isotype switching from 
IgM, IgD to secondary isotypes IgA, IgE and IgG (Parkin and Cohen, 2001). 
Secondary isotype secretion results in a variety of humoral-mediated adaptive 
immune responses including the enhancement of innate immune cell responses 
and ultimate clearance of infection. However, inappropriate production of these 
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antibodies can underlie pathological processes, as is the case for IgE and allergic 
disease (Table 1.1).  
T cells play vital roles in mediating both cellular and humoral-specific adaptive 
immune responses. There are various types of T cells present within the body as 
discussed later in this chapter, each with distinctive functions that provide 
protective anti-viral, anti-tumour, anti-parasitic, anti-bacterial and anti-fungal 
immunity. However, T cell dysregulation is an underlying cause of a variety of 
autoimmune and allergic disorders. In order to fully understand the function of the 
T cell, it is imperative to gain an insight into their development and importantly 
their activation by the potent innate APC, the DC. 
1.4 T cell development 
T Lymphocytes possess a diverse TCR repertoire enabling recognition of a diverse 
range of antigens with high specificity. How they achieve this crucial function for 
targeting a variety of pathogens, lies within the events associated with their 
development and differentiation into mature T cells in the thymus as illustrated in 
Figure 1.1. Initially, T lymphocytes arise from Common lymphoid progenitors (CLPs) 
in the bone marrow which migrate to the thymus via the blood stream. Within the 
thymus, CLPs receive direct instructions to differentiate into early commited T cells 
termed double negative (DN) which lack expression of co-receptors CD4 and CD8 
(CD4-CD8). As DN cells travel through the thymic cortex and the cortical sub-
capsular zone (SCZ), they undergo four stages of differentiation as distinguished by 
their expression of CD44 and CD25; CD44+CD25− (DN1), CD44+CD25+ (DN2), 
CD44−CD25+ (DN3) and CD44−CD25− (DN4) (Figure 1.1)(Carpenter and Bosselut, 
2010). Interactions with thymic stromal cells facilitate the progession of the 
immature thymocytes through stages DN1- DN3 (Maillard et al., 2005). At the DN3 
stage, T cells undergo T cell receptor β (TCRβ) chain somatic gene rearrangement 
also known as β-selection. The recombined TCRβ chain couples with an invariant 
pre-TCRα chain resulting in the assembly of the pre-TCR. Competent signal 
transduction through the pre-TCR facilitates progression from DN3-DN4 (Carpenter 
and Bosselut, 2010). Robust cell proliferation occurs during DN4 maturation, 
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followed by TCRα chain somatic rearrangement, resulting in the formation of a 
functional heterodimeric TCRαβ. These cells begin to co-express CD4 and CD8, 
ultimately giving rise to the CD4+CD8+ double positive (DP) thymocyte population 
(Figure 1.1)(Germain, 2002). The survival of these DP cells and subsequent 
maturation into single positive CD8 and CD4 T cells, is dependent upon their 
interaction with self-peptides displayed by residual cortical epithelial cells in the 
context of MHCI and MHCII molecules, respectively (Germain, 2002). Double 
positive T cells containing TCRs that interact poorly with self-peptide:MHC 
complexes, do not receive survival signals and are thus deleted from the T cell 
repertoire via programmed cell death mechanisms. Double positive T cells that do 
recognise self-peptides:MHC complexes presented by epithelial cells are positively 
selected (Germain, 2002). As a consequence of positive selection, DP T cells lose co-
expression of CD4 or CD8 and subsequently migrate to the thymic medulla where 
they reside as single positive (SP) CD8 and CD4 T cells, respectively (Figure 
1.1)(Germain, 2002). Following positive selection, SP T cells which recognise self-
peptide:MHC complexes presented by medullary epithelial cells or thymic DCs too 
avidly and thus have the potential to initiate peripheral autoimmune responses, 
receive strong cell death signals resulting in their deletion. This process is known as 
negative selection which underlies T cell central tolerance (Germain, 2002). Mature 
non-autoreactive SP CD4 and CD8 T cells are then free to migrate to peripheral 
secondary lymphoid organs such as the spleen and lymph nodes, where they await 
activation from APCs. Natural occurring immunosuppressive CD4+CD25+Foxp3+ T 
regulatory cells (nTregs) also develop within the thymus but the precise signals 
involved in their development remain elusive (Sakaguchi, 2004). They have been 
shown to be derived from SP CD4 T cells in the thymic medulla (Figure 1.1) 
(Sakaguchi, 2004). T regulatory cells play an imperative role in maintaining T cell 
homeostasis and in the prevention of autoimmune responses as discussed in 
section 1.11.4. 
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Figure 1.1 Schematic diagram of T cell development within the thymus 
Immature thymocytes undergo consecutive phases of differentiation and endure stringent 
positive and negative selection processes as they travel through the thymus. This results in 
the selection of mature non-self reactive CD4 and CD8 T cells which subsequently egress 
from the thymus and migrate to peripheral lymphoid organs. BM: bone marrow; CLPs: 
common lymphoid progenitors; DN: double negative; DP: double positive; MHC: major 
histocompatibility complex; SCZ: sub-capsular zone; SP: single positive; TCR: T cell 
receptor. 
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Table 1.2. Contrasting roles and features of immature and mature DCs. 
CCR: chemokine (C-C motif) receptor; CD: cell surface molecule; IL-8: interleukin-8; MHCII: 
major histocompatibility complex II; MIP-3β: Macrophage inflammatory protein-3β also 
known as chemokine (C-C motif) ligand 19 (CCL19); SDF-1: stromal cell-derived factor-1 
Adapted from (Banchereau et al., 2000) 
 
1.5 Dendritic cells 
Dendritic cells are specialised APCs present in the blood, skin, peripheral organs e.g. 
gut, lung and liver, and lymphoid organs e.g. the spleen and thymus. They are 
responsible for the initiation and modulation of primary adaptive immune 
responses (Banchereau et al., 2000). They exist in two functional states; immature 
steady state DCs (iDCs) and mature DCs (mDCs) as determined by their morphology, 
phenotypic expression of cell surface proteins which promote T cell activation 
(known as co-stimulatory molecules), chemokine expression and their immune 
function as shown in Table 1.2 (Banchereau et al., 2000).  
 
Feature Immature DC (iDC) Mature DC (mDC) 
Morphology Spherical shape Large cytoplasmic 
protrusions (dendrites) 
Residence Periphery Secondary lymphoid 
organs 
Function - Antigen capture 
- High phagocytosis 
- Poorly immunogenic 
- Maintenance of CD8 T 
cell tolerance 
- Antigen presentation 
- Low phagocytosis 
- Highly immunogenic 
- Modulation of 
adaptive immune 
responses 
Chemokine expression - High CCR1, CCR5, SDF-
1, IL-8 
- Low CCR7, MIP-3β 
- Low CCR1, CCR5, SDF-
1, IL-8 
- High CCR7, MIP-3β 
Co-stimulatory receptor 
expression  
- Low CD80, CD86, 
CD40, CD83 
- High intracellular 
MHCII 
- High CD80, CD86, 
CD40, CD83 
- High cell surface 
MHCII 
 
 
Dendritic cells arise from haematopoietic stem cells (HSCs) in the bone marrow. The 
development pathways for DCs are complex as they are derived from both CLP and 
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CMP lineages (Kushwah and Hu, 2011). The resultant heterogenic DC population is 
classified into a variety of subtypes in the mouse and human, each with their own 
specific set of cell surface molecules, anatomical location and functional response 
in the body (Villadangos and Schnorrer, 2007). In spite of their diversity, they 
collectively share a common function in the processing and presentation of 
antigens to the adaptive immune system, thus provding a bridge between the 
innate and adaptive immune system.  Dendritic cells can be broadly classified into 
two major subtypes; plasmacytoid DCs (pDCs) and conventional DCs (cDCs) (Barchet 
et al., 2005; Villadangos and Schnorrer, 2007). Plasmacytoid DCs are distinctive 
from the cDC subtype due to their low phagocytic capacity, unique cytokine profile 
and low expression of cell surface CD11c and MHCII. Plasmacytoid DCs are present 
throughout the periphery, blood and lymphoid organs and specialise in the 
recognition and presentation of viral-derived antigens. Moreover, they secrete 
large amounts of type I interferons (IFNs), IFNα and IFNβ, upon activation, thus play 
an imparetive role in instructing adaptive anti-viral immune responses (as reviewed 
in (Reizis et al., 2011)). In contrast, cDCs encompasses all other types of DCs present 
in lymphoid and non-lymphoid tissues that express high levels of CD11c and MHCII. 
In contrast to pDCs, cDCs are more efficient at capturing, processing and presenting 
antigens to naive T cells and directing the nature of the adaptive immune response 
elicited (Merad et al., 2013). Murine cDCs can be further subdivided into lymphoid 
organ-resident DCs found in the spleen, thymus and lymph nodes, migratory DCs 
subsets e.g. langerhans cells present in the skin and interstitial DCs which are in 
peripheral organs including the gut (Kushwah and Hu, 2011). The precise phenotype 
for each cDC subset is reviewed elsewhere (Merad et al., 2013). Migratory DCs are 
named such due to unique ability at acquiring antigens from the periphery and 
migrating via the blood to lymphoid organs (Villadangos and Schnorrer, 2007), The 
bone-marrow derived DCs utilised in this thesis are akin to this non-lymphoid 
migratory CD11c+MHCII+ subset. It is important to note that the function of the 
cDCs differ depending on the location. For example, splenic-resident CD8+ DCs are 
highly efficient at cross presenting cell-associated antigens to CD8 T cells and 
initiating CD8 T cell responses whereas DCs present in the gut play an important 
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role in inducing tolerance and directing CD4 T regulatory cell polarisation 
(Maldonado-Lopez et al., 1999; Belz et al., 2005; Scott et al., 2011).  
1.6 Dendritic cells: drivers of the immune response 
Dendritic cells survey the peripheral environment for potential infectious pathogens 
subsequently directing cells of the adaptive immune system to execute finely tuned 
immune responses, ultimately resulting in the clearance of infection and are thus 
important sentinels of the immune system (Banchereau et al., 2000). In the 
periphery, DCs reside in an antigen-capturing immature state sampling their 
environment for potential pathogenic invasion. The iDC can ingest exogenous 
pathogens, dying and infected cells through engagement of their endocytic and 
phagocytic receptors. Receptors engaged include dectin-1 for β-glucans, FcγR for 
IgG opsonised bacteria) and phosphatidylserine receptor (PS), scavenger receptor 
CD36, and C-type lectin domain family 9A (CLEC9A, also known as DNGR-1) for 
apoptotic and necrotic cells (Dalgaard et al., 2005; Bratton and Henson, 2008; 
Geijtenbeek and Gringhuis, 2009; Sancho et al., 2009; den Dunnen et al., 2012). 
Receptor engagement consequently induces a variety of actin-dependent 
phagocytic processes facilitating the efficient internalisation of the pathogen and 
formation of the phagosome (Underhill and Goodridge, 2012).   
In the absence of infection, host-associated (self) antigens are constitutively 
acquired, processed and presented by iDCs to T cells in lymphoid organs (Wilson et 
al., 2004). Presentation of self-antigens is critical for maintaining T cell tolerance. 
This instructs the deletion of those autoreactive T cells that have escaped normal 
central tolerance mechanisms within the thymus, thus dampening detrimental 
autoimmune responses and the occurrence of autoimmune diseases (Table 1.2) 
(Kurts et al., 1997; Kurts et al., 1998). How the DC signals the presence of antigens 
associated with pathogenic infection i.e. non-self-antigens is driven through 
additional cues provided by the selective engagement of TLRs (Mellman and 
Steinman, 2001; Schulz et al., 2005; Blander and Medzhitov, 2006b; den Dunnen et 
al., 2012). Upon encounter with an infectious pathogen, molecular patterns 
associated with the invading pathogen (PAMPs) are recognised by the TLRs. The TLR 
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family is comprised of 10 members in humans and 12 in mice and can collectively 
recognise common constituents derived from multifarious pathogens including 
bacteria, parasites, viruses and fungi (Kawai and Akira, 2011). Toll-like receptor 
signalling results in the activation of the mitogen-activated protein kinases 
(including p38 MAPK, JNK and ERK1/2) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) signalling pathways which promote the 
nuclear translocation of transcription factors, activator protein 1 (AP-1) and NF-κB, 
respectively (Kawai and Akira, 2011).  As a consequence, these transcription factors 
drive the transcription of a variety of genes involved in DC maturation including 
lymphoid-homing chemokine receptor CCR7, inflammatory cytokines e.g. IL-1β, 
TNFα, IL-12 and IL-6, cell surface expression of MHCII and the upregulation of co-
stimulatory receptors e.g. CD80, CD86 and CD40 (Table 1.2) (Sallusto et al., 1998; 
Ardeshna et al., 2000; Nakahara et al., 2006; Neves et al., 2009). The phenotypic 
and morphological changes associated with DC maturation alter the immune 
function of the dendritic cell from highly phagocytic iDCs efficient at antigen 
capture, to low phagocytic, highly immunogenic mDCs proficient at antigen 
presentation (Table 1.2). Consequently, mDCs efficently migrate to lymphoid 
organs where they present processed antigens to naive T cells in such a context, 
resulting in the initiation of an adaptive immune response. Importantly, these 
events enable DCs to greatly influence the nature of the T cell response elicited by 
guiding naive T cell differentiation into functionally distinct effector subtypes as 
reviewed later in this chapter. 
1.7 Dendritic cell antigen presentation 
In order for a DC to present antigens to naive T cells, they must first process and 
load the antigen onto specialised proteins known as major histocompatibility 
complex (MHC) molecules (Trombetta and Mellman, 2005). These molecules are 
synthesised in the ER and are crucial for permitting the efficient presentation of the 
antigen at the surface of the DC for subsequent recognition by the TCR (Trombetta 
and Mellman, 2005). How the antigen is processed and presented depends upon 
the type of pathogen intially encountered. This also influences the type of T cell 
(CD4 or CD8) that becomes activated. In general, endogenous proteins generated 
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from within the cell or from intracellular viruses, parasites or bacteria derived from 
e.g. intracellular bacteria, viruses, self-defective ribosomal products (DRiPs) or 
misfolded proteins are processed and loaded onto MHC class I molecules, which are 
specifically recognised by CD8 T cells (Trombetta and Mellman, 2005). In contrast, 
internalised exogenous antigens derived from e.g. extracellular bacteria and 
parasites, are loaded onto MHC II molecules and presented to CD4 T cells 
(Trombetta and Mellman, 2005). However, there are exceptions to this rule as 
observed with exogenous dying or viral infected cell MHCI-mediated presentation 
to CD8 T cells, a unique process known as cross-presentation (section 1.7.3) 
(Trombetta and Mellman, 2005). The mechanistic basis of the various types of DC 
antigen processing and presentation are dicussed below. 
1.7.1 Endogenous classical MHCI pathway 
Dendritic cells use the classical MHCI pathway to present processed cytosolic 
proteins (generated from within the cell or from intracellular viruses, parasites or 
bacteria) in conjunction with MHCI to naive CD8 T cells. This type of presentation 
relies on the cytosolic proteasomal machinery for efficient antigen processing, and 
transport of peptides from cytosol to the ER for efficient loading onto MHCI via the 
transporter associated with antigen processing (TAP) as illustrated in Figure 1.2A. 
Dendritic cells constitutively present antigens via this pathway independently of the 
maturation status of the DC.The distinction between DC presentation of self or non-
self-antigenic peptides and the subsequent CD8 T cell response (tolerance vs. 
immunity) is dependent on the presence of DC maturation signals. Under normal 
physiological conditions, the absence of TLR ligands does not initiate DC maturation 
and keeps CD8 T cell in a tolerant state (Blum et al., 2013). However under viral 
infectious conditions, the viruse enters the DC and produces dsRNA as it replicates. 
dsRNA activates intracellular TLR3 contained within endosomal compartments, 
resulting in DC maturation (Kawai and Akira, 2011). The MHCI:peptide complexes 
that are transported to the surface of the DC in this context will result in an antigen-
specific CD8 T cell immune response. 
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1.7.2  Exogenous MHCII pathway 
Dendritic cells present exogenous peptides derived from internalised extracellular 
bacteria, fungi and parasites through the exogenous MHCII pathway. Processed 
antigenic peptides are then presented in the context of MHCII molecules to CD4 T 
cells. This type of presentation relies on the phagosomal vesicular pathway for the 
processing and transportation of exogenous antigenic peptides onto translocated 
MHCII molecules. Unlike endogenous MHCI presentation, efficient exogenous 
MHCII presentation only proceeds in mature DCs following TLR engagement (Blum 
et al., 2013). With reference to extracellular Escherichia coli bacterial infection, LPS 
is recognised by TLR4 which promotes the phagocytosis and internalisation of the 
bacteria into the phagosome. The phagosome then enters a sequential vesicular 
pathway in which its contents are subsequently delivered to increasingly proteolytic 
enzyme-rich late endosomal and lysosomal compartments, a process known as 
phagosome maturation (Blander and Medzhitov, 2006a). Transportation of the 
MHCII molecule itself relies on the activity of the protease cathespin S which is also 
activated upon TLR signalling. The precise details of MHCII presentation are 
illustrated in Figure 1.2B. (Blander and Medzhitov, 2006b).  
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Figure 1.2. DC antigen presentation pathways 
A. Endogenous classical MHCI pathway (i) Intracellular viral proteins are ubiquitinated and 
degraded by the proteasome. (ii) Peptides are transported from the cytosol to the ER via 
TAP. (iii) Antigenic peptides are loaded onto MHC I molecules with the ER. (iv) The 
MHCI:peptide complex is then actively transported from the ER to the cytosol and 
ultimately displayed on the surface of the DC to naive CD8 T cells. B. Exogenous MHCII 
pathway (i) Bacterial pathogens are internalised resulting in the formation of the 
phagosome. This fuses with the late endosomal compartment, MIIC where the bacteria are 
proteolytically degraded into smaller antigenic peptides. (ii) Within the ER, MHCII 
molecules are formed which are stabilised by the binding of type II membrane spanning 
chaperone protein, Ii. (iii) MHCII:li complex is transported to lysosomes where Ii is cleaved 
to a smaller peptide CLIP by cathespin S. (iv) The lysosome fuses with the MIIC containing 
the chaperone protein, HLA-DM which dissociates CLIP from MHCII. (v) Specific antigenic 
peptide contained within the MIIC are loaded onto the MHCII and transported to the 
surface of the DC where it is displayed to naive CD4 T cells. CATS: cathespin S; CLIP: MHC 
class II–associated invariant-chain peptide, DC: dendritic cell; ER: endoplasmic reticulum; 
HLA-DM: human leukocyte antigen-DM; li: invariant chain; MHC: major histocompatibility 
complex; MIIC: MHC class II-rich compartment; TAP: transporter associated with antigen 
processing.  
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1.7.3 Cross-presentation 
Certain DC subsets notably the CD8+ lymphoid DCs can uniquely present exogenous 
cell-associated antigens from dying or infected cells in the context of  MHCI 
molecules to naive CD8 T cells, a phenomenon known as “cross-presentation” (den 
Haan et al., 2000; Belz et al., 2005). In the case of intracellular viral infection, 
presentation of MHCI:peptide complex to CD8 T cells relies on the DC to be infected 
itself as illustrated with the classical endogenous MHCI pathway. However, viruses 
can utilise mechanisms to severely impede MHCI presentation in infected DCs thus 
evading cytotoxic CD8 T cell immunity (Nopora et al., 2012). Cross priming 
mechanisms provides a means by which uninfected DCs can initiate CD8 T cell 
immune responses through the processing of cell-associated antigens derived from 
internalised viral infected cells (Nopora et al., 2012). Furthermore, it is essential for 
priming CD8 T cell anti-tumour responses to exogenous tumour self-antigens 
expressed by dying cells (Hoffmann et al., 2000). Unlike, the exogenous MHCII 
pathway, cross-presentation occurs in nascent phagosomes (Houde et al., 2003) or 
early endosomes typified by their neutral pH and generally relies on transport of 
their exogenous material into the cytosol for proteasomal degradation (Blum et al., 
2013). Therefore, phagosomal maturation into late proteolytically active endosomal 
compartments is not required. Similarly to MHCI presentation, cross-presentation is 
a constitutive process in iDCs and plays an imperative role in maintaining CD8 T cell 
tolerance (Kurts et al., 1998). This proceeds through iDC presentation of 
extracellular self-antigens in the context of MHCI to autoreactive CD8 T cells, which 
results in their deletion from the T cell repertoire and ultimately prevents the 
initiation of autoimmune responses (Kurts et al., 1997; Kurts et al., 1998; Heath and 
Carbone, 2001). The differential pathways involved in cross-presentation are 
illustrated in Figure 1.3. Take for example the cross-presentation of cell-associated 
antigens derived from apoptotic or necrotic cells. These cells are internalised 
through phagocytic mechanisms into phagosomes and are partially degraded, after 
which they are expulsed from the phagosome to the cytosol, ubiquitinated and 
directed for proteasomal degradation (Figure 1.3A, black arrows) (Blum et al., 
2013). The resultant antigenic peptides are subsequently transported to the ER via 
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TAP where they are loaded onto MHCI molecules and transported to the surface of 
the cell (Kovacsovics-Bankowski and Rock, 1995). The phagosome itself can also 
acquire the optimum components for efficient exogenous MHCI peptide loading via 
fusion with ER-derived vesicles (Figure 1.3B, green arrows). In this respect, the 
acquired dying cell is partially degraded in the ER-fused phagsosme and the 
resultant proteins are transported from the fused phagosome to the cytosol via the 
transporter Sec61, where they are directed to the proteasome for further 
degradation. The resultant peptides are then re-translocated back into the 
phagosome via TAP where the peptide is loaded onto the MHCI and transported to 
the surface of the DC (Houde et al., 2003). Cross presentation can also proceed via a 
TAP and proteasome-independent mechanism (Figure 1.3C, red arrows) (Bachmann 
et al., 1995). In this process, acquired dying cells are transported via the phagosome 
to vacuolar post-golgi compartments where they are broken down into smaller 
peptide fragments via proteases. Recycled MHCI from the surface of the DC are 
acquired within these phagocytic vesicles. The peptide is loaded onto the MHCI and 
the MHCI:peptide complex is then transported to the surface of the DC (Trombetta 
and Mellman, 2005).  
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1.8 DC-mediated antigen-specific T cell activation 
Once the antigen is processed and displayed on the DC cell surface, it is now 
available for specific recognition by naive T cells in lymphoid organs. In order for 
competent T cell activation to occur, three activation signals are required (Figure 
1.4). The T cell must specifically recognise the peptide:MHC presented by the mDC 
via its distinct TCR (signal 1) (Murphy et al., 2012). CD8 and CD4 TCRs will 
specifically recognise peptides complexed to MHCI and MHCII molecules, 
respectively. Co-stimulatory receptor engagement between CD28 on T cells and 
CD80/86 on DCs comprises the second critical signal (signal 2) necessary for T cell 
Figure 1.3 DC cross presentation pathways 
Cross presentation of exogenous dying cell-associated antigens in conjunction with MHCI 
molecules to naïve CD8 T cells can proceed via three mechanisms (A) proteasome- and 
TAP dependent pathway (B) proteasome- and TAP-dependent ER fusion (C) protesome and 
TAP independent processing  via the vacuolar post-golgi compartment. ER: endoplasmic 
reticulum; MHC: major histocompatibility complex; TAP: transporter associated with 
antigen processing. 
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Figure 1.4. Schematic diagram of DC-mediated T cell activation within peripheral 
lymphoid organs  
Ag: antigen; IL-12: interleukin-12; mDC: mature DC; MHC: major histocompatibility 
complex; TCR: T cell receptor.  
 
 
 
activation (Murphy et al., 2012). Co-stimulatory receptor signal transduction lowers 
the threshold for T cell activation, prevents T cell anergy, enhances T cell survival 
via up regulation of anti-apoptotic protein Bcl-xL and facilitates IL-2 cytokine 
secretion (Bachmann et al., 1997; Okkenhaug et al., 2001; Acuto and Michel, 2003). 
It is important to note that as iDCs express low levels of co-stimulatory receptors, 
they present the antigen to T cells in the absence of signal 2, thus resulting in T cell 
tolerance (Kurts et al., 1998). Signal 3 represents cytokines secreted by the DC itself 
e.g. IL-12 or from other innate immune cells at the site of infection. This teriary 
signal is vital for the functional differentiation of CD4 and CD8 T cells into mature 
effector T cells. Once all signals are in place, this will result in the induction of 
competent antigen-specific naïve T cell activation. T cell activation proceeds via the 
triggering of complex tyrosine kinase cascades and other signalling pathways 
including p38 MAPK as reviewed in (Smith-Garvin et al., 2009). This results in the 
downstream activation and nuclear translocation of  transcription factors Nuclear 
factor of activated T cells (NFAT), NF-κB and AP-1, which work in concert  in the 
transcriptional upregulation of an array of genes responsible for T cell survival, 
proliferation, differentiation and cytokine secretion such as IL-2 (Macian et al., 
2001; Hayden and Ghosh, 2011).  
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1.9 T cells and the immune response 
Once a naïve T cell has recognised a specific antigen presented by the DC and is 
consequentially fully activated, it will undergo several rounds of proliferation. This 
results in its clonal expansion and functional differentiation into effector T cells. 
Naïve T cells are identified by their distinct cell surface expression of CD62L and 
chemokine receptors CCR7 and CXCR4 (Bromley et al., 2008; Kesarwani et al., 
2012). Expression of CD62L, CXCR4 and CCR7 allow entry and residence in lymphoid 
tissues. Differentiation into effector cells is associated with down regulation of the 
aforementioned surface markers thus enabling them to leave the lymph node 
(Kesarwani et al., 2012). Migration to peripheral tissues and sites of infection 
through the blood stream and lymphatics is achieved through the upregulation of 
chemokine receptors such as CXCR3, CCR4, CCR5 and CCR6 (Bromley et al., 2008). 
Herein they perform specific adaptive immune responses upon re-exposure to the 
antigen and ultimately result in the clearance of infection and attainment of 
immunological memory. There are two major types of effector T cells, cytotoxic CD8 
T cells (CTLs) and CD4 T helper cells. The type of T cell that is activated by an APC, 
depends on whether the pathogen was processed via the endogenous classical 
MHC I pathway or the exogenous MHC II pathway. CD8 CTLs and CD4 T cells are 
fundamental for providing defence against invading intracellular and extracellular 
pathogens, respectively. As stated previously, functional differentiation into 
competent effector T cells is highly dependent upon the cytokines present within 
their microenvironment (Figure 1.4, signal 3). For CD8 T cells, IL-12 acts as the third 
signal since its absence limits the capacity of the CD8 T cells to proliferate and to 
produce IFNγ (Curtsinger et al., 1999). Abrogation of this third signal also results in 
CD4 hyporesponsiveness (Tse et al., 2007). At the peak of the immune response, a 
minor population of cells diverge into memory T cells as typified by their expression 
of IL-7R (Zielinski et al., 2011). In contrast to naïve and effector cells, memory cells 
rely solely on cytokines IL-7 and IL-15 for their survival (Surh and Sprent, 2008). 
Therefore, once the infection and its associated antigen have cleared, the majority 
of T cells die en masse via various pro-apoptotic mechanisms within 7 days post-
infection. The small population of memory cells which survive possess the 
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immunological memory of that specific antigen (Zimmerer et al., 2012). Unlike 
short-lived effector cells, antigen-experienced memory cells can survive for the 
lifetime of the human body providing long lasting immunity to that particular 
antigen (Zimmerer et al., 2012). Upon secondary encounter with the same antigen, 
memory cells undergo robust clonal expansion resulting in the rapid elimination of 
that specific pathogen (Zielinski et al., 2011). 
1.10 CD8 T cells 
Effector CTLs provide vital protection against an array of intracellular bacterial and 
viral infections and are responsible for anti-tumour responses (Barber et al., 2006; 
Bos et al., 2012; Condotta et al., 2012). As MHC class I proteins exist on the surface 
of nearly every nucleated cell of the body, infected cells display pathogenic 
peptides derived from cytosolic proteins which can be recognised by CD8 T cells. 
The importance of CTL function is highlighted in a variety of disease settings such as 
chronic viral infections including hepatitis C virus (HCV), hepatitis B virus (HBV), 
human immunodeficiency virus (HIV) and malignancies including melanoma, 
ovarian, prostate and lung tumours which are a consequence of CTL dysfunction 
(Shin and Wherry, 2007; Matsuzaki et al., 2010; Chou et al., 2012; Fourcade et al., 
2012; Prado-Garcia et al., 2012). Upon DC-mediated antigen stimulation and 
competent co-stimulation in the lymph node, activated antigen-specific CD8 T cells 
begin to secrete IL-2. This works in an autocrine fashion by binding to its high 
affinity IL-2R on the T cell surface, thus driving its exponential clonal expansion and 
functional differentiation into effector CTLs (Boyman and Sprent, 2012). CD8 T cell 
differentiation is highly dependent upon the transcriptional activity of T-box 
transcription factors, T box expressed in T cells (T-bet) and eomesodermin (EOMES) 
(Kaech and Cui, 2012). The resultant CTLs then enter the blood stream and migrate 
to sites of infection where their effector responses generally peak at day 7 post-
infection (Obar et al., 2008). Cytotoxic T lymphocytes target infected cells through 
numerous mechanisms including cellular-mediated cytotoxicity and cytokine 
secretion (Topham et al., 1997; La Gruta et al., 2004). Upon recognition of the 
antigen in conjunction with MHCI on the target cell, CTLs release cytolytic effector 
molecules including proteases granzyme A and B and the pore-forming perforin. 
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Perforin perturbs the membrane of the target cell allowing entry of granzyme A and 
B, the latter of which initiates a caspase-dependent apoptotic pathway, ultimately 
resulting in cell death (Lieberman, 2003). Additionally, CTLs release 
proinflammatory cytokines such as IFNγ and TNFα (La Gruta et al., 2004). 
Interferon-γ inhibits viral replication and promotes MHCI expression on infected 
cells thus increasing their probability of being targeted by activated CTLs. Tumour 
necrosis factor-α secretion activates innate immune cells and induces caspase-
dependent cellular apoptosis via ligation with its cognate receptor TNFR-1 on the 
target cell (Murphy et al., 2012). Co-stimulation is critical for CTL effector function. 
Notably, CD28 signalling is associated with induction of IL-2 production. This 
subsequently enhances functional differentiation of CTLs through increasing 
granzyme and perforin expression (Janas et al., 2005; Williams et al., 2006).  
CD8 TCR antigen affinity is an important factor that influences the CTL effector 
response. Generally, cross-presented self/tumour antigens with low avidity will be 
ignored by CD8 T cells, resulting in an absent effector response even in the 
presence of a viral infection (Bos and Sherman, 2010). CD8 T cells with a greater 
affinity for the tumour antigens, results in enhanced perforin and granzyme B 
expression, reduction in co-inhibitory receptor expression and induction of tumour 
irradiation (Bos et al., 2012). In these settings the requirement for enhanced CTL 
effector function is facilitated by the provision of CD4 T cell help (Bos and Sherman, 
2010). CD4 T cells enhance CD8 T cell activation and differentiation via a variety of 
mechanisms including activated CD4 T cell secretion of IL-2 and IFNγ (Bos and 
Sherman, 2010). CD4 T cells can also directly interact with DCs via CD40:CD40L 
ligation. This enables the “licensing” of DCs and upregulation of DC CD80/86 co-
stimulatory receptor expression, resulting in more efficient priming of CTL immune 
responses (Murphy et al., 2012).  
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Figure 1.5. Dendritic cell-mediated CD4 T cell differentiation 
Dendritic cells present extracellular-derived antigenic peptides in conjunction with MHCII 
molecules to naive CD4 T cells in secondary lymphoid organs. Upon TCR recognition of the 
specific antigen:MHCII complex and engagement of DC B7 CD80/86 with cognate T cell 
CD28 co-stimulatory molecules, this results in competent antigen-specific T cell activation, 
proliferation and differentiation. The cytokines present within the T cells’ 
microenvironment encompass the vital tertiary signal necessary for instructing CD4 T cell 
differentiation into unique CD4 various subtypes: Th1, Th2, iTreg, Th17, Tfh, Th9 and Th22. 
Cytokines essential for inducing CD4 differentiation into the aforementioned subsets are 
shown in black. Each subtype is distinguished by their characteristic cytokine profile 
(shown in purple) and effector function. Dysregulation of CD4 differentiation is implicated 
in a variety of allergic disorders e.g. asthma and autoimmune diseases e.g. rheumatoid 
arthritis. Ag: antigen; DC: dendritic cell; IFNγ: interferon-γ; IL-: interleukin-; iTreg: inducible 
T regulatory cell; MHCII: major histocompatibility complex class II molecule; TCR: T cell 
receptor; Tfh: CD4 T follicular helper cell; TGFβ: transforming growth factor β; Th: CD4 T 
helper cell; TNFα: tumour necrosis factor α.   
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1.11 CD4 T helper cells 
CD4 T cells orchestrate complex immune responses against a myriad of pathogens. 
They can be categorised into a variety of subsets based on their distinctive cytokine 
profile, chemokine cell surface receptor pattern and immune function such as 
amplifying CD8 T cell immunity, facilitating B cell activation and preventing 
autoimmune responses (Figure 1.5). The earliest subtypes to be identified were the 
classical CD4 T helper 1 (Th1) and T helper 2 (Th2) cells (Mosmann et al., 1986). 
However, upon further investigation a variety of new distinct subsets were 
discovered including T regulatory T (Tregs), follicular helper T (Tfh) and the most 
recent T helper 17 (Th17), T helper 9 (Th9) cells and T helper 22 (Th22) cells (Chen 
et al., 2003; Harrington et al., 2005; Dardalhon et al., 2008; Eyerich et al., 2009; 
Craft, 2012). In contrast to CD8 T cells, CD4 T cells have greater plasticity in their 
differentiation which are not only dependent upon their cytokine milieu and the 
strength and duration of TCR signalling; but are also further regulated by a network 
of lineage-specific transcription factors and corresponding activation of specific 
signalling transducer and activator of transcription (STAT) proteins (Zhu and Paul, 
2010). For the purposes of this introduction the main types of CD4 T cells (Th1, Th2, 
Th17 and Treg) and their dynamic interplay with one another are discussed in 
greater detail below. 
1.11.1 Th1 cells 
Effector Th1 cells play critical roles in mounting cell-mediated immune responses to 
intracellular viruses and pathogens such as Listeria (Hsieh et al., 1993). Effector Th1 
cells are characterised by their secretion of IFNγ, TNFα and IL-2 as illustrated in 
Figure 1.5 (Hsieh et al., 1993). Functional differentiation into Th1 is dependent 
upon exposure to proinflammatory cytokines e.g. IL-12 and IFNγ derived from 
innate immune cells (Hsieh et al., 1993; Lighvani et al., 2001). Notably, activated 
CD8+ DCs represent a major source of IL-12 and are thought to be the main drivers 
of Th1 deriviation (Maldonado-Lopez et al., 1999). Recently, DC-derived IL-27 
secretion has also been shown to be potent inducer of Th1 differentiation, playing a 
crucial role in the pathogenesis of skin inflammation associated with psoriasis 
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(Shibata et al., 2013). Induction of Th1 IFNγ secretion through DC-derived IL-12 
secretion, activates innate immune cells including macrophages and neutrophils, 
enhancing their phagocytic function and microbial killing (Murphy et al., 2012); 
whilst Th1 IL-2 production promotes CD8 T cell activation and subsequent cytolytic 
capabilities (Janas et al., 2005). Multiple transcription factors play important roles 
in Th1 lineage development including the master transcription factor T-bet, Runx3, 
EOMES, NF-κB and importantly STAT1 and STAT4 (Szabo et al., 2000; Lighvani et al., 
2001; Malmberg et al., 2001; Djuretic et al., 2007; Yang et al., 2008; Kesarwani et 
al., 2012; Zhu et al., 2012). The strength of the TCR signal is important in 
determining Th1 lineage commitment. A strong TCR stimulation promotes Th1 
differentiation whereas a weak TCR stimulation favours Th2 differentiation. (Tao et 
al., 1997). Increased Th1 differentiation and effector function has been implicated 
in the pathogenesis a variety of autoimmune diseases including Crohn’s disease 
(Fuss et al., 1999; Neurath et al., 2002), MS (Frisullo et al., 2012), type 1 diabetes 
(Bluestone et al., 2010) and lupus nephritis (Ooi and Kitching, 2012).  
1.11.2 Th2 
Effector Th2 cells are central for the execution of humoral immunity in response to 
extracellular pathogens such as parasitic helminths and allergens (Pulendran and 
Artis, 2012). Effector Th2 cells are characterised by their production of IL-4, IL-5 and 
IL-13 (Figure 1.5). Interleukin-4 and IL-13 enhance B cell immune responses by 
promoting B cell immunoglobulin class switching from IgM towards IgE. This 
subsequently activates basophils and mast cells which secrete proinflammatory 
mediators which enhance the expulsion of helminth infection (Kool et al., 2012). 
Interleukin-5 enhances the activation and differentiation of eosinophils which are 
also involved in parasitic killing (Kool et al., 2012). Functional differentiation into 
Th2 is dependent upon naive T cell exposure to IL-2 and IL-4 (Figure 1.5). 
Interleukin-4 secretion is thought to be derived from innate immune cells such as 
eosinophils and basophils (Voehringer, 2013). Furthermore, thymic stromal 
lymphopoietin (TSLP) production by activated basophils, mast cells and epithelial 
cells at the site of infection can direct DCs to induce Th2 differentiation (Pulendran 
and Artis, 2012; Voehringer, 2013). Cd11c+ CD8- DCs and monocyte-derived 
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inflammatory DCs play vital roles in Th2 differentiation during infection (Kool et al., 
2012). Moreover, DCs matured under suboptimal or inflammatory conditions 
instruct the polarisation of CD4 T cells to Th2 phenotype (Pletinckx et al., 2011). 
Multiple transcription factors play an important role in Th2 lineage development 
including the master transcription factor GATA binding protein-3 (GATA-3), c-maf, 
growth factor independent-1 (Gfi-1), Interferon regulatory factor 4 (IRF4), Notch 
and importantly STAT proteins, STAT5 and STAT6 (Shimoda et al., 1996; Zhu et al., 
2003; Pai et al., 2004; Fang et al., 2007; Luckheeram et al., 2012). The strength of 
the TCR signal is also important for determining Th2 differentiation. Lower peptide 
concentration induced activation of the TCR results in the increased production of 
CD4+ IL-4 producing cells (Yamane et al., 2005). Furthermore, weak TCR stimulation 
through the use of altered peptide ligands which possess a lower avidity for the 
receptor, results in the induction of Th2 cytokine production. This is also exclusively 
dependent upon CD28 co-stimulatory engagement (Tao et al., 1997). Weak TCR 
stimulation results in reduced ERK activation, favouring Th2 induction (Yamane et 
al., 2005). Although Th2 cells are vital for mounting humoral responses against 
helminth invasion, they are notorious for their role in triggering immune responses 
to innocuous environmental allergens, resulting in chronic inflammation associated 
with allergic diseases such as eczema, allergic rhinitis and asthma (Holgate, 2012; 
Murphy et al., 2012).  
1.11.3 Th17 cells 
In the past decade, a new CD4 subtype has been identified due to its distinguishing 
cytokine profile and transcriptional regulation atypical of the classical Th1/Th2 
paradigm (Harrington et al., 2005; Ivanov et al., 2006). Furthermore, recognition of 
this new subtype was based on its observed pathophysiological role in experimental 
autoimmune models such as Experimental Autoimmune Encephalomyelitis (EAE), 
the animal model for human MS (Harrington et al., 2006). Previous studies 
concluded that the pathology exhibited in EAE was solely a result of a dominant Th1 
phenotype (Liblau et al., 1995). The Th1 cytokine IL-12 composed of p40 and p35 
subunits, was initially thought to be involved in Th1-driven pathology in EAE as IL-
12p40−/− mice were resistant to this autoimmune model (Gran et al., 2002). 
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However, further studies using IL-12p35-/- mice showed a surprisingly enhanced 
susceptibility to EAE. This indicated that IL-12 was not involved but rather a 
structurally related cytokine to IL-12, IL-23 was responsible for promoting EAE (Gran 
et al., 2002). Furthermore, deficiency in IFNγ surprisingly exacerbated disease 
severity, ruling out Th1 cells as the main culprit behind the inflammatory-driven 
pathology associated with EAE (Ferber et al., 1996). Upon closer inspection, it was 
determined that a novel IL-17-producing CD4 effector T cell which is dependent on 
IL-23 rather than IL-12 for their expansion was in fact the actual offender in 
question (Harrington et al., 2005; Langrish et al., 2005; Komiyama et al., 2006). This 
was further clarified through the use of blocking IL-17 antibodies resulting in 
inhibition of EAE severity (Langrish et al., 2005; Komiyama et al., 2006). This 
effector subtype designated Th17 cells, play a pivotal role in orchestrating the 
host’s defence against extracellular microbial and fungal pathogens, but also 
promote chronic inflammation associated with a variety of autoimmune diseases 
such as MS, Rheumatoid arthritis (RA), psoriasis and Systemic lupus erythematosus 
(SLE) (Zhu and Qian, 2012). Effector Th17 cells are characterised by their secretion 
of IL-17A, IL-17F, IL-21 and IL-22 (Figure 1.5) (Zhu et al., 2010). Th17-mediated 
cytokine functions include recruitment and expansion of neutrophils to sites of 
infection, activation of macrophages and DCs and the release of TNFα and IL-1β, 
which collectively result in a heightened inflammatory response. (Zhu and Qian, 
2012). Moreover, IL-17 promotes the activation and subsequent transformation of 
B cells into antibody secreting plasma cells (Zhu and Qian, 2012). Furthermore, IL-
17 in conjunction with B cell activating factor (BAAF) has been shown to 
synergistically promote self-reactive B cell mediated pathogenesis in autoimmune 
SLE (Doreau et al., 2009). Functional differentiation into effector Th17 cells is 
governed by the secretion of TGFβ, IL-6 and IL-23 from DCs (Figure 1.5) (Mangan et 
al., 2006; Veldhoen et al., 2006). Although IL-23  has been shown to be dispensable 
for the development of Th17 cells in vitro, it is essential for their phenotypic 
stability, expansion and effector function against microbial infection in vivo 
(Oppmann et al., 2000; Mangan et al., 2006; McGeachy et al., 2007). 
Proinflammatory cytokines IL-1β and TNFα have also been shown to promote Th17 
differentiation (Veldhoen et al., 2006). Co-stimulatory receptor engagement of 
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CD28, CD40L and ICOS are also necessary for Th17 generation (Park et al., 2005b; 
Huang et al., 2012). Multiple transcription factors play an important role in Th17 
lineage development including the master transcription factor retinoic acid-related 
orphan receptor-γt (RORγt or RORC2 human equivalent), nuclear aryl hydrocarbon 
receptor (AHR), IRF4, B cell-Activating Transcription Factor (BTAF), Runx1 and STAT3 
(Ivanov et al., 2006; Mathur et al., 2007; Huber et al., 2008; Veldhoen et al., 2009; 
Zhu et al., 2010), Expression of RORγt is obligatory for Th17 development which is 
upregulated by TGFβ and IL-6 (Ivanov et al., 2006; Burgler et al., 2010). It has been 
shown that DCs are the main drivers of the pathogenic Th17 phenotype (Veldhoen 
et al., 2006; Huang et al., 2012; Shi et al., 2012). Furthermore, DC signalling via the 
p38 MAPK pathway is necessary for the promotion of Th17 differentiation and 
subsequent pathogenesis of EAE as highlighted in p38 MAPK deficient mice (Huang 
et al., 2012).  
1.11.4 T regulatory cells (Treg) 
T regulatory cells are specialised suppressors of the immune responses. They are 
responsible for the maintenance of immune homeostasis, elimination of self-
reactive T cells and subsequent prevention of autoimmune responses (Sakaguchi et 
al., 2008). Reduced numbers of Tregs are observed in a variety of autoimmune 
diseases such as MS, RA and SLE revealing the fundamental role of this subset in 
maintaining self-tolerance (Ozdemir et al., 2009). There are two main types of 
Tregs; natural occurring CD4+CD25+Foxp3+ (nTregs) and inducible Tregs (iTregs) 
which can be differentiated from CD4+CD25-Foxp3- T cells in the periphery (Ozdemir 
et al., 2009). The former are derived from the thymus and are positively selected 
based on strong interactions with thymic stromal cells (Sakaguchi et al., 2008). 
Natural occurring Tregs constitutively express CD25 and the master transcription 
factor Foxp3, the latter of which is vital for their development and suppressive 
function (Burchill et al., 2007). Natural occurring Tregs elicit their suppressive 
function in response to extremely low concentrations of antigen in comparison to 
concentrations required to activate naive CD4 T cells (Takahashi et al., 1998). 
Suppression is achieved via a variety of contact-dependent mechanisms such as 
inhibiting IL-2 formation by responder T cells (Takahashi et al., 1998), targeted 
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killing of CD8 and NK T cells (Cao et al., 2007) and directly outcompeting responder 
T cell interactions with APCs (Yamaguchi et al., 2011). Additionally, the co-inhibitory 
receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) which is highly expressed on 
nTregs, further enables their suppressive activity. (Wing et al., 2008). Within the 
appropriate context, peripheral CD4+CD25-Foxp3- T cells can differentiate into 
CD4+CD25+Foxp3+ T cells which acquire the unqiue characteristics of nTregs; these 
polarised effector CD4 T cells are termed iTregs (Chen et al., 2003). Upon antigen 
stimulation and TGFβ exposure, Foxp3 is upregulated in peripheral CD4+ T cells, 
resulting in their conversion to CD4+CD25+Foxp3+ T cells (Figure 1.5) (Chen et al., 
2003; Zheng et al., 2004). Inducible Tregs secrete the immunosuppressive cytokines 
IL-10 and TGFβ which dampen inflammatory responses, but can also further 
instruct the differentiation of peripheral CD4 T cells to become suppressor T cells 
(Figure 1.5) (Zheng et al., 2004). Interleukin-10 secretion can in turn induce 
tolerogenic DCs, further dampening immune responses (Yamaguchi et al., 2011). 
Dendritic cells play a pivotal role in the differentiation of peripheral iTregs 
(Yamazaki et al., 2007). Splenic steady-state DCs  presenting low antigen 
concentrations in the presence of exogenous TGFβ, results in the induction of 
Foxp3 in peripheral CD4+ T cells (Yamazaki et al., 2007). The gut which is constantly 
exposed to a myriad of infectious and innocuous microbes is a prime location for 
DC-mediated iTreg differentiation. Within this region, tolerance to harmless 
antigens is necessary to avoid regular induction of aberrant immune responses 
(Scott et al., 2011). In support of this, it has been shown that tolerogenic 
mesenteric lymph node (MLN) DCs have an enhanced  ability to convert CD4 T cells 
into iTregs in the presence of TGFβ and IL-2 in comparison to skin draining LN DCs 
(Yamazaki et al., 2007). 
1.11.5 Other effector CD4 T cell subtypes: Tfh, Th9, Th22  
T follicular helper (Tfh) cells are a B cell helper T cell subset responsible for the 
facilitation of B cell survival, differentiation and immune function (Craft, 2012). 
They are localised in B cell-rich germinal centres, where upon activation they form 
contacts with B cells, promoting B cell maturation, immunoglobulin antibody class 
switching to IgE and subsequent plasma cell antibody production (Craft, 2012). They 
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secrete IL-4 and IL-21 which are essential for B cell help and are transcriptionally 
regulated by B cell lymphoma-6 (BCL6) (Craft, 2012). Dysregulation of Tfh cells have 
been shown to play a detrimental role in B cell-mediated autoimmune responses 
observed in SLE (Craft, 2012).  
Another subset of T cells namely Th9 (once thought to be Th2 cells) are distinctive 
in their cytokine production of IL-9 and IL-10 and transcriptional regulation via PU.1, 
IRF4 and GATA-3 (Dardalhon et al., 2008; Noelle and Nowak, 2010). Furthermore 
STAT6 is necessary for their development (Noelle and Nowak, 2010). Upon antigen 
stimulation naive CD4 T cells differentiate into Th9 cells in the presence of IL-4 and 
TGFβ (Dardalhon et al., 2008). Effector Th9 cells have been shown to promote 
tissue inflammation in murine colitis model and it is becoming increasingly 
apparent that this subset plays a key pathogenic role in allergic and autoimmune 
diseases (Dardalhon et al., 2008; Noelle and Nowak, 2010). 
In recent years accumulating evidence of a novel CD4 specific lineage designated 
Th22 cells has emerged, that can secrete IL-22 independently of IL-17 and is present 
in a variety of allergic skin disorders (Eyerich et al., 2009). Furthermore, these cells 
express chemokine receptors CCR6, CCR4 and CCR10 (Duhen et al., 2009). Effector 
Th22 cells have been shown to be localised in the skin epidermis in patients with 
psoriasis, atopic eczema and allergic contact dermatitis. They are suggested to be 
involved in epidermal tissue remodelling and hyperplasia associated with these skin 
diseases (Eyerich et al., 2009). Differentiation into Th22 cells is dependent upon the 
presence of IL-6 and TNFα within the T cell microenvironment (Duhen et al., 2009). 
Furthermore, mature pDCs and not cDCs can efficiently produce high levels of IL-6 
and TNFα thus are involved in promoting Th22 differentiation (Duhen et al., 2009). 
1.12 Interplay between the CD4 subsets 
In addition to the suppressive actions of Tregs in regulating immune function and 
immunological tolerance, the varying CD4 populations themselves control the 
development and differentiation of one another, sustaining a quintessential 
balance between the unique CD4 T cell subtypes and ultimately maintaining 
immune homeostasis. It is also worthy to note that CD4 subsets are not terminally 
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differentiated in that if exposed to different optimal polarising conditions, they can 
acquire the characteristics of other CD4 subsets (Veldhoen et al., 2006; Lee et al., 
2009). The relationships between the differing subtypes are discussed below. 
1.12.1 Th1/Th2 cross talk  
Numerous studies have dissected the integral relationship between Th1 and Th2 
cells. It is obvious that Th1 cells counter regulate the differentiation of Th2 cells and 
vice versa. Moreover, neutralising antibodies for IL-4 and IFNγ, or IL-12 lineage-
specific cytokines are routinely used in in vitro studies in optimal polarising 
conditions for Th1 and Th2 differentiation, respectively (Nurieva et al., 2007). 
Indeed, T-bet expression results in the downregulation of GATA-3, the converse 
also true (Usui et al., 2006; Gu et al., 2012). Furthermore, overexpression of GATA-3 
and T-bet in CD4 T cells results in the differentiation of Th2 and Th1 cells, 
correspondingly (Szabo et al., 2000; Usui et al., 2003; Usui et al., 2006). 
Additionally, GATA-3 and T-bet inhibit the activity of the lineage specific STAT4 and 
STAT5, respectively (Usui et al., 2003; Shatynski et al., 2012). Reciprocal regulation 
of Th1/Th2 cells has been observed in other lineage specific transcription factors 
such as c-maf mediated IFNγ suppression (Ho et al., 1998), Gfi-1 negative regulation 
of Th1 differentiation (Zhu et al., 2009), Th2 GATA-3 regulation of Runx3 (Djuretic et 
al., 2007) and Runx3-mediated suppression of IL-4 (Djuretic et al., 2007). Disease 
settings in which the Th1/Th2 balance is disrupted permitting a dominant Th2 
phenotype, as seen in allergic disorders e.g asthma and eczema highlights the 
importance of equilibrium between these crucial CD4 effector populations in 
immune responses (Holgate, 2012).  
1.12.2 Th1/Th2/th17 cross talk  
In addition to the Th1/Th2 paradigm, it has become increasingly apparent that cross 
regulation exists between Th1/Th2 and Th17 subtypes. It has been shown that IFNγ 
and IL-4 both inhibit Th17 development (Harrington et al., 2005). Generally in vitro 
treatment with neutralising antibodies for IL-4 and IFNγ in conjunction with Th17 
inducing cytokines is the typical approach employed for induction of optimal Th17 
differentiation (Harrington et al., 2005; Park et al., 2005b; Nurieva et al., 2007). 
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Both STAT1 and T-bet have been shown to inhibit CD4+IL-17+ producing cells 
(Harrington et al., 2005). Furthermore, GATA-3 overexpression results in STAT3 and 
RORγt inhibition and subsequent impairment of Th17 differentiation (van Hamburg 
et al., 2008). Moreover, increased CD4+IL-17-producing cells are observed in STAT5 
deficient mice (Laurence et al., 2007). Th2 transcription factors c-maf and Gfi-1 has 
also been shown to negatively regulate Th17 differentiation, the latter of which also 
impairs iTreg differentiation in the presence of TGFβ (Park et al., 2005b; Zhu et al., 
2009). Both IL-23 and IL-21 have been shown to inhibit the expression of T-bet 
(Nurieva et al., 2007; Mus et al., 2010). Interleukin-27 also inhibits RORγt 
expression and subsequent Th17 differentiation in murine naive CD4 T cells (El-behi 
et al., 2009). Donor CD4 T cells derived from IFNγ deficient mice exhibit enhanced 
Th2 and Th17 differentiation in GVHD murine model, further emphasising the cross 
regulation between the various subtypes (Yi et al., 2009).  
1.12.3 Treg/Th17 cross talk 
Not surprisingly, an integral link between Treg and Th17 also exists in the immune 
system as they both require TGFβ in different contexts for their development. 
Under normal conditions where TGFβ is present but IL-6 limiting, the 
immunosuppressive Treg population prevails over the Th17 population. However 
upon inflammatory conditions whereby both cytokines are present, the Treg 
differentiation is hindered whilst allowing the proinflammatory Th17 phenotype to 
dominate (Bettelli et al., 2006; Veldhoen et al., 2006; Burgler et al., 2010; Laurence 
et al., 2012) Indeed, the lineage specific transcriptions factors Foxp3 (Treg) and 
RORγt/RORC (Th17) are known to antagonise the expression of one another; thus 
Tregs and Th17 cells express low levels of RORγt and Foxp3, respectively (Bettelli et 
al., 2006; Mangan et al., 2006; Burgler et al., 2010). Th17 cytokines such as IL-6, IL-
23 and IL-21 have also been shown to suppress Foxp3 expression (Bettelli et al., 
2006; Nurieva et al., 2007; Huber et al., 2008; Mus et al., 2010; Laurence et al., 
2012). Similarly, while essential for Treg development, IL-2 potently inhibits Th17 
differentiation (Laurence et al., 2012). The gut localised CD103+ DCs release retinoic 
acid that supports iTreg differentiation, while hampering Th17 development (Scott 
et al., 2011). Moreover, under inflammatory conditions associated with GVHD, 
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STAT3 inhibits Foxp3 expression and subsequent iTreg differentiation whilst 
promoting Th17 development (Laurence et al., 2012).  
1.13 Redox and its role in immune cell function 
Cellular redox is a state arising from the combined contribution of oxidising and 
reducing elements. It impacts on numerous physiological processes involved in cell 
activation, proliferation, differentiation, cell survival and apoptosis (Valko et al., 
2007). The maintenance of cellular redox homeostasis is imperative for proper 
immune cell functioning (Kesarwani et al., 2012). Cellular redox homeostasis is 
achieved via an equilibrium between oxidising agents such as electrophiles, reactive 
oxygen species (ROS), chemical, drugs and their respective metabolites, and 
reducing systems including enzymatic anti-oxidants e.g. Superoxide dismutase 
(SOD), ROS scavenging vitamins and the non-protein thiol glutathione (GSH) 
(Nathan and Cunningham-Bussel, 2013). During cellular metabolic processes, highly 
reactive oxygen-derived free radicals namely ROS are produced as by-products 
(Valko et al., 2007). Mitochondrial oxidative metabolism, in which the consumption 
of oxygen and subsequent oxidation of NADH mediated by NAPDH oxidase (NOX) 
enzyme, produces the ROS superoxide anion (O2
.-) (Ma, 2010). Other ROS include 
hydroxyl radical (.OH), peroxyl radical (RO2
.) and the non-radical hydrogen peroxide 
(H2O2) (Ma, 2010). Reactive oxygen species can also be generated through the 
induction of other enzymes including xanthine oxidase (XO), lipoxygenases, and 
phase I cytochrome P450s (CYP450) drug metabolising enzymes. Other endogenous 
sources of ROS include heme groups, metal storage proteins and free iron and 
copper ions (Yu, 1994; Valko et al., 2007; Imlay, 2008; Ma, 2010; Nathan and 
Cunningham-Bussel, 2013) Moreover, environmental factors such as diesel exhaust 
fumes, smoking, metal exposure, Ultraviolet (UV) radiation and xenobiotic 
metabolism all influence ROS production (Nathan and Cunningham-Bussel, 2013). 
Due to their instability and heightened reactivity within the body, ROS are generally 
thought of as dangerous by-products owing to their capacity to induce cellular 
damage if housekeeping anti-oxidant defence systems are limiting (Nathan and 
Cunningham-Bussel, 2013). Nonetheless, it is evident that transient ROS production 
plays a positive physiological role within the body (Nathan and Cunningham-Bussel, 
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2013). ROS operate as important messengers of signal transduction. This is through 
the oxidative modification of kinases and phosphatases which are present in many 
signalling pathways including MAPK and NF-κB. Therefore, ROS are crucial for the 
proper functioning of both the innate and adaptive arms of the immune system 
(Ryan et al., 2004; Matsuzawa et al., 2005; Ma, 2010; Nathan and Cunningham-
Bussel, 2013). With reference to innate immune cell function, activated neutrophils 
and macrophages are reliant upon the generation of ROS via oxidative metabolism 
in order to efficiently engulf and destroy noxious pathogens, a process that is highly 
dependent upon their expression of NOX (Morel et al., 1991). ROS are necessary for 
efficient TLR signalling in innate immune cells including monocytes and DCs. This 
results in the elevation of downstream p38 MAPK and NF-κB activation, mediating 
enhanced proinflammatory cytokine production e.g. IL-1β, IL-8 and IL-6 which in 
turn shape the adaptive immune response (Ryan et al., 2004; Matsuzawa et al., 
2005). The differentiation of DCs from haematopoietic progenitor cells is highly 
dependent on GMCSF-induced mitochondrial ROS generation (Del Prete et al., 
2008; Sheng et al., 2010). Moreover, ROS promotes LPS-induced DC maturation 
through the up regulation of CD86 subsequently enhancing DC-mediated CD4 T cell 
proliferation and effector function (Matsue et al., 2003) In contrast, O2
.- can induce 
DC maturation in the absence of LPS mediated TLR signalling, through enhanced 
NF-κB activation associated with increased CD86 expression and subsequent 
increased DC-mediated antigen presentation ((Kantengwa et al., 2003). ROS have 
also been shown to potentiate TLR4-mediated DC cytokine production of IL-12 in 
response to the cysteine protease papain, resulting in downregulation of Th1 
differentiation (Tang et al., 2010). Therefore, ROS generation is important for 
maintaining DC mediated CD4 T cell differentiation towards a Th2 phenotype.  
From an adaptive T cell perspective, mild ROS generation is necessary for optimal 
TCR signalling and T cell activation resulting in enhanced IL-2 production (Lu et al., 
2007). Furthermore, mitochondrial generation of ROS in T cells induces the 
increased cell surface expression of the T cell activation markers CD25 and CD69 
(Sena et al., 2013). ROS are also required for CD4 antigen-specific TCR-dependent 
proliferation and effector function in vivo and is associated with appropriate IL-4, IL-
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5 and IL-13 production in response to allergen (Sena et al., 2013). ROS are 
necessary for mediating antigen-specific CD8 T cell activation, expansion and 
increased effector IFNγ production in response to Listeria monocytogenes infection 
(Sena et al., 2013). T cell NOX2-dependent ROS generation is essential for the 
induction of Th2 differentiation associated with increased STAT5 activation and 
GATA-3 expression (Shatynski et al., 2012). This suggests that similar to DC-
mediated ROS generation, T cell-mediated ROS generation during naïve T cell 
activation is also essential for modulating CD4 T cell differentiation enabling Th2 
dominance over Th1 (Shatynski et al., 2012).  
Intracellular ROS accumulation is normally counterbalanced by an array of intricate 
anti-oxidant defence mechanisms, which effectively detoxify hazardous free 
radicals, enabling their safe removal from the body. The cellular tripeptide 
glutathione (γ-L-glutamyl-L-cysteinyl-glycine) (GSH) is the main 
reductant/antioxidant found ubiquitiously throughout the body (Lu, 2009). This non 
protein thiol is found mainly in the cytoplasm in its reduced state where it operates 
as a cellular redox buffer (Lu, 2009). It has many physiological functions including 
the detoxification of oxidising drugs and their respective metabolites, and the 
decomposition of H2O2 into water. Furthermore, GSH can participate in thiol-
disulphide exchange reactions with proteins, thus protecting protein thiol groups 
from ROS or electrophilic-mediated oxidation (Talalay et al., 2003; Zhang et al., 
2011). The specific role of GSH in immune cell function is exemplified in Table 1.3. 
Glutathione biosynthesis proceeds via a two-step mechanism. The initial rate 
limiting step involves the binding of L-glutamate to L-cysteine to form γ-glutamyl-L-
cysteine catalysed by enyzme glutamate cysteine ligase (GCL) which is composed of 
catalytic (GCLc) and regulatory modifier (GLCm) subunits (Lu, 2009). The final step 
involves the enzymatic GSH synthase-mediated generation of GSH from γ-glutamyl-
L-cysteine and L-glycine (Lu et al 2009). One of the drivers of GSH biosynthesis is the 
redox sensitive transcription factor Nuclear factor-erythroid 2 (NF-E2)–related 
factor 2 (Nrf2) which is discussed in section 1.15. 
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Table 1.3 The role of the antioxidant glutathione in the maintenance of immune cell 
function 
DC: dendritic cell; GSH: glutathione; IL-: interleukin-; JNK: c-Jun N-terminal kinase; LPS: 
lipopolysaccharide; p38: p38 mitogen-activated protein kinase (MAPK); Teff: CD4 efector T 
cell; Th: CD4 helper T cell; TSLP: thymic stromal lymphopoietin 
Cell type Immune function Reference 
Dendritic 
cells 
 Regulates DC-mediated antigen 
specific T cell proliferation  
 Modulates differentiation from 
monocyte precursors 
 Controls DC-mediated Th1/Th2 
differentiation towards Th1 
dominance through modulation of DC 
IL-12 and IFNγ secretion 
 Enhances IL-27 and IL-12 DC secretion 
resulting in Th1 dominance  
 Limits DC-mediated T cell secretion of 
IL-13 in the presence of Th2-inducing 
cytokine TSLP 
 Provides DC-mediated extracellular 
reducing environment for optimal T 
cell proliferation 
(Peterson et al., 
1998; Kuppner et 
al., 2003; D'Angelo 
et al., 2010; Yan et 
al., 2010; Kamide et 
al., 2011) 
Macrophages  Modulates LPS-induced IL-12 secretion 
through JNK and p38 MAPK regulation 
 Potentiates LPS-induced IL-6 secretion 
 Maintains macrophage-mediated 
Th1/Th2 balance 
(Dobashi et al., 
2001; Murata et al., 
2002a; Murata et 
al., 2002b; Utsugi et 
al., 2003) 
NK cell  Promotes cytolytic capacity in 
response to Mycobacterium 
tuberculosis infection 
(Millman et al., 
2008) 
T cell  Regulates T cell-activated induced cell 
death  
 Provides reducing environment for 
DNA synthesis within the T cell and 
progression through the cell cycle 
 Tregs inhibit Teff proliferation through 
decreasing DC intracellular GSH levels. 
This limits extracellular cysteine 
availability for reducing environment 
for Teff activation.  
 Tregs prevent redistribution of 
intracellular GSH from nucleus to 
cytoplasm within Teff which is 
necessary for Teff proliferation.  
(Messina and 
Lawrence, 1989; 
Suthanthiran et al., 
1990; Chiba et al., 
1996; Lee et al., 
2010) 
(Yan et al., 2010) 
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1.14 Oxidative stress and immune cell function 
Sustained oxidative stimuli e.g. excessive ROS production, leads to a depletion of 
cellular GSH. This overpowers the anti-oxidant defence systems and disrupts the 
cellular redox equilibrium by shifting it towards an oxidative state, ultimately 
resulting in oxidative stress (Kesarwani et al., 2012). Moreover, defects in the 
detoxification machinery itself can often lead to a similar outcome (Case et al., 
2011). Prolonged oxidative stress can lead to cellular dysfunction, apoptosis or  
necrosis (Durackova, 2010). Increased ROS can cause the aberrant oxidation of 
proteins resulting in their modification, denaturation and subsequent proteasomal 
degradation (Yu, 1994). Furthermore, it enhances lipid peroxidation ensuing loss of 
cellular membrane integrity. Importantly, it attacks nucleic acids resulting in double 
stranded DNA breaks or base mutations (Yu, 1994).  
Oxidative stress has a major impact on the appropriate functioning of DCs. It has 
been shown to induce DC maturation as typified by enhanced CD80, CD86 and 
MHCII expression (Traidl-Hoffmann et al., 2005; Csillag et al., 2010; Wang et al., 
2011). Conversely, oxidative stress can perturb LPS-induced DC maturation through 
down regulation of MHCII, CD86, CD54 (Chan et al., 2006), CD40, and lymphoid 
homing receptor CCR7 (Vassallo et al., 2005). Similarly, oxidative stress can either 
enhance (Traidl-Hoffmann et al., 2005; Wang et al., 2011) or potentiate (Vassallo et 
al., 2005) DC-mediated T cell proliferation. This highlights the variable role of 
oxidative stress in the DC maturation process and subsequent DC-mediated T cell 
activation. Consistently, oxidative stress influences DC regulation of Th1/Th2 
polarisation mediating a shift towards the Th2 phenotype (Ohtani et al., 2005; 
Traidl-Hoffmann et al., 2005; Vassallo et al., 2005; Chan et al., 2006; Csillag et al., 
2010).  
With reference to T cell function, excess mitochondrial production of superoxide at 
the stage of Lck activation in developing T cells, enhances thymocyte apoptosis 
resulting in a reduction of mature CD4 and CD8 T cell populations in the thymus and 
in peripheral lymphoid organs. Furthermore, the resultant peripheral CD4 and CD8 
T cells exhibit an enhanced activation state associated with increased CD44 
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expression (Case et al., 2011). Similarly, a marked downregulation of CD62L in naïve 
CD4 T cells is observed upon oxidative stress exposure (Foster et al., 2013). 
Increased ROS levels have been associated with T cell hyporesponsiveness due to 
dysregulated TCR signalling (Malmberg et al., 2001; Gringhuis et al., 2002; Cemerski 
et al., 2003). Excessive ROS production reduces CD8 T cell survival and IFNγ 
production in response to viral infection, which is associated with delayed viral 
clearance (Lang et al., 2013). In line with oxidative stress-mediated DC dysfunction, 
chronic oxidative stress has been known to influence CD4 T cell functional 
differentiation through disruption of the Th1/Th2 balance. This is evident in a 
variety of Th2 driven inflammatory allergic settings such as asthma and atopic skin 
diseases (Dieckhoff et al., 2005; Holgate, 2012). Oxidative stress-mediated 
reduction in Th1 effector function in AD T cells was associated with decreased 
nuclear translocation of NF-κB (Malmberg et al., 2001; Dieckhoff et al., 2005).  
Oxidative stress also influences Th1/Th17 polarisation skewing towards the Th17 
phenotype within a collagen induced arthritis murine model (Zhi et al., 2012). 
Furthermore oxidative stress mediated an increased pulmonary Th17 phenotype in 
a murine model of asthma (Wang et al., 2011). Oxidative stress is counterbalanced 
by antioxidant and cytoprotective defence responses which are controlled by the 
transcriptional activity of Nrf2.  
1.15 Nrf2: Master regulator of the anti-oxidant defence response 
The induction of cytoprotective and anti-oxidant defence systems in response to 
electrophilic and oxidative insult, and ultimate maintenance of cellular redox is 
governed by the transcriptional activity of the cap‘n’collar (CNC) basic region 
leucine zipper (bZip) transcription factor Nrf2 (Copple et al., 2010). Nrf2 is present 
in many tissues including heart, pancreas, muscle and particularly in tissues that are 
continually subjected to environmental toxins such as the lungs, gastrointestinal 
(GI) tract and skin (Moi et al., 1994; Aleksunes and Manautou, 2007). Furthermore, 
Nrf2 is highly concentrated in drug metabolising regions such as liver and kidney 
tissues, where it plays an essential role in the metabolism and detoxification of 
xenobiotics and their respective reactive metabolites (Moi et al., 1994; Ma and He, 
2012). Under resting conditions Nrf2 is sequestered in the cytosol by the repressor 
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Figure 1.6 Schematic diagram of the Nrf2-Keap-1 pathway 
Nrf2 is sequestered in the cytosol by Keap-1, which directs Nrf2 for proteasomal 
degredation. Upon oxidative insult, Nrf2 is liberated from Keap-1 enabling Nrf2 to 
accumulate within the nucleus and transactivate cytoprotective genes. ARE: antioxidant 
response element; GCL: glutamate cysteine ligase; GSH: glutathione; GST: glutathione S 
transferase; Keap-1: Kelch-like ECH-associated protein 1 NQO1: NAD(P)H: quinone 
oxidoreductase; Nrf2: NF-E2 -related factor 2; SOD: superoxide dismutase.   
protein Kelch-like ECH-associated protein 1 (Keap-1) (Zipper and Mulcahy, 2002). 
Keap-1 targets Nrf2 for polyubiquination and rapid degradation by the proteasome 
(Figure 1.6). However under oxidative stress conditions, cellular levels of GSH are 
markedly depleted, resulting in the oxidation and modification of the Keap-1 
protein. This induces a conformational change in Keap-1 disabling it from directing 
Nrf2 for proteasomal degredation (Copple, 2012). As a result, Nrf2 saturates Keap-
1. Once Keap-1 is saturated, newly synthesised Nrf2 is available to freely 
translocate into the nucleus (Figure 1.6). Within the nucleus, Nrf2 binds to the cis-
acting element, namely antioxidant response element (ARE), present in the 
promoter regions of an array of Nrf2-regulated cytoprotective and antioxidant 
genes (Itoh et al., 1997). This results in the induction of transcription of genes 
involved in GSH synthesis e.g. GCL, enzymatic antioxidants e.g. SOD, and 
detoxification enzymes e.g. NQO1 (Figure 1.6) (Copple, 2012). Consequently, GSH 
cellular content is increased resulting in cellular protection and maintenance of 
redox homeostasis. The main function and immunological relevance of the Nrf2-
regulated cytoprotective and antioxidant defence proteins is depicted in Table 1.4.  
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Protein 
Function Immune relevance References 
Glutamate 
cysteine ligase 
(GCL): 
Catalytic subunit 
(GCLc) 
Regulatory 
modifier subunit 
(GCLm) 
Rate limiting 
enzyme in GSH 
synthesis. 
Catalyses the 
ligation of 
glutamate with 
cysteine to form 
γ-glutamyl-L-
cysteine 
 
 Regulate neutrophil 
infiltration and 
inflammatory 
cytokine production 
in response to air 
pollutant in the lung 
 Important role in 
senescence, mellitus 
diabetes and cancer 
all associated with 
immune 
dysregulation 
(Lu, 2009; 
Weldy et al., 
2011; Zhang et 
al., 2011) 
Glutathione 
peroxidise (GPX) 
Catalyses the 
reduction of 
H2O2 to H2O 
using GSH as a 
substrate 
 Protects host against 
viral-induced 
pathogenesis 
 Regulates T cell 
intracellular ROS 
levels in response to 
CD3 and CD28 
stimulation 
 Controls TCR-
mediated T cell 
proliferation and IL-2 
production  
 Important for 
maintenance of CD4 
differentiation into 
Th1, Th2 and Th17 
cells 
 
 (Beck et al., 
1998; Zhang et 
al., 2011) 
 (Beck et al 
1998)(Won et 
al., 2010) 
 
Glutathione 
reductase (GSR) 
Catalyses the 
reduction of 
glutathione 
disulphide 
(GSSG) into GSH 
with NADPH 
utilisation 
 Required for 
mounting innate 
immune response to 
bacterial infection  
 Regulates 
phagocytosis, 
respiratory burst and  
bactericidal activity in 
neutrophils 
(Yan et al., 
2012; Lu, 
2013) 
 
Glutathione-S-
transferase (GST) 
Catalyses the 
conjugation of 
GSH to a variety 
of electrophilic 
compounds  
 
 Regulates 
proinflammatory 
mediator expression 
in skin cancer 
(Henderson et 
al., 2011; Lu, 
2013) 
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Heme-oxygenase 
1 (HO-1) 
 
 
 
 
 
 
 
 
 
Catabolizes 
cellular heme to 
biliverdin, carbon 
monoxide and 
free iron 
 Regulates splenic 
CD4:CD8 ratio 
 Modulates Th1, Th2 
and Th17 
differentiation 
 Controls LPS-induced 
monocyte IL-1β and 
TNFα production 
 Required for APC-
mediated Treg 
immunosuppressive 
function 
 Important for 
macrophage 
secretion of IFNβ and 
anti-viral immunity 
 Protects against EAE 
and modulates Th17 
polarisation 
(Poss and 
Tonegawa, 
1997; 
Kapturczak et 
al., 2004; 
George et al., 
2008; 
Rushworth et 
al., 2008; Xia 
et al., 2008; 
Tzima et al., 
2009) 
NAD(P)H:quinine 
oxidoreductase 1 
(NQO1) 
Catalyze two-
electron 
metabolic 
reduction 
and 
detoxification of 
quinones and 
derivatives 
 Controls LPS-induced 
monocyte IL-1β and 
TNFα production 
 Regulates B cell 
mediated humoral 
immunity 
 Important for 
maintenance of T cell 
tolerance  
(Iskander et 
al., 2006; 
Rushworth et 
al., 2008) 
Peroxiredoxin 1 
(PRX1) 
Catalyses the 
decomposition of 
H2O2 into H2O 
and O2 
 Implicated in 
regulation of T cell 
anti-viral immunity  
 Potentiates NK cell 
cytotoxicity 
 Regulates Th1/Th2 
balance in response 
to allergen challenge 
(Zhang et al., 
2011; Ishii et 
al., 2012) 
Superoxide 
dismutase (SOD) 
Catalyzes the 
conversion of 
superoxide 
radicals into H2O2 
and O2 
 Involved in T cell 
development in the 
thymus and 
subsequent T cell 
populations in 
lymphoid organs 
 Necessary for 
elicitation of adaptive 
immune response to 
viral infection 
(Yu, 1994; 
Case et al., 
2011) 
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Thioredoxin (TRX) 
 
 
 
Catalyses the 
reduction of 
disulphide bonds 
to sulphydryls 
Acts as a ROS 
scavenger for 
singlet oxygen 
and hydroxyl 
radicals 
 Regulates neutrophil 
migration and 
adhesion to 
endothelial cells via 
modulation of MCP-1 
and RANTES in 
response to LPS  
 Regulates Th1 
cytokine production  
(Das and Das, 
2000; 
Nakamura et 
al., 2001; Kang 
et al., 2008) 
Thioredoxin 
reductase (TRXR) 
Catalyses the 
reduction of 
oxidised TRX into 
TRX with NAPH 
utilisation 
 Essential for VSIG4 
expression in 
macrophages.  
 VSIG4 expression in 
APC is important for 
the maintenance of T 
cell reactivity 
(Nakamura et 
al., 2005; Vogt 
et al., 2006; 
Carlson et al., 
2011) 
 
1.16 The role of Nrf2 in the maintenance of redox homeostasis 
The role of Nrf2 in the regulation of cellular defence in response to oxidative stress, 
protection against oxidative stress-induced tissue injury and disease has been 
demonstrated in investigations where the Nrf2 pathway has been perturbed. This is 
mainly through the use of Nrf2 deficient mice, genetic manipulation of Nrf2 through 
siRNA knockdown in murine and human primary cells, and Nrf2 amplification 
studies using Keap-1 siRNA and Nrf2-inducing drugs such as CDDO-Me (Rangasamy 
et al., 2005; Thimmulappa et al., 2006b; Thimmulappa et al., 2007; Yates et al., 
Table 1.4. Cytoprotective and antioxidant proteins encoded by Nrf2-related genes and 
their immunological relevance. 
The immunological evidence is based on findings that use knockout mice and/or knockdown 
siRNA methods to delineate the precise role of the relevant proteins in immune cell 
function. VSIG4 is a member of the B7 protein family functioning as an APC co-inhibitory 
receptor (in a similar way to CTL4-4) involved in the negative regulation of T cell activation. 
APC: antigen-presenting cell; EAE: experimental autoimmune encephalomyelitis; GSH: 
glutathione; H2O: water; H2O2: hydrogen peroxide; IFNβ: interferon-β; IL-: interleukin-; 
MCP-1: monocyte chemotactic protein-1 also known as chemokine (C-C motif) ligand-2 
(CCL2); NADPH: Nicotinamide adenine dinucleotide phosphate; O2: oxygen; RANTES: 
Regulated on Activation, Normal T cell Expressed and Secreted also known as CCL5; ROS: 
reactive oxygen species;  Th: CD4 T helper cell; TNFα: tumour necrosis factor-α; Treg: T 
regulatory cell; VSIG4: V-set and immunoglobulin domain containing 4. Adapted from 
(Copple et al., 2010) 
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2007; Williams et al., 2008; Reddy et al., 2009a; Williamson et al., 2012; Cui et al., 
2013). 
With emphasis on Nrf2 deficient mice, the genetic absence of Nrf2 does not appear 
to affect murine development. However, they do develop complex disease 
manifestations which are similar to that of human autoimmune SLE. This is typified 
by female dominance, multi-organ inflammation, presence of nuclear auto-antigens 
and immune complex deposition in blood vessels and glomerular nephritis (Ma et 
al., 2006). Nrf2 deficiency results in a lowered basal and compromised induction of 
antioxidant genes e.g. HO-1 and GCLC as observed in a variety of immune cells such 
as bone marrow cells (BM) (Merchant et al., 2011) myeloid-derived suppressor cells 
(MDSCs) (Satoh et al., 2010), DCs (Williams et al., 2008), macrophages (Kong et al., 
2010; Kong et al., 2011), neutrophils (Kong et al., 2011) and T cells (Rangasamy et 
al., 2005), and other cell types including hepatocytes (Xu et al., 2008), epithelial 
cells (Reddy et al., 2007b) keratinocytes (Schafer et al., 2010) and mouse embryonic 
fibroblasts (MEFs) (Thimmulappa et al., 2006a).  
Nrf2 has been shown to protect against hyperoxia-induced acute lung injury and 
susceptibility to bacterial infection (Reddy et al., 2009a; Reddy et al., 2009b), diesel 
exhaust particle-induced allergic airway inflammation (Li et al., 2008; Li et al., 
2010b), cigarette smoke-induced increase in severity of viral flu infection and 
associated lung inflammation (Yageta et al., 2011), ovalbumin-induced airway hyper 
responsiveness and pathogenesis of asthma (Rangasamy et al., 2005), cigarette 
smoke-induced emphysema (Sussan et al., 2009), LPS-induced sepsis-associated 
morbidity (Thimmulappa et al., 2006a; Thimmulappa et al., 2006b; Kong et al., 
2010) LPS-induced neuroinflammation (Innamorato et al., 2008) and the onset of 
EAE disease (Johnson et al., 2010).  
Synthetic triterpenoids including 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid 
(CDDO), its imidazolide derivative CDDO-Im and particularly the methyl ester CDDO-
Me (also known as Bardoxolone methyl) have all proven to potently induce the Nrf2 
signalling pathway, resulting in the enhancement of Nrf2 antioxidant genes such 
including NQO1 and HO-1 (Liby et al., 2005; Yates et al., 2007). These triterpenoid 
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derivatives provide an effective tool for investigating the role of Nrf2 in the 
maintenance of oxidative stress. Pre-treatment with CDDO-Im attenuates LPS-
induced proinflammatory cytokine production and ROS generation in human 
PBMCs and neutrophils, respectively (Thimmulappa et al., 2007). Furthermore, 
CDDO-Im reduces cigarette smoke-induced oxidative stress in the lungs of Nrf2+/+ 
but not Nrf2-/- mice, highlighting the Nrf2-dependent mechanism involved in the 
inhibition of oxidative stress in this model (Sussan et al., 2009). Additionally, CDDO-
Me/Bardoloxone treatment reduces the induction of proinflammatory cytokines 
following in vivo LPS challenge in mice, which is associated with improved mortality 
(Auletta et al., 2010). Furthermore, it has been shown to delay acute GVHD through 
suppression of donor T cell expansion after bone marrow transplantation (Li et al., 
2010a).   
Taken together, this suggests in addition to its role in the maintenance of cellular 
redox, Nrf2 is a key negative regulator of inflammation, conferring protection 
against the onset of variety of diseases.   
1.17 The role of Nrf2 in cellular adaptation to xenobiotic incursion 
As stated previously Nrf2 plays a critical role in the detoxification of drugs and 
protection against xenobiotic stress, though the induction of many phase II 
enzymes and in upregulation of glutathione synthesis (Ma and He, 2012). Nrf2 has 
been shown to protect against acetaminophen-induced hepatotoxicity (Enomoto et 
al., 2001; Goldring et al., 2004), cisplatin-induced nephrotoxicity (Aleksunes et al., 
2010) and bleomycin-induced pulmonary fibrosis (Cho et al., 2004; Kikuchi et al., 
2010). This reveals a potential role of Nrf2 in the modulation of adverse drug 
reactions (ADRs). Adverse drug reactions are a significant health problem 
contributing to 6.5% of hospital admissions and resulting in post market drug 
attrition (Pirmohamed et al., 2004). The majority of these ADRs (80%) are 
predictable relating to the pharmacological action of the drug, which are easily 
managed clinically through drug cessation (Edwards and Aronson, 2000). However, 
a proportion of ADRs (20%) are unpredictable and are associated with high 
mortality (Edwards and Aronson, 2000). These idiosyncratic reactions are generally 
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immune-mediated e.g. Sulfamethoxazole-induced eczema (Castrejon et al., 2010). 
Understanding the mechanism behind these off target ADRs is further complicated 
due to inter-individual variation in responses to various drugs ranging from mild to 
severe reactions (Edwards and Aronson, 2000). An important issue to consider is 
whether inter-individual variation in responses to various drugs ranging from Nrf2-
mediated adaptation to severe ADRs could be correlated with variability in the Nrf2 
pathway induction in humans? This requires intense investigation. 
1.18 Role of Nrf2 in human immune-mediated diseases 
Nrf2 has been implicated in a variety of immune-mediated human diseases, 
including chronic obstructive pulmonary disease (COPD) (Malhotra et al., 2008; 
Suzuki et al., 2008), asthma (Fitzpatrick et al., 2011), MS (van Horssen et al., 2010), 
nephritis (Cordova et al., 2010), Helicobacter pylori-induced gastritis (Arisawa et al., 
2007) and ulcerative colitis (Arisawa et al., 2008). Furthermore, it has been 
suggested that Nrf2 dysfunction plays a pivotal role in the immunological decline 
associated with the aging process (Kim et al., 2007; Suzuki et al., 2008). 
Immunosenenescene is associated with chronic levels of oxidative stress resulting 
in immune cell dysfunction, decreased immunosurveillance, and autoimmunity 
(Ponnappan and Ponnappan, 2011).  
1.19 Role of Nrf2 in immune cell function 
It appears clear from the aforementioned evidence presented, that Nrf2 plays key 
roles in cellular physiology and pathology. Its precise role in immune cell function, 
however, is not well established and requires further investigation. Nrf2 has been 
shown to regulate innate immune responses in a murine sepsis model 
(Thimmulappa et al., 2006a). Furthermore, targeted deletion of Keap-1 in murine 
myeloid cells prevented sepsis morbidity (Kong et al., 2011). Nrf2 has been shown 
to regulate macrophage-mediated bacterial clearance and proinflammatory 
cytokine production of IL-6, TNFα in hyperoxia-induced lung injury (Reddy et al., 
2009a). Chemokines e.g. CCL11, CXCL10, CXCL2, which are important innate 
immune cell chemoattractants and mediators of inflammation, are also 
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downregulated by Nrf2 and GSH, further highlighting the vital role of Nrf2 in the 
regulation of the innate immune responses (Reddy et al., 2007b). 
The role of Nrf2 in DC immune function has not been fully elucidated. A study by 
the Biswal laboratory group in which they exposed Nrf2 deficient murine DCs to 
ambient particulate matter (PM), suggested that Nrf2 plays a role in DC maturation 
through regulation of co-stimulatory receptor expression of CD80, CD86 and MHCII 
and DC endocytic function (Williams et al., 2008). Treatment with the antioxidant 
N-acetylcysteine (NAC), which has been shown to replenish GSH levels, resulted in a 
down modulation of co-stimulatory receptor expression in both resting and PM-
activated DCs (Williams et al., 2008). This finding points towards a role of GSH in 
maintaining DC function. Furthermore, Nrf2 is implicated in the regulation DC 
cytokine production and DC-meditated antigen-specific Th1/Th2 differentiation in 
response to oxidative stress (Williams et al., 2008). Although the groundwork has 
been laid out in the role of Nrf2 in particular aspects of DC function many questions 
remain unanswered. How does Nrf2 affect murine DC immune function? Is it 
through GSH regulation? What role does Nrf2 play in DC phagocytic function in 
relation to the uptake of apoptotic and necrotic cells? Does it influence DC antigen 
cross-presentation, DC-mediated antigen-specific CD8 T cell activation, proliferation 
and subsequent effector function? Is Nrf2 implicated in the regulation of DC-
mediated peripheral CD8 T cell tolerance?  
The role of Nrf2 in T cell immune function is also poorly understood. A study by the 
same group depicted a similar role of Nrf2 in regulating Th2 differentiation in an 
ovalbumin (OVA) allergen-driven asthma murine model (Rangasamy et al., 2005). 
Nrf2 deficient OVA-challenged splenic CD4 T cells exhibited enhanced production of 
IL-4 and IL-13 in response to CD3 and CD28 restimulation (Rangasamy et al., 2005). 
Taken together, this illustrates the emerging role of Nrf2 in the maintenance of 
Th1/Th2 balance in response to oxidative stress. Numerous points need to be 
addressed in relation to the role of Nrf2 in T cell immune function. Does Nrf2 play a 
role in T cell development in the thymus and in peripheral lymphoid organs? What 
role does Nrf2 play in naïve and effector T cell activation proliferative capacity? 
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Does it affect T cell polarisation in relation to other CD4 subtypes such as the newly 
identified Th17?   
In line with a previously stated issue that needs to be addressed is the role of Nrf2 
mediated adaptive responses to xenobiotic stress in humans. Does human inter-
individual variation in Nrf2 adaptive responses to xenobiotics underlie another 
mechanism that gives rise to differential responses to drugs ranging from 
adaptation to ADRs? In order to begin answering these complex questions a 
suitable model must first be established to assess inter-individual variation in the 
the Nrf2 pathway in response to a known Nrf2 probe.   
1.20 THESIS AIMS 
The main scope of this thesis is based on testing the hypothesis that Nrf2 regulates 
DC and T cell immune function. We have utilised the Nrf2 deficient mouse as the 
experimental system for exploring the role of Nrf2 in DC and T cell immune cell 
function. This thesis proposes to address the aforementioned questions in relation 
to DC antigen acquisition capacity, presentation and T cell stimulatory capabilities. 
Furthermore it aims to investigate the role of Nrf2 in T cell development, activation 
and T cell polarisation with a concluding focus on the Th17 subtype. The final 
chapter of the thesis is grounded on the hypothesis that inter-individual variation in 
Nrf2 activity in response to a known Nrf2 inducer exists in humans. This chapter 
proposes to investigate variation in the Nrf2 pathway and downstream events in 
human immune cells derived from healthy subjects in response to the chemical 
Nrf2 inducer, CDDO-Me.  
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CHAPTER TWO 
 
METHODS 
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2.1 Materials and Reagents 
Nunclon cell culture flasks and multi-well plates were purchased from Nalge-Nunc 
International [c/o VWR International, Lutterwork, UK]. Microbiological petri dishes 
were purchased from sterilin [Newport, UK].  All chemicals and reagents were of 
analytical grade and purchased from Sigma-Aldrich [Dorset, UK], unless otherwise 
stated. Foetal Bovine Serum (FBS) was purchased from Gibco [Paisley, UK]. 
LymphoprepTM was purchased from Axis-Shield [Kimbolton, UK]. 
2.2 Antibodies 
For murine T cell stimulation, anti-mouse CD3 and CD28 antibodies were purchased 
from eBioscience [Hatfield, UK]. The intracellular fluorescent dye, 
carboxyfluorescein succinimidyl ester (CFSE) and fluorescein (FITC)-dextran [40,000 
MW] were both purchased from Invitrogen [Paisley, UK].  For flow cytometric 
analyses of cell surface molecules, FITC-conjugated anti-mouse CD40 (Clone 3/23), 
FITC-conjugated anti-mouse CD86 (GL1), PE-conjugated anti-mouse I-A/I-E 
(M5/114.15.2), FITC-conjugated anti-mouse CD62L (MEL-14),  FITC-conjugated anti-
mouse CD69 (H1.2F3),  FITC-conjugated anti-mouse CD44 (IM7), APC-conjugated 
anti-human CD3 (UCHT1)  were all purchased from BD Biosciences [Oxford, UK]. 
FITC-conjugated anti-mouse CD4 (RM4-5), PE-conjugated anti-mouse CD4 (RM4-5), 
TC-conjugated anti-mouse CD8 (5H10), PE-Cy®5.5 conjugated anti-mouse CD11c 
(N418), FITC-conjugated Annexin V, Alexafluor®488-conjugated anti-mouse CD25 
(PC61 5.3) were all purchased from Invitrogen [Paisley, UK]. FITC-conjugated anti-
human CD11b (ICRF44) was purchased from eBioscience [Hatfield, UK]. For 
intracellular fluorescence activated cell staining (FACS) staining, FITC-conjugated 
anti-mouse IFNγ (XMG1.2) and PE-conjugated anti-mouse IL-17A (eBio17B7) were 
purchased from BD Biosciences [Oxford, UK] and eBioscience [Hatfield, UK], 
respectively. For western blotting anti-human Nuclear factor-erythroid 2 (NF-E2)–
related factor 2 (Nrf2) antibody (EP1808Y- Carboxyterminal end) and anti-mouse 
beta actin antibody (AC-15) were purchased from Abcam [Cambridge, UK]. The 
HRP-conjugated anti-mouse and anti-rabbit antibodies were purchased from Sigma-
Aldrich [Dorset, UK]. 
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2.3 Peptides and cytokines 
NP68 (366ASNENMDAM374)and NP34 (ASNENMETM) nonameric peptides derived 
from the  virus A/NT/60/68  nucleoprotein used to stimulate F5 specific CD8 T cells, 
were synthesised by Peptide Protein Research Ltd [Fareham, UK]. Recombinant 
human IL-2, IL-1β, TGFβ, IL-6 and recombinant mouse GM-CSF were all purchased 
from PeproTech [London, UK]. Mouse recombinant IL-23 was purchased from R&D 
systems [Abingdon, UK]. 
2.4 Mice 
Black C57BL/6J wild type (Nrf2+/+) and Nrf2 deficient (Nrf2-/-) mice were obtained 
from Riken BRC (Ibaraki, Japan) (Itoh et al., 1997). Nrf2-/- colonies were maintained 
as heterozygous breeders and homozygous offspring were routinely genotyped via 
allele specific polymerase chain reaction (PCR) assays. Mice (C57BL/6) homozygous 
for the H-2Db-restricted TCR-αβ transgene, F5, which specifically recognizes NP68 
and NP34 nonameric peptides, were a kind gift from Dr James Matthews [Cardiff, 
Wales]. All animals were housed under controlled conditions at the Biomedical 
Services Unit, University of Liverpool.  All experiments were undertaken in 
accordance with criteria outlined in licenses granted under the Animals (Scientific 
Procedures) Act of 1986 (PPL 40/2937 and PPL 40/2544) and approved by the 
Animal Ethics Committee of the University of Liverpool. Animals were euthanized 
under schedule 1 carbon dioxide (CO2) induced asphyxiation procedure and femora, 
tibiae, thymi, spleens and lymph nodes (axillary, brachial, inguinal and mesenteric) 
were removed. 
 
2.5 Complete medium  
Complete medium (CM) was composed of the following; Roswell Park Memorial 
Institute-1640 (RPMI-1640) medium, 10 % FBS, 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 µg/ml penicillin- 10,000 U/ml streptomycin, 50 µM 2- 
mercaptoethanol (2-ME) and 2 mM HEPES solution.  
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2.6 Cell lines 
The human leukemic Jurkat T cell line, E6.1 was purchased from American Type 
Culture Collection (ATCC). These cells were utilised for the dendritic cell 
phagocytosis assay (see section 2.15.3). Cells were cultured in CM at a density of 
0.56 cells / ml in nunclon cell culture flasks and media was changed every two days 
until required for functional assays. 
2.7 Generation of Bone Marrow Derived Dendritic cells (BMDCs) 
Bone marrow (BM) cells were flushed from femora and tibiae of Nrf2+/+ and Nrf2-/- 
mice. Cells were washed with Hank's Balanced Salt Solution (HBSS), resuspended in 
CM and viable cells were counted using a haemocytometer and trypan blue 
exclusion. Bone marrow cells at a density of 3 x 106/plate were then cultured in 
microbiological petri dishes containing 10 ml of CM supplemented with 20ng/ml 
GMCSF. Cultures were kept in a fully humidified incubator at 37 °C under 5 % CO2. 
CM was changed on day 3 and differentiated immature dendritic cells (iDCs) were 
used between days 6 or 7 for functional assays.  
2.8 Glutathione assay 
Dendritic cell total glutathione levels (reduced glutathione (GSH) + oxidised 
glutathione (GSSG)) were determined using a microtitre plate assay. In brief, DCs 
were washed with HBSS and resuspended in 400 ml 10 mM HCl. Appropriate 
aliquots were taken to enable the determination of total protein content (Bradford 
assay). To the remaining samples, sulphosalicylic acid was added at a final 
concentration of 1.3% (w/v), and protein precipitation was facilitated by incubating 
on ice for 10 min. Protein was then pelleted by centrifugation at 14000 g for 5 min. 
The supernatant was removed and used to determine total glutathione content 
spectophotometrically at 412 nm using 5,5’-dithio-bis(2-nitrobenzoic acid) (DNTB), 
β-nicotinamide adenine dinucleotide phosphate (NADPH) and GSH reductase, as 
described by (Vandeputte et al., 1994) The results were compared to GSH standards 
(0-50 nMol/ml), and were normalised to protein content using Bradford assay.  
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2.9 Harvesting of thymocytes, splenocytes and lymph node cells 
Isolated thymi, spleens and lymph nodes (inguinal, brachial axillary and mesenteric) 
excised from Nrf2+/+ and Nrf2-/- mice and spleens excised from F5 TCR transgenic 
mice, were homogenised using Jencons Uniform Grade B-24 Tissue Homogeniser 
[Jencons Scientific Ltd., Leighton Buzzard, UK]. Dispersed tissue was then filtered 
through 40 µm gauge Nylon Cell Strainers [BD Falcon, Oxford, UK] and washed with 
HBSS in two consecutive 5 minute washing/centrifugation cycles. Thymocytes and 
lymph nodes were centrifuged at 400 x g and 900 x g, respectively. Splenocytes 
were centrifuged at 300 x g and a red cell lysis step was incorporated between the 
washing cycles to concentrate nucleated white blood cells. Herein, the cell pellet of 
the first wash was treated with red blood cell (RBC) lysis buffer (8.3 g/L ammonium 
chloride in 0.01 M Tris-HCl buffer) for 6 min at RT (25 °C) and quenched using ice 
cold CM. These cells were then filtered before the second washing step. All cell 
pellets were re-suspended in CM after the final wash. Viable cells were counted by 
trypan blue exclusion using a haemocytometer and microscope (Leica DME).  
2.10 Immunomagnetic separation of CD4+ T cells 
Purified CD4 positive Nrf2+/+ and Nrf2-/- T cells were isolated using MACS LS+ 
immunomagnetic separation columns [Miltenyi Biotec, Bisley, UK]. Splenocytes 
were washed and resuspended at a density of in 1 x 106 cells per 90 µl of ice cold 
MACS buffer (HBSS without phenol red supplemented with 2 mM EDTA and 0.5 % 
bovine serum albumin (BSA)). Cells were magnetically labelled using anti-CD4 
conjugated magnetic microbeads [MACS Microbeads, Miltenyi Biotec, Bisley, UK] 10 
µl per 1 x 106 cells, and refrigerated for 15 min. Cells were washed with MACS 
buffer (2ml per 1 x 106 cells), centrifuged at 300 g for 10 min and resuspended in 
500 µl MACS buffer. MACS LS+ Separation Columns were attached to MidiMACS 
magnets and set up on a MidiMACS stand. The columns were washed three times 
with 3 ml of MACS buffer. The magnetically labelled cell suspensions were pipetted 
onto the column. Unlabelled cells run through and were collected as the negative 
fraction whereas labelled cells were retained within the column. A thorough elution 
of the negative fraction was facilitated by washing the columns three times with 3 
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ml of MACS buffer. The columns were then removed from the magnet and flushed 
with 5ml of buffer using a column plunger. The magnetically retained CD4+ cells 
were eluted as the positive fraction with a percentage purity of approximately 90 % 
(data not shown). 
2.11 Immunomagnetic separation of CD11c+ DCs (For ELISA only) 
Purified CD11c positive Nrf2+/+ and Nrf2-/- BMDCs were isolated using MACS LS+ 
immunomagnetic separation columns [MACS Microbeads, Miltenyi Biotec, Bisley, 
UK]. Cells were washed and resuspended at a density of in 1 x 106 cells per 80 µl of 
ice cold MACS Buffer. Cells were magnetically labelled using anti-CD11c conjugated 
magnetic microbeads 20 µl per 1 x 106 cells, and refrigerated for 15 min. Cell 
separation proceeded as above. This procedure yielded positive cell populations of 
approximately 90 % purity (data not shown). 
2.12 Murine Nrf2+/+ and Nrf2-/- effector T cell set up  
For T cell stimulation anti-mouse CD3 (2 µg/ml) and CD28 (2 µg/ml) mAbs were 
immobilized by wet-coating onto a 24 well microtitre plate.  Processed Nrf2+/+ and 
Nrf2-/- CD4 T cells were seeded at a density of 0.5 x 106 per well in CM for 72 h at 37 
°C under 5 % CO2. Cells were then washed twice with HBSS and re-cultured in CM 
supplemented with 100 U/ml IL-2 at a density of 1 x 106 cells/ml for 3-4 days. 
Functional assays were carried out on day 6-7. The initial T cell experiments were 
conducted using non-purified stimulated Nrf2+/+ and Nrf2-/- splenocytes. Purified 
CD4+ T cells were used for experiments requiring Th17 cell polarisation. The Th17 
polarising conditions were created by supplementing the CM with 50 ng/ml IL-1β, 
10 ng/ml IL-23, 5 ng/ml TGFβ and 25 ng/ml of IL-6 (Mangan et al., 2006; Veldhoen 
et al., 2009).  
2.13 Dendritic cell-mediated F5 antigen-specific T cell proliferation assay 
Immature DCs derived from Nrf2+/+ and Nrf2-/- mice were pulsed with increasing 
concentrations of antigenic peptide NP68 or partial agonist NP34 for 2 h at 37 °C. 
Harvested F5 transgenic murine splenic T cells were added to a 96 well U-bottom 
microtitre plate (1 x 105 cells per well). Murine F5 CD8 T cells specifically recognise 
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the NP68 antigenic peptide or NP34 presented by the C57BL/6J BMDCs on the 
mouse MHC Class I molecule H-2Db. The pre-pulsed iDCs  were washed with HBSS 
and co-cultured (5,000 BMDC per well) with the F5 CD8 T cells in quadruplicate at 
37 °C for 18 h. Murine T cell mitogen Concanavalin-A (CON-A, 4 µg/ml) was used as 
a positive control. Tritiated-thymidine [Moravek Biochemicals, Brea, CA, U.S.A] (0.5 
µCi per well) was added to the wells for the last 16 h of culture. Cells were 
harvested onto glass-fibre filter mats using a plate harvester [TomTec Mach III, 
Hamden, CT, USA] and counted in the scintillation counter [Microbeta Trilux, Perkin 
Elmer, Waltham, MA, USA] after 72 h of incubation. 
2.14 Cross presentation assay 
Immature DCs derived from Nrf2+/+ and Nrf2-/- mice were added to 24 well plates at 
a density of 2 x 106 cells per well. Cells were allowed to adhere for 2 h at 37 °C and 1 
µg/ml of LPS was added during the final 30 min of adherence to induce DC 
maturation. Cells were washed twice with warm CM in preparation for addition of 
necrotic C57BL/6J splenocytes. Harvested murine C57BL/6J splenocytes were 
pulsed with or without NP68 (200μM) for 2 h at 37 °C. Unbound NP68 peptide was 
removed by extensive washing with HBSS. Necrosis was induced by snap freezing in 
liquid nitrogen. Necrotic cells were then co-cultured with adherent DCs at a ratio of 
2:1 and incubated at 37 °C under 5 % CO2 for 24h. Cells were then washed and co-
cultured in quadruplicate with splenic F5 CD8 T cells (1 x 105 cells/well) at increasing 
DC:T cell ratios (1:1000 – 1:2) in 96-well U-bottom microtitre plates. Splenic T cell 
proliferation was measured as above. 
2.15 Fluorescence activated cell staining   
All protocols in this section were performed using flow cytometric analyses. All cells 
were acquired on a BD FACSCanto II flow cytometer [BD Biosciences, Oxford, UK] 
and the post acquisition analysis of flow cytometry data (FCS) files was done using 
Cyflogic version 1.2.1 software (CyFlo Ltd). 
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2.15.1 Cell surface receptor expression 
For DC phenotyping, cells were scraped from petri dishes and washed in HBSS, 
counted and dispensed into FACS tubes at a density of 1 x 106 cells/tube. Cells were 
washed with stain buffer (sheath fluid [BD Biosciences, Oxford, UK] supplemented 
with 2 % FBS and 2 mM EDTA). Cells were then resuspended in 50 µl stain buffer 
and incubated in the dark at 4 °C for 10 min. Appropriate amounts of CD40FITC, 
CD86FITC and I-A/I-EPE in combination with CD11cPE-Cy®5.5 were dispensed to each 
tube in 50 µl stain buffer and tubes incubated for 30 min in the dark at 4 °C. After 
incubation, cells were washed twice with 4ml sheath fluid and resuspended in 700 
µl sheath fluid prior to analyses via flow cytometry. 
For splenic, thymic and lymph node T cell phenotyping, cells were processed and 
dispensed into FACS tubes at a density of 1 x 106 cells/tube. Cell surface staining 
was performed as above using combination of CD4PE, CD8TC and CD25FITC 
antibodies. Splenic T cell activation status was also assessed using CD62LFITC, 
CD69FITC and CD44FITC antibodies in combination with CD4PE and CD8TC. 
2.15.2 Dendritic cell endocytosis assay 
Endocytic ability of Nrf2+/+ and Nrf2-/- iDCs was determined using DextranFITC as 
previously described (Sallusto et al., 1995). Harvested iDCs were resuspended at a 
density of 1 x 106 cells in 100 µl CM and incubated with 0.5 µg/ml DextranFITC 
(40,000 MW) for 60 min at 37 °C or 4 °C (as negative control). Cells were washed 
twice in stain buffer, cell surface staining for CD11cPE-Cy®5.5 was performed as above 
and analysed via flow cytometry.  
2.15.3 Dendritic cell phagocytosis assays 
Nrf2+/+ and Nrf2-/- iDCs were scraped from petri dishes, washed in HBSS, counted 
and plated out into 24 well plates at a density of 2 x 106 cells per well. Cells were 
allowed to adhere for 2 h at 37 °C. Cells were washed twice with warm CM in 
preparation for addition of apoptotic or necrotic cells.  
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To assess phagocytosis of apoptotic cells, processed thymocytes derived from 
C57BL/6J mice were incubated with 1 µM dexamethasone at 37 °C under 5 % CO2 
for 18 h. Dexamethasone induces apoptosis in murine thymocytes (Cifone et al., 
1999). The proportion of apoptotic thymocytes was determined by staining with 
FITC Annexin V. Over 90% of thymocytes stained positive for Annexin V (as 
illustrated in Figure 3.4). Apoptotic thymocytes were labelled with CFSE (2 μM) for 
20 min at 37 °C in the dark. Cells were washed with media to remove non-
incorporated dye and then co-cultured with adherent iDCs at a ratio of 2:1 for 2 h at 
37 °C.  
To assess the phagocytosis of necrotic cells, Jurkat T cells were fluorescently 
labelled with 0.5 μM CFSE for 30 min at 37 °C in the dark and necrosis was induced 
via snap freeze in liquid nitrogen. More than 90 % of cells became necrotic as 
determined by trypan blue exclusion (data not shown). Necrotic cells were co-
cultured with DCs as above. 
Cells were then harvested, washed with stain buffer and stained with CD11cPE-Cy®5.5 
prior to analysis by flow cytometry. 
2.15.4 Annexin V assay 
The extent of apoptosis on dexamethasone-treated thymocytes was determined 
using the FITC Annexin V Apoptosis Detection Kit [BD Biosciences, Oxford, UK] 
according to the manufacturer’s instructions. One of the early events in apoptosis is 
the inversion of the cell’s phospholipid bilayer resulting in the exposure of 
phosphatidylserine molecules. These molecules are readily detected by Annexin V 
antibody (Fadok et al., 1992). Briefly, dexamethasone-treated C57BL/6J thymocytes 
(1 x 106 cells per FACS tube) were washed with 1X binding buffer, centrifuged and 
resuspended in 100 µl of 1X binding buffer. Cells were gently vortexed and 
incubated with Annexin VFITC antibody for 15 min at RT in the dark. Cells were then 
washed with 1X binding buffer, centrifuged, resuspended in binding buffer and 
analysed via flow cytometry.  
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2.15.5 Interferon-γ intracellular staining for DC mediated re-stimulation of F5 CD8 
T cells 
Immature DCs derived from Nrf2+/+ and Nrf2-/- mice were scraped from petri dishes, 
washed in HBSS and counted. Immature DCs were pulsed with or without NP68 (1 x 
10-7 M) for 2 h at 37 °C. Cell were then extensively washed to remove unbound 
NP68 and plated out in a 6 well plate (300,000 DCs per well). Cells were allowed to 
adhere for 2 h at 37 °C. Processed F5 CD8 T cells were co-cultured with the 
adherent iDCs at a density of 7 x 106 cells per well for 72h at 37 °C under 5 % CO2. 
These F5 CD8 T cells were then re-stimulated in 24 well plate with mature Nrf2+/+ 
DCs (treated with 1 µg/ml LPS overnight) which were either pulsed or unpulsed 
with NP68 (1 x 10-7 M). This co-culture was at a density of 1 x 106 F5 CD8 T cells and 
50,000 Nrf2+/+ mDCs per well. Cells were co-cultured for 6 h in total. Golgi plug 
inhibitor Brefeldin A (contained within Cytofix/Cytoperm kit as stated below) was 
added 1 hour after start of culture to allow intracellular cytokine accumulation. 
Cells were then stained with CD8TC antibody as per 2.15.1 method. Intracellular 
cytokine staining for IFNγ was achieved using the BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Solution Kit with BD GolgiPlug™ [BD Biosciences, Oxford, 
UK] according to manufacturer’s instructions. After cell surface staining, cells were 
washed with stain buffer and fixed & permeabilised in one step using 1x BD 
Cytofix/Cytoperm solution for 20 min at 4 °C in the dark. Cells were washed twice 
with 1x BD Perm/Wash™ buffer and incubated with IFNγFITC plus 1x BD 
Perm/Wash™ buffer for 30 min at 4 °C in the dark, followed by two final washes 
with 1x BD Perm/Wash™ buffer and resuspended in 2-4% paraformaldehyde (PFA).  
Flow cytometric analysis was performed the following day 
2.15.6 Effector T cell IFNγ intracellular staining 
Day 6 Nrf2+/+ and Nrf2-/- effector T cells were re-stimulated in 24 well plate at a 
density of a density of 1 x 106 T cells per well with plate bound anti-mouse CD3 (2 
µg/ml) and CD28 (2 µg/ml) antibodies for 6 h. Unstimulated cells were used as a 
background control. Golgi plug inhibitor Brefeldin A (contained within 
Cytofix/Cytoperm kit as stated above) was added 1 hour after start of culture to 
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allow intracellular cytokine accumulation. Cells were then stained with CD8TC 
antibody as per 2.15.1 method. IFNγ intracellular staining was performed as above. 
2.15.7 Effector T cell IL-17A/IFNγ intracellular staining 
Day 6 Nrf2+/+ and Nrf2-/- effector CD4+ T cells were re-stimulated in a 24 well plate 
at a density of 1 x 106  T cells per well either under non-polarizing or Th17 polarizing 
conditions with 50 ng/ml PMA, 1 µg/ml ionomycin and plate bound anti-mouse CD3 
(2 µg/ml). Cells that were left without stimulation were used as background control. 
Golgi plug inhibitor Brefeldin A (contained within Cytofix/Cytoperm kit as stated 
above) was added 1 hour after start of culture to allow intracellular cytokine 
accumulation. Cells were then stained with CD4R-PE antibody as per 2.15.1 method. 
Interferon-γ intracellular staining was performed as above with addition of IL-
17APerCp-Cy5.5 antibody. 
2.15.8 Measurement of reactive oxygen species  
Processed Nrf2+/+ and Nrf2-/- splenocytes were washed with HBSS and resuspended 
in serum-free RPMI 1640. Subsequently, cells (5x 105 cells/ tube) were treated with 
or without H2O2 for 10 minutes, washed and resuspended in HBSS without phenol 
red. The ROS indicator dihydroethidium (DHE) (10 µM) was then added to the 
appropriate tubes and incubated at 37°C for 10 minutes. Dihydroethidium is a 
colourless substance that can freely diffuse across the cell membrane. Upon 
oxidation with intracellular superoxide radials specifically, DHE forms into an 
oxidised red fluorescent product which is easily detected by for flow cytometric 
analysis (Burnaugh et al., 2007). Immediately after DHE incubation, cells were 
analysed on a flow cytometer.  
2.16 Antibody stimulated T cell proliferation assay 
Tissue culture 96 well plate was treated with increasing equivalent concentrations 
of anti-mouse CD3 and CD28 antibodies (0-1 µg/ml) in 50 µl HBSS for 2 h at 37 °C to 
allow for antibody binding. Non-plate bound antibody was washed off with HBSS in 
preparation for T cell treatment. Processed Nrf2+/+ and Nrf2-/- T cells were 
dispensed onto the plate bound antibody treated plate (50,000 T cells per well) in 
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CM and incubated for 72 h at 37 °C under 5 % CO2. CON-A (4 µg/ml) was used as a 
positive control. Tritiated-thymidine (0.5 µCi per well) was added to the wells for 
the last 16h of culture. Cells were harvested onto glass fibre filter mats using and 
counted in the scintillation counter after 72h of incubation. 
2.17 Dendritic cell Enzyme-linked immunosorbent assay (ELISA) sample 
preparation 
Day 6 Purified CD11c+  Nrf2+/+ and Nrf2-/- DCs were plated in 2 ml CM supplemented 
with 3 % GMCSF at 0.8 x 106 cells/ml on a 24 well plate. 1 µg/ml LPS were added to 
appropriate wells to induce DC maturation. Cells were incubated at 37 °C under 5 % 
CO2 for 24 h. Cells were then spun down at 900 x g for 5 min and sample 
supernatants were stored at -80 °C in preparation for enzyme-linked 
immunosorbent assay (ELISA). 
2.18 Murine T cell ELISA sample preparation 
Day 6 effector Nrf2+/+ and Nrf2-/- DCs T cells were re-stimulated with plate bound 
anti-mouse 2 µg/ml CD3 and 1 µg/ml CD28 antibodies in a 24 well plate (1 x 106 
cells/ml) in CM supplemented with 100 U/ml IL-2. Cells were incubated at 37 °C 
under 5 % CO2 for 24 h. Cells were pelleted at 700 x g for 5 min and sample 
supernatants were stored at -80 °C in preparation for ELISA. 
2.19 Measurement of cytokine production by ELISA. 
The levels of murine IL-12p70, IL-2, IFNγ, IL-13 and TNFα were measured using 
mouse IL-12p70, IL-2, IFNγ, IL-13 and TNFα Quantikine ELISA kits, respectively [R&D 
systems, Abingdon, UK]. The levels of murine IL-17A, IL-5 and IL-22 were measured 
using mouse IL-17A, IL-5 and IL-22 ELISA Ready-SET-Go kits, respectively. All 
experiments were performed through strict adherence to manufacturer’s 
instructions. To briefly explain the procedure for the Ready-SET-Go sandwich 
immunoassays, a 96-well ELISA plate was initially coated with the relevant capture 
antibody in coating buffer (provided in kit) and incubated at 4 °C overnight.  The 
following day, the plate was washed three time with ELISA wash buffer (0.5 % 
TWEEN in 1 x PBS) and tapped dried to remove the remaining wash buffer from the 
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wells. This was followed by two hour incubation with blocking buffer (provided in 
kit) at RT. The plate was then washed as described earlier. Relevant standards were 
added by serial dilution to the designated wells and finally 50 μL of supernatant was 
added to the appropriate wells and incubated for 2 h at RT. The plate was then 
washed thoroughly as before and incubated with detection antibody for 1 hour. 
This was followed by careful washing cycles and incubation with the enzyme 
concentrate; avidin-HRP in the dark for 20 min. The plate was again washed six 
times and incubated in the dark for 20 min with 100 μL of TMB substrate. This 
reaction was quenched by the addition of 100 μL of 1M H2SO4. The OD (Optical 
Density) was then measured using a spectrophotometer [Varioskan, Thermo 
scientific Hudson, NH, USA] at 450 nm. Based on the raw OD450 data obtained, a 
standard curve was plotted and the concentrations of each cytokine were then 
calculated. The above method is relatively similar for the Quantikine ELISAs, 
however, kits were supplied with ELISA plates that were pre-coated with the 
relevant capture antibodies and all reagents required for the immunoassays were 
included in the kits.  
2.20 Isolation of human Peripheral blood mononuclear cells (PBMCs) 
Blood was taken from 15 healthy donors (age range 20-35; 7 male and 8 female) 
after signed informed consent. This was approved by the Local Research Ethics 
Committee. Human PBMCs were isolated from 50ml of heparinised venous whole 
blood using LymphoprepTM (density of 1.077 g/ml, 9.1 % (w/v) sodium diatrizoate 
and 5.7 % (w/v) polysaccharide) density gradient centrifugation. Cells of lower 
density such as PBMCs form a distinct band above the LymphoprepTM layer. In 
contrast, RBCs and granulocytes which have a higher density collect at the bottom 
of the LymphoprepTM layer. In brief, the heparinised blood was gently layered onto 
an equal volume of LymphoprepTM. The blood was then centrifuged at 700 g 
without brakes for 25min at RT. The PBMC layer above the LymphoprepTM was 
gently aspirated and washed three times with HBSS. Cells were then resuspended in 
CM and viable cells were counted by trypan blue exclusion using a haemocytometer 
and microscope. 
63 
 
2.21 Human T cell activation 
Isolated human PBMCs were activated with the human T cell mitogen 
phytohaemagglutinin (PHA, 2.5 μg/ml) in CM supplemented with 360 U/ml IL-2 at a 
density of 2 x 106 cells per ml in a culture flask. Human T cells were allowed to 
expand for 72h at 37 °C under 5 % CO2. Cells were then washed twice with HBSS and 
returned to culture with CM supplemented with 100 U/ml IL-2 for a further 48 h. T 
cell purity was determined by human CD3APC cell surface staining and flow 
cytometric analysis. This procedure yielded CD3 positive cell populations of 85% 
and above (represented in Figure 5.1A). Human T cells were used on day 5 for 
functional assays. 
2.22 Detergent lysis of human cells 
Day 5 stimulated human T cells and fresh human neutrophils were harvested and 
resuspended in serum-free RPMI 1640. Cells (5 x 106) were treated with increasing 
concentrations of CDDO-Me (0-100 nM) for 2 h at 37 °C. Cells were then 
centrifuged and lysed in 500 µL 1x radio-immunoprecipitation assay (RIPA) buffer 
(150 mM NaCl, 1.0 % IGEPAL® CA-630, 0.5 % sodium deoxycholate, 0.1 % SDS, 50 
mM Tris, pH 8.0) plus protease inhibitors (10 μg/ml Aprotinin, 10 μg/ml Leupeptin 
and 10 μg/ml Pepstatin A) for 30 min on ice. Cells were then centrifuged at 16000 x 
g for 10 min at 4 °C. Supernatants were the removed and stored at -80 °C for future 
use.   
2.23 Nuclear extraction of human T cells 
Day 5 stimulated human T cells were harvested, washed twice with HBSS and 
resuspended in serum-free RPMI 1640.  8 x 106 T cells were dispensed into 
eppendorfs and treated with increasing concentrations of CDDO-Me (0-100nM) to 
induce Nrf2 activation for 2 h at 37°C. The proteasome inhibitor MG132 (100 nM) 
which prevents Nrf2 proteasomal degradation resulting in enhanced nuclear Nrf2 
accumulation (McMahon et al., 2003) was used as a positive control for Nrf2 
induction. Nuclear Lysates were achieved using NE-PER nuclear and cytoplasmic 
extraction kit [Fischer Scientific, Loughborough, UK] via strict adherence to 
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manufacturer’s instructions. Briefly, 8 x 106 CDDO-Me treated T cells were 
centrifuged, supernatant was removed and pellets resuspended in 100 μL 
Cytoplasmic extraction reagent I (CER I) plus protease inhibitors. Cells were left on 
ice for 10 min after which 5.5 μL CER II was added to each eppendorf, vortexed and 
left on ice for a further 1 min. Samples were then spun at 16,000 g at 4°C for 5min 
and the supernatant containing cytoplasmic fractions were removed and stored at -
80°C for future use. The remaining pellets were resuspended in 50 μL Nuclear 
extraction reagent (NER) and left on ice for 45min with intermittent vortexing every 
15 min. Cells were then spun at 16,000 g at 4°C for 10min and the supernatant 
containing nuclear fractions was carefully removed and stored at -80°C for future 
use. 
2.24 Protein content determination via Bradford assay 
Whole cell lysates, nuclear extract from cell samples and HCl treated cells were 
generated as required for each experimental protocol. The total protein content of 
samples was determined using Protein Assay Dye Reagent [Bio-rad; Hemel 
Hempstead, UK] according to the manufacturer’s instructions. This assay relies on 
the binding of Coomassie Brilliant Blue G-250 dye to basic and aromatic amino 
acids, resulting in a change in colour of the dye (red to blue) (Bradford and Ward, 
1976). This change in the dye colour is proportional to the amount of bound dye 
and can be measured in the absorbance at 570 nm with a MRX plate reader [Dynex; 
Lincoln, UK]. Total protein content of samples was calculated from the absorbance 
values of a 0.25-5 μg BSA standard curve prepared for each assay. 
2.25 Western blotting: Human Nrf2 protein expression 
Whole cell lysates and nuclear extracts (20µg as determined by the Bradford assay) 
were denatured via the addition of 5μL loading buffer (70 % (v/v) NuPAGE sample 
loading buffer, 30 % (v/v) NuPAGE reducing agent) and incubated at 80 °C for 5 min. 
Denatured samples were loaded onto pre cast 15 lane NuPAGE® 4-12% Bis Tris gels 
[Life Tecnologies, Paisley, UK] alongside PrecisionPlus protein Kaleidoscope 
standards. Samples were resolved by electrophoresis in a X Cell Surelock mini-cell 
using a 3-(N-morpholino) propanesulphonic acid (MOPS) running buffer (50 mM 
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MOPS, 50 mM Tris base, 3.5 mM sodium dodecyl sulphate, 1 mM EDTA, 0.25 % 
(v/v) NuPAGE antioxidant), at 90 V for 10 min, followed by 80 min at 170 V. 
Resolved proteins were transferred onto nitrocellulose membrane [GE Healthcare 
Life Sciences, Buckinghamshire, UK] at 200mA for 90min with ice. Subsequently, 
nitrocellulose membranes were stained with Ponceau S solution to allow visibility of 
resolved proteins. Membranes were then cut along the 50 kDa marker and blocked 
overnight in a covered container at 4 °C in blocking buffer consisting of Tris-
buffered saline (TBS)-Tween (TBST) solution ((TBS; 0.15 M NaCl, 25 mM Tris base, 3 
mM KCl, pH 7.0) with 0.1 % (v/v) Tween 20) containing 10 % non-fat milk powder. 
For Nrf2 expression, membranes were treated with primary anti-human Nrf2 
antibody at a concentration of 1:400 in TBST containing 2 % non-fat milk powder for 
3 h. For actin expression, membranes were treated with primary anti-mouse beta-
actin antibody at concentration of 1:40,000 in TBST containing 2 % non-fat milk 
powder for 30 min. Membranes were then washed 4 times with TBST for 15 min 
intervals. Membranes were then treated with anti-rabbit (for Nrf2) and anti-mouse 
(for actin) secondary antibodies for 1 hour at 1:10,000 in TBST containing 2 % non-
fat milk powder and washed as before. Finally, immunoblots were visualised using 
Western Lightning® Plus–ECL, Enhanced Chemiluminescence Substrate reagents 
[Perkin Elmer, Bukinghamshire, UK] and exposed to Hyperfilm ECL [GE healthcare 
Life Sciences, Buckinghamshire UK] under darkroom conditions, using a Kodak 
BioMax MS intensifying screen. Blots were developed using Kodak developer and 
fixer solutions. 
Films were scanned using a GS-710 calibrated imaging densitometer [Bio-rad; 
Hemel Hempstead, UK], immunoreactive band volumes were quantified using 
TotalLab 100 software [Total lab Ltd; Garth heads, Newcastle upon Tyne, UK], in 
accordance with the manufacturer’s instructions, and normalised to β-actin. 
2.26 Sample preparation for RNA extraction 
Day 5 human stimulated T cells were harvested, washed twice with HBSS and 
resuspended in CM supplemented with 100 U/ml IL-2. Cells were plated out at 2 x 
106 cells per well in a 24 well plate and treated with 50 nM CDDO-Me over a 0-24 
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hour time course. Subsequently, cells were washed twice with HBSS and pellets 
were lysed in 600 µl RLT buffer [Qiagen, UK] containing 1 % 2-ME and stored at -
80°C for RNA extraction.  
2.27 Ribonucleic acid extraction 
Total Ribonucleic acid (RNA) was isolated from CDDO-Me stimulated human T cell 
lysates using the RNeasy Mini kit [Qiagen, UK] according to manufacturer’s 
instructions.  All surfaces and equipment were rendered RNase-free, by wiping with 
RNasezap, prior to the isolation of RNA. Deoxyribonucleic acid (DNA) was digested 
during the RNA purification process using DNase derived from the RNase-free 
DNase set [Qiagen, UK]. Briefly, lysates were spun at maximum speed, transferred 
to RNAse free microcentrifuge tubes and mixed with 1 volume of 70 % ethanol. The 
mixture was then transferred onto the spin columns and centrifuged for 15 seconds 
at 8000 x g. High salt concentration and ethanol containing buffers were 
sequentially added to the columns followed by centrifugation. Finally, RNA was 
eluted from the membrane via centrifugation using 30 µl RNase free water. The 
concentration and purity of each RNA sample was assessed spectrophotometrically 
using a NanoDrop ND-1000 [Thermo Scientific, UK]. The purity of RNA in each 
sample was determined via reference to the 260/280 nm ratio, as protein is 
detected at 280 nm. RNA samples with a 260/280nm ratio of below 2 were rejected 
as impure. RNA was stored at -80 °C until required. 
 
2.28 Complementary DNA synthesis 
Ribonucleic acid was reverse-transcribed to complementary DNA (cDNA) using the 
ImPromptII reverse transcription system [Promega, Southampton, UK] according to 
manufacturer’s instructions. Reactions (20 μL) containing 1 μg RNA, 0.5 µg random 
primer and nuclease free water were heated at 70°C for 5 min and rapidly cooled 
on ice. 20 μL of reverse transcriptase reaction stock solution (2.5 % 5X reaction 
buffer, 8 mM MgCl2, 0.5 mM deoxyribonucleotide triphosphate (dNTP), 1 % reverse 
transcriptase, nuclease free water) was added to each sample immediately after 
and heated at 25 °C for 5 min, followed by 42 °C for 60 min and 70 °C for 15 min. 
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Samples were then rapidly cooled on ice and 80 μL nuclease free water added to 
each tube. Samples were stored at -80 °C until required. 
2.29 Real-time PCR  
Complementary DNA (1.5 μL, approximately 0.1 μg) was combined with 10 μL of 2X 
SYBR green jumpstart TaqMan ready mix (includes the intercalating fluorescent dye 
SYBR green that binds to double stranded DNA)  [Sigma, UK], 2 µl of forward and 
reverse primers for human NAD(P)H:quinine oxidoreductase 1  (NQO1) (forward 
sequence 5’-TCCAGTTCCCCCTGCAGTGGT-3’ and reverse sequence 5’-
CCGTGGATCCCTTGCAGAGAGT-3’) or the housekeeping gene Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (forward sequence 5’- 
CAAGGTCATCCATGACAACTTTG-3’ and reverse sequence 5’- 
GGGCCDTCCACAGTCTTCTG-3’) and 5.5 μL DNase/RNase free water in a clear 96-
well PCR microplate plate [Greiner Bio-One Ltd, Stonehouse, UK]. Plates were 
sealed with Absolute QPCR seals, using an adhesive seal applicator, and briefly 
centrifuged at 900 x g to remove air bubbles. Gene expression was analysed by 
quantitative real-time PCR on an ABI PRISM 7000 Sequence Detection System, in 
accordance with the manufacturer’s instructions. Levels of NQO1 gene expression 
were calculated via reference to their cross threshold (CT) values and normalised to 
GAPDH. 
 
2.30 Statistical analysis 
Where appropriate, experiments were performed in triplicate, and all experiments 
were replicated on separate occasions. Depending on the results set, data are 
expressed as either mean ± standard deviation of the mean (SD) or  mean ± 
standard error of the mean (SEM). One-way analysis of variance (ANOVA), with 
Tukey’s post-test applied, the unpaired Student’s t test or the Mann-Whitney U test 
were used to assess the significance of any differences in the data compared to 
appropriate controls. A two-sided P value of ≤ 0.05 was considered to be 
statistically significant. 
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CHAPTER THREE 
 
THE ROLE OF NRF2 IN DENDRITIC CELL IMMUNE 
FUNCTION 
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3.1 INTRODUCTION 
Maintenance of the DC intracellular redox status is imperative for the execution of 
appropriate DC immune function (Chan et al., 2006). Cellular redox disequilibrium 
involving oxidative stress is known to induce DC maturation and alter DC cytokine 
production, further influencing the nature of the adaptive immune response 
elicited (Kantengwa et al., 2003; Ohtani et al., 2005; Chan et al., 2006). The 
powerful antioxidant GSH plays a crucial role in the nullification of oxidative stress. 
It is therefore implicated in the regulation of DC redox homeostasis (Kim et al., 
2007). Glutathione biosynthesis is governed by the transcriptional activity of Nrf2 
(Copple, 2012). The redox sensitive transcription factor Nrf2 is responsible for the 
induction of an array of cytoprotective and anti-oxidant defence genes e.g. GCLC 
and NQO1 in response to oxidative and electrophilic insult, thus plays an important 
role in regulating cellular redox homeostasis (Copple, 2012). Within DCs, Nrf2 
regulates co-stimulatory receptor expression and DC-mediated Th1/Th2 
polarisation (Williams et al., 2008; Rangasamy et al., 2010). However, its precise 
role in DC immune function has not been fully elucidated and requires intense 
investigation. It is unknown whether Nrf2 plays a role in regulating the capacity of 
DC antigen acquisition or whether the effect of Nrf2 on DC phenotype and function 
is attributable to their basal GSH content. Furthermore, the role of Nrf2 in DC-
mediated antigen-specific CD8 T cell activation and subsequent effector function 
has yet to be established. The hypothesis of the work described in this chapter is 
that Nrf2 regulates DC immune function. Using the Nrf2 deficient mouse model as a 
means by which to test this hypothesis, the following phenotypic and functional 
parameters were investigated: role of Nrf2 and DC GSH content on DC co-
stimulatory receptor expression, antigen acquisition and DC-mediated CD8 T cell 
stimulatory capacity. Furthermore, the influence of Nrf2 on the ability of DCs to 
cross-present cell associated antigens to naïve CD8 T cells and its role in activated 
DC cytokine secretion were also examined. 
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3.2 RESULTS 
3.2.1 Loss of Nrf2 results in lowered basal GSH content in immature DCs 
The redox sensitive transcription factor Nrf2 is a key player in the regulation of GSH 
biosynthesis in response to oxidative insult (Reddy et al., 2007b). It is recognised 
that loss of Nrf2 results in the inhibition of the basal and inducible expression of 
genes necessary for GSH synthesis including the GCL rate limiting enzyme subunits 
GCLm and GCLc (Reddy et al., 2007b; Williams et al., 2008). Although it has been 
established that Nrf2 deficient mice exhibit diminished GSH levels in a variety of cell 
types including hepatocytes (Toyama et al., 2011), mouse embryonic fibroblasts 
(MEFs) (Harvey et al., 2009), lung epithelial cells (Reddy et al., 2007a), thymocytes 
(Morito et al., 2003) and macrophages (Kong et al., 2010), it has not been assessed 
in DCs. Accordingly, we hypothesised that loss of Nrf2 in DCs would result in 
lowered GSH levels and thus examined total reduced GSH content in Nrf2+/+ and 
Nrf2-/- iDCs. Results revealed that Nrf2-/- bone marrow-derived iDCs exhibited a 
significant decrease in GSH levels in relation to their wild type counterpart as 
illustrated in Figure 3.1 (Nrf2+/+ 36.6 ± 11.5 nmol/mg versus Nrf2-/- 24.4 ± 7.8 
nmol/mg, p < 0.05), thus highlighting the pivotal role of Nrf2 in the maintenance of 
GSH content and potentially redox homeostasis within DCs.  
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  3.2.2 Enhanced co-stimulatory expression in Nrf2 deficient DCs is not a direct 
consequence of reduced GSH levels 
It is known that DC intracellular redox influences DC maturation events through the 
regulation of DC co-stimulatory molecule expression (Kantengwa et al., 2003; 
Matsue et al., 2003). Previous studies have illustrated a role of intracellular GSH 
levels in governing DC co-stimulatory expression (Verhasselt et al., 1999; Mizuashi 
et al., 2005; Kim et al., 2007; Williams et al., 2008). Furthermore, it has been 
established that Nrf2 deficient iDCs exhibit enhanced co-stimulatory receptor 
expression of CD86 and MHCII (Williams et al., 2008). We have illustrated that loss 
of Nrf2 results in reduced intracellular GSH levels. However, it is unknown whether 
the changes in co-stimulatory receptor expression observed in the Nrf2 deficient 
iDCs are simply attributable to the observed lowered GSH content or rather due to 
an Nrf2 deficient cell intrinsic effect. Initially, we attempted to reaffirm the findings 
presented in the aforementioned study concluding that loss of Nrf2 mediates 
enhanced co-stimulatory receptor expression in iDCs (Williams et al., 2008). 
Immature DCs are composed of subpopulations that express low or high levels of 
co-stimulatory molecules (Figure 3.2Ai). We focussed our flow cytometric analysis 
on Nrf2+/+ and Nrf2-/- iDCs expressing high levels of co-stimulatory molecules (Figure 
Figure 3.1 Loss of Nrf2 results in attenuation of basal GSH content in immature DCs. 
Basal GSH levels were measured in resting bone marrow-derived dendritic cells generated 
from Nrf2+/+ and Nrf2-/- mice. Total amount of GSH was normalised to total protein 
content. Error bars represent S.E.M. Statistical significance was tested by unpaired 
Student’s t test. Data is derived from 3 independent experiments (*, p < 0.05).  
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3.2Ai, highlighted underneath markers) as changes in these subpopulations would 
highly influence the DC maturation status and their subsequent immune function. 
Results confirmed that Nrf2-/- iDCs exhibited a near 3 fold increase in MHCII (Nrf2+/+ 
10.5 ± 1.6% versus Nrf2-/- 30.5 ± 2.1%, p = 0.0003) and more than 2 fold increase in 
CD86 (Nrf2+/+ 12.5 ± 0.6% versus Nrf2-/- 29.8 ± 1.3%, < 0.0001) expression in 
comparison to the wild type control as quantified in Figure 3.2Aii. In contrast to the 
previous report, we also observed a significant increase in Nrf2-/- iDC CD40 
expression (Nrf2+/+ 11.8 ± 0.5% versus Nrf2-/- 26.5 ± 0.5%, p < 0.0001). Our results 
therefore confirm that loss of Nrf2 augments co-stimulatory expression in iDCs. 
Next we investigated the impact of altered GSH levels on iDC co-stimulatory 
receptor function. We hypothesised that lowering GSH levels in Nrf2+/+ iDCs would 
recapitulate the enhanced maturation phenotype exhibited in the Nrf2 iDCs. To 
address this, Nrf2+/+ iDCs were treated with buthionine sulfoximine (BSO) and 
intracellular GSH levels were evaluated. Buthionine sulfoximine is a potent inhibitor 
of the GCLc enzyme (Griffith and Meister, 1979) and has previously been shown to 
pharmacologically deplete GSH levels in human DCs (Kamide et al., 2011). Results 
illustrated that BSO significantly reduced GSH intracellular levels in Nrf2+/+ iDCs 
when compared to the untreated control (Figure 3.2B, Nrf2+/+ 20.4 ± 2.1 nmol/mg 
versus BSO 24hr 5.1 ± 1.6 nmol/mg, p < 0.05). Further examination of MHCII, CD86 
and CD40 expression in BSO-treated and untreated Nrf2+/+ iDCs revealed no 
detectable changes in co-stimulatory receptor expression between both groups as 
depicted as overlay histograms in Figure 3.2C. Taken together, our findings suggest 
that the enhanced maturation phenotype exhibited in the Nrf2 deficient iDCs is not 
a direct consequence of reduced GSH content. 
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Figure 3.2 Loss of Nrf2 results in a GSH-independent increase in co-stimulatory receptor 
expression in iDCs. Immature Nrf2+/+ and Nrf2-/- iDCs were stained CD11cPE-Cy®5.5 in 
conjunction with MHC IIPE, CD86FITC and CD40FITC and analysed by flow cytometry. Cell 
were gated on CD11c+ iDCs and percentage of co-stimulatory receptors expression was 
determined within this population as represented in (Ai) and quantified in (Aii). GSH levels 
were measured in; B. Nrf2+/+ iDCs untreated or treated with BSO (100 M) for 24h. Error 
bars S.E.M. C. Immature Nrf2+/+ DCs untreated or treated with BSO (100 M) for 24h were 
stained CD11cPE-Cy®5.5  in conjunction with MHC IIPE, CD86FITC and CD40FITC and analysed by 
flow cytometry as above. Histogram overlays show fluorescence intensity of respective co-
stimulatory receptors. Statistical significance was tested by unpaired Student’s t test (*, p 
< 0.05; **, p < 0.01). Data are derived from 4 independent experiments.  
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3.2.3 Loss of Nrf2 impairs endocytic capacity of iDCs independently of lowered 
GSH levels 
The fundamental role of iDCs is to continuously sample their environment for 
potential infectious pathogens. Thus they are highly efficient at acquiring antigens 
from the periphery (Banchereau et al., 2000). Immature DCs capture antigens 
through a variety of endocytic and phagocytic mechanisms including mannose 
receptor-mediated endocytosis of sugars and glucan carbohydrate structures 
(Geijtenbeek and Gringhuis, 2009). It is recognised that upon maturation, DCs lose 
their antigen acquisition capabilities whilst developing into highly immunogenic 
APCs (Garrett et al., 2000). As we have shown that Nrf2-/- iDCs exhibited an 
enhanced maturation phenotype associated with increased co-stimulatory receptor 
expression, we hypothesised that this would be accompanied by a down regulation 
in endocytic capacity. To examine the latter, Nrf2+/+ and Nrf2-/- iDCs were treated 
with fluorescently conjugated DextranFITC and analysed by flow cytometry to assess 
mannose receptor-mediated endocytosis, a routinely utilised method for examining 
endocytosis (Sallusto et al., 1995). Results demonstrated that Nrf2-/- iDCs had a 
diminished capacity to endocytose dextran in comparison to their wild type 
counterpart (Figure 3.3A, Nrf2+/+ 48.0 ± 8.6% versus Nrf2-/- 84.7 ± 5.4%, p < 0.01). 
Similarly to our previous result, we sought to decipher whether this impairment in 
endocytosis was a consequence of lowered GSH levels, thus we compared dextran 
uptake between Nrf2+/+ and BSO-treated Nrf2+/+ iDCs. Our results revealed no 
differences in endocytic capacity between the two treatment groups (Figure 3.3B). 
Taken together, this demonstrates that loss of Nrf2 in iDCs results in impairment in 
antigen acquisition capacity through endocytosis which is not a direct consequence 
of their lowered cellular GSH content.  
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3.2.4 Loss of Nrf2 results in impaired capacity of iDCs to phagocytose dying cells 
independently of lowered GSH levels  
Immature DCs are also capable of phagocytosing dying cells which have undergone 
apoptosis as a consequence of normal cellular homeostasis or necrosis due to 
infection (Bratton and Henson, 2008; Sancho et al., 2009). The ability to ingest 
apoptotic and necrotic cells by phagocytosis ultimately leads to the induction of DC 
mediated-CD8 T cell peripheral tolerance or CD8 T cell immunity, respectively (Kurts 
et al., 1997; Kurts et al., 1998; Sauter et al., 2000; Sancho et al., 2009; Nopora et al., 
2012). We reasoned that loss of Nrf2 in iDCs would also impair their ability to 
phagocytose dying (apoptotic and necrotic) cells. Initially, we assessed the ability of 
Nrf2+/+ and Nrf2-/- iDCs to uptake fluorescently labelled apoptotic thymocytes. This 
was achieved by treating isolated C57BL/6J thymocytes with dexamethasone 
overnight to induce apoptosis (Cifone et al., 1999). One of the early events involved 
in apoptosis is the inversion of the phospholipid bilayer thus exposing 
A B 
Figure 3.3 Loss of Nrf2 impairs endocytic capacity of iDCs which is not a direct 
consequence of lowered GSH levels. Nrf2+/+ and Nrf2-/- iDCs (A) or Nrf2+/+ DCs untreated or 
treated with BSO (100 M) for 24h (B) were incubated with DextranFITC for 60 min at 37C. 
Cells were subsequently stained with CD11cPE-Cy®5.5 and DextranFITC uptake by CD11c+ gated 
iDCs was assessed by flow cytometry. Data are presented as average percentage uptake ± 
SD. Statistical significance was tested by unpaired Student’s t test (**, p < 0.01). Data are 
derived from 4 independent experiments. 
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phophatidylserine molecules. These molecules are readily detected by Annexin V 
antibody (Fadok et al., 1992). The proportion of apoptotic cells were thus 
determined by staining with Annexin-V as shown in Figure 3.4.  
 
Apoptotic cells were subsequently fluorescently labelled with CFSE, co-cultured 
with Nrf2+/+ and Nrf2-/- iDCs at 4°C or 37°C and analysed by flow cytometry. Results 
were converted into fold increase in phagocytosis from the 4°C basal control. 
Results revealed that Nrf2-/- iDCs had a reduced capacity to phagocytose apoptotic 
cells in relation to their wild type counterpart (Figure 3.5Ai, Nrf2+/+ 4.7 ± 1.0 versus 
Nrf2-/- 2.8 ± 0.4, p = 0.02). To test whether GSH content contributed to this 
diminished phagocytic function, we examined uptake of apoptotic cells in Nrf2+/+ 
and BSO-treated Nrf2+/+ iDCs. Results showed no differences in phagocytosis 
between both treatment groups (Figure 3.5Aii). Next we examined Nrf2+/+ and Nrf2-
/- iDCs capacity to phagocytose necrotic cells. This was achieved by labelling Jurkat 
cells with CFSE and inducing necrosis via snap freeze in liquid nitrogen. Necrotic 
cells were subsequently co-cultured with the Nrf2+/+ and Nrf2-/- iDCs as before and 
analysed by flow cytometry. Results highlighted that Nrf2-/- iDCs exhibited a 
decreased capacity to phagocytose necrotic cells (Figure 3.5Bi, Nrf2+/+ 4.8 ± 1.8 
versus Nrf2-/- 1.7 ± 0.7, p < 0.01). We further confirmed that no differences in 
Figure 3.4 Dexamethasone induces apoptosis in murine thymocytes. Isolated C57BL/6J 
thymocytes were treated with or without 1μM dexamethasone for 24 h. Cells were 
subsequently stained with Annexin VFITC and analysed by flow cytometry. Percentages of 
Annexin V+ thymocytes are indicated in the right hand panels. Apoptotic thymocytes were 
required for dendritic cell phagocytosis assay. Data are representative of 3 independent 
experiments 
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Figure 3.5 Loss of Nrf2 results in impaired capacity of iDCs to phagocytose dying cells 
which is not a direct consequence of lowered basal GSH levels. Nrf2+/+ and Nrf2-/- iDCs (Fig. 
3.5Ai and Bi) and Nrf2+/+ iDCs untreated or treated with BSO (100 M) for 24h (Fig. 3.5Aii 
and Bii) were co-cultured with CFSE labelled (A) apoptotic thymocytes or (B) necrotic Jurkat 
cells at 37°C for 2 hours. DC phagocytic capacity was measured by flow cytometry as an 
increase in CFSE levels compared to corresponding 4°C baseline control samples. Data is 
presented as average fold-changes ± SEM. Statistical significance was tested by the Mann-
Whitney U test (*, p < 0.05; **, p < 0.01). Data are derived from 5 independent experiments. 
 
phagocytosis of necrotic cells were observed between Nrf2+/+ and BSO-treated 
Nrf2+/+ iDCs as illustrated in Figure 3.5Bii. Taken together, our results demonstrate 
that loss of Nrf2 in iDCs results in an enhanced maturation phenotype which is 
associated with a defect in capacity to phagocytose dying cells. Importantly, our  
results emphasise that the latter is not a direct consequence of lowered GSH levels. 
Ai Aii 
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3.2.5 Enhanced co-stimulatory receptor expression of Nrf2-/- iDCs is associated 
with enhanced antigen-specific CD8 T cell stimulatory capacity 
CD8 T cells provide vital protection against an array of intracellular pathogens 
including viruses and are also fundamental for the implementation of anti-tumour 
responses (Barber et al., 2006; Bos et al., 2012; Condotta et al., 2012). Naïve CD8 T 
cells specifically recognise antigenic peptides bound to MHC class I complexes on 
DCs via their distinctive T cell receptor (TCR) (Trombetta and Mellman, 2005). 
Competent CD8 T cell activation only occurs, however, in the presence of additional 
secondary signals provided through the binding of co-stimulatory molecules 
present on the surface of the DC and T cell (Bachmann et al., 1997). The low co-
stimulatory molecule expression on iDCs renders them inept at inducing competent 
T cell activation (Banchereau et al., 2000). Given that Nrf2 deficient iDCs express 
enhanced levels of CD86, CD40 and MHCII, we anticipated that this would equip 
them to induce an antigen-specific CD8 T cell response. Assessing antigen-specific T 
cell activation is extremely problematic, however, given the diverse range of T cells 
expressing distinctive TCRs that specifically recognise an infinite number of 
antigens. In order to address this issue, we utilized a TCR transgenic mouse model, 
F5, wherein the majority of CD8 T cells exclusively express a T cell receptor 
originally derived from a CTL clone, F5 (Mamalaki et al., 1992; Mamalaki et al., 
1993). The F5-TCR specifically recognises the MHC I-Db restricted antigenic peptide 
NP68, derived from the nucleoprotein of the influenza virus strain A/NT/60/68 
(Mamalaki et al., 1992; Mamalaki et al., 1993). The Nrf2+/+ and Nrf2-/- iDCs were 
pre-pulsed with increasing concentrations of NP68 and co-cultured with naïve F5 
CD8 T cells. Functional consequences of changes in DC co-stimulatory receptor 
expression were assessed by the ability of the NP68 bearing DCs to stimulate 
antigen-specific F5 CD8 T cell proliferation. Results revealed that Nrf2+/+ iDCs were 
unable to induce significant antigen-specific F5 CD8 T cell proliferation until 10nM 
NP68 which was further increased by over 3-fold at the highest 100nM NP68 
concentration (Figure 3.6Ai). In contrast, Nrf2-/- iDCs significantly induced CD8 T cell 
proliferation when pre-pulsed with the lowest 1nM NP68 concentration followed 
by an approximate 1.5-fold NP68 concentration dependent significant increase in T 
80 
 
cell proliferation (Figure 3.6Ai, p < 0.05). Nrf2-/- iDCs induced significantly enhanced 
F5 CD8 T cell proliferation at all given NP68 concentrations in relation to their wild 
type control (Figure 3.6Ai, p < 0.05). Similar to the results observed in the previous 
phenotype and antigen capture experiments, pharmacologically depleting GSH with 
BSO in Nrf2+/+ iDCs did not influence CD8 T cell activation (Figure 3.6Aii). Taken 
together these data demonstrate that the enhanced maturation phenotype of Nrf2-
/- iDC is associated with an increased capacity to induce antigen-specific CD8 T cell 
stimulation and is not a consequence of lowered GSH levels.  
Peripheral naive T cells exhibit low affinity for self-peptides and rely on continuous 
contact with self-peptide:MHC complexes presented by iDCs for their survival (Surh 
and Sprent, 2008). The iDC phenotype is characterised by low co-stimulatory 
receptor expression which provides the appropriate signals for T cell survival and 
maintenance of T cell tolerance (Kurts et al., 1997; Kurts et al., 1998; Steinman et 
al., 2000). Increases in co-stimulatory receptor expression in iDCs have been shown 
to induce overt T cells activation which may lead inappropriate autoimmune 
responses (Hawiger et al., 2001). 
As the Nrf2 deficient iDCs exhibit an enhanced maturation phenotype with 
increased CD40, CD86 and MHCII, we reasoned that this would result in 
inappropriate T cell activation in response to a self-peptide and breach in self-
tolerance. To examine this, Nrf2+/+ and Nrf2-/- iDCs were pre-pulsed with increasing 
concentrations of the altered peptide ligand (APL) NP34. The APL NP34 is a peptide 
analogue of NP68 in which amino acid residues present within the TCR contact 
sequence have been modified to lower the affinity of NP34 for the F5 TCR (Williams 
et al 1996). This APL does not induce F5 CD8 T cell activation and thus simulates to 
a degree, the interaction between self-peptides with TCRs on naïve CD8 T cells 
(Williams et al 1996). The results verified that NP34-pulsed Nrf2+/+ iDCs failed to 
induce T cell proliferation at any given NP34 in F5 CD8 T cell proliferation at the 
10nM NP34 concentration and above relative to unpulsed iDCs (Figure 3.6Bi). 
Conversely, NP34-pulsed Nrf2-/- iDCs induced a 2-fold increase in F5 CD8 T cell 
proliferation at the 10nM NP34 concentration and above in comparison to 
unpulsed iDCs (Figure 3.6Bi). There were no differences in F5 CD8 T cell 
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Figure 3.6 Increased co-stimulatory receptor expression by Nrf2 -/- iDCs is associated with 
enhanced antigen-specific CD8 T cell immunostimulatory capacity. A. Nrf2 +/+ and Nrf2 -/- 
iDCs and B. Untreated Nrf2 +/+ and BSO (100μM) treated Nrf2 +/+ iDCs were pulsed with 
increasing concentrations of; (i) NP68 antigenic peptide or; (ii) NP34 altered peptide ligand 
and were co-cultured with F5 CD8 T cells for 72 hours. 3H-Thymidine (3H-Thy) was added for 
the last 16 hr. Proliferation of T cells was determined by scintillation counting of 
incorporated 3H-Thymidine. Data are presented as average [3H]thymidine scintillation 
counts ± S.D. Statistical significance was tested by unpaired Student’s  t test (*, p < 0.05). 
Data is representative of 4 independent experiments. 
  
 
proliferation observed between BSO-treated and untreated Nrf2+/+ iDCs (Figure 
3.6Bii). These results demonstrate that the enhanced co-stimulatory receptor 
expression exhibited by the Nrf2-/- iDCs is associated with enhanced CD8 T cell 
proliferation in the context of a self-peptide.  
 
Ai Aii 
Bi Bii 
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3.2.6 Enhanced co-stimulatory receptor expression of Nrf2-/- iDCs is associated 
with enhanced antigen-specific CD8 T cell effector function 
Dendritic cell-activated CD8 T cells undergo several rounds of proliferation followed 
by functional differentiation into effector CD8+ CTLs that characteristically secrete 
large amounts of the cytokine IFNγ. Co-stimulatory signal transduction is known to 
enhance the expansion of CD8+IFNγ+ producing T cells in response to intracellular 
bacterial infection (Mittrucker et al., 2001). From our observation that the Nrf2 
deficient iDCs exhibit enhanced co-stimulatory receptor expression associated with 
increased antigen-specific F5 CD8 T cell proliferation, we hypothesised that these 
Nrf2-/- iDC-activated F5 CD8 T cells would have enhanced effector function in terms 
of the number of antigen-specific CD8 T cell IFNγ producing effector cells in relation 
to the Nrf2 wild type iDCs. In order to address this, NP68-prepulsed Nrf2+/+ and 
Nrf2-/- iDCs were co-cultured with naïve F5 CD8 T cells for 72 hours. Antigen-specific 
CD8 T cells were subsequently restimulated with NP68-pulsed mature Nrf2+/+ DCs 
and intracellular IFNγ production was assessed by flow cytometry.  It appeared that 
Nrf2-/- iDCs induced a small increase in the percentage of antigen-specific CD8+IFNγ+ 
producing T cells in comparison to their wild type control (Figure 3.7A, percentage 
of F5 CD8+IFNγ+ T cells, Nrf2+/+ 6.5% versus Nrf2-/- 10.1%). However, when 
comparing the number of CD8+IFNγ+ T cells produced from the starting culture of F5 
T cells, Nrf2-/- iDCs generated between 1.4- and 2.4-fold enhanced numbers of 
effectors cells from the naïve F5 CD8 T cells when compared to Nrf2+/+ iDCs as 
illustrated in Figure 3.7B. These results highlight the association between increased 
co-stimulatory receptor expression of Nrf2-/- iDCs with enhanced capacity to induce 
antigen-specific CD8 T cell functional differentiation into IFNγ producing effector 
CTLs. 
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Figure 3.7 Nrf2 deficient iDCs enhanced maturation phenotype is associated with 
enhanced DC-mediated antigen-specific CD8 T cell effector function. Naïve F5 CD 8 T cells 
were co-cultured with Nrf2+/+ or Nrf2-/- iDCs pre-pulsed with 10-7 M NP68 for 72hrs. F5 T 
cells were then re-stimulated with Nrf2+/+ mDC pre-pulsed with or without 10-7 M NP68 for 
6 hrs and assessed for IFN- production by intracellular cytokine staining (ICS). A.  
Representative dot plot of IFN-  ICS for re-stimulated F5 CD8 T cells. Percentages of cells 
are indicated in the panels. B. Collated table of total number of IFN- producing effectors 
generated. Data are derived from 3 independent experiments.  
 
 
 
Animal 
Pair 
Stimulating DC 
genotype 
Starting F5 CD8 T 
cell numbers 
No. of IFNγ producing 
effectors generated 
1 
Nrf2+/+  7 x 106 2.08 x 106 
Nrf2-/-   7 x 106 5.10 x 106 
2 
Nrf2+/+  7 x 106 3.74 x 106 
Nrf2-/-   7 x 106 6.12 x 106 
3 
Nrf2+/+  7 x 106 11.40 x 106 
Nrf2-/-   7 x 106 15.76 x 106 
 
A 
B 
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3.2.7 Loss of Nrf2 enables DCs to cross-present cell-associated peptide antigens to 
CD8 T cells 
Generally proteins derived from exogenous material are presented as processed 
antigenic peptides in conjunction with MHCII molecules to naïve CD4 T cells thus 
initiating CD4 T cell immune responses (Trombetta and Mellman, 2005). However, it 
has long been recognised that DCs can uniquely present exogenous cell-associated 
antigens derived from phagocytosed dying or infected cells in conjunction with 
MHCI molecules to naive CD8 T cells through a phenomenon known as “cross-
presentation” (den Haan et al., 2000; Belz et al., 2005). Cross-priming mechanisms 
have been shown to facilitate CD8 anti-viral and anti-tumour immunity (Hoffmann 
et al., 2000; Nopora et al., 2012). Furthermore, this constitutive process is crucial 
for maintenance of peripheral CD8 T cell tolerance (Kurts et al., 1997; Kurts et al., 
1998). We have previously established that Nrf2 deficient iDCs have a reduced 
capacity to phagocytose dying cells. We therefore investigated whether this defect 
in phagocytosis would impact on the ability of Nrf2 deficient DCs to cross-present 
necrotic cell-associated antigens to CD8 T cells.  In order to evaluate the influence 
of Nrf2 on DC cross-presentation, we adapted the aforementioned F5-TCR 
experimental system by supplying NP68 pre-pulsed necrotic C57BL/6J splenocytes 
to LPS-stimulated Nrf2+/+ and Nrf2-/- DCs overnight, to enable phagocytosis and the 
processing of cell-associated NP68 antigen. Subsequently, the DCs were co-cultured 
with naïve F5 CD8 T cells at varying DC:T cell ratios and the level of antigen-specific 
CD8 T cell proliferation was used as a direct determinant of the DC cross-
presentation capacity. Results revealed that Nrf2-/- DCs were able to cross-present 
cell-associated NP68 more efficiently than their wild type counterpart as evidenced 
by the significantly enhanced CD8 T cell proliferation exhibited at increasing DC:T 
cell ratios from 1:50 to 1:5 (Figure 3.8, p < 0.05). Intriguingly, Nrf2+/+ DCs failed to 
induce CD8 T cell proliferation at any given DC:T cell density (Figure 3.8, stimulation 
index < 2 at all DC:T cell ratios). 
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Figure 3.8. Nrf2 deficient iDCs have increased capacity to cross-present cell-associated 
antigens to naïve CD8 T cells. Necrotic splenocytes preloaded with NP68 were cultured 
overnight in the presence of LPS with Nrf2 +/+ and Nrf2-/- iDCs to enable phagocytosis and 
cross-presentation of cell-associated antigen. Dendritic cells were harvested, washed and 
co-cultured at various ratios with F5 CD8 T cells for 72 hr. 3H-Thymidine was added for the 
last 16 hours. Proliferation of T cells was determined by scintillation counting of 
incorporated 3H-Thymidine by T cells and converted to stimulation indices by dividing total 
F5 CD8 T cell proliferation activated by 200 M NP68 over the control group (0 M NP68). 
Error bars represent S.E.M. Statistical significance was tested by Mann–Whitney U test (*, 
p < 0.05). Data are derived from 4 independent experiments.   
 
 
 
3.2.8 Loss of Nrf2 in activated DCs results in a lowered Th1 cytokine profile  
Dendritic cells produce an array of cytokines as a consequence of differential 
engagement of innate recognition receptors including TLRs (Banchereau et al., 
2000). Dendritic cell cytokine production provides a vital tertiary signal to naïve CD4 
T cells governing their differentiation into functionally distinct CD4 effector 
subtypes including the cytotoxic Th1 and allergic Th2 subsets (Kim et al., 2007; 
Williams et al., 2008). Dendritic cell regulation of Th1/Th2 polarisation is crucial for 
the normal functioning of the immune system (Maldonado-Lopez and Moser, 2001; 
Kidd, 2003). Oxidative stress influences DC cytokine production, resulting in a 
perturbation of the Th1/Th2 balance and permitting a dominant Th2 phenotype as 
exhibited in a variety of allergic disorders e.g. asthma and eczema (Kim et al., 2007; 
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Williams et al., 2008; Holgate, 2012). We sought to investigate the impact of loss of 
Nrf2 on basal and LPS-induced DC Th1 TNFα, IL-12p70 and Th2 IL-2 cytokine 
secretion. We hypothesised that loss of Nrf2 would enhance Th2 cytokine 
production within this context. In order to achieve this, we purified day 6 CD11c+ 
Nrf2+/+ and Nrf2-/- iDCs by CD11c positive magnetic separation, stimulated the DCs 
with or without LPS for 48hr and analysed the levels of TNFα, IL-12p70 and IL-2 by 
ELISA. Results revealed that although the difference is very small, Nrf2-/- basal iDCs 
secreted significantly lower levels of TNFα in comparison to their wild type control 
(Figure 3.9A, Nrf2+/+ 212.6 ± 7.0 versus Nrf2-/- 191.6 ± 6.3, p = 0.02). Dendritic cell  
treatment with LPS resulted in significantly increased TNFα levels for both 
genotypes (p < 0.002), however similarly to basal findings, LPS-treated Nrf2-/- DCs 
produced significantly lower TNFα levels in comparison to their wild type control 
(Figure 3.9A, Nrf2+/+ 1596.3 ± 60.6 pg/ml versus Nrf2-/- 936.1 ± 54.7, p < 0.0001). 
Basal levels of IL-12 were undectable for both genotypes (Figure 3.9B). Upon LPS 
stimulation, Nrf2-/- DCs secreted significantly lowered levels of IL-12p70 in relation 
to their wild type counterpart (Figure 3.9B, Nrf2+/+ 49.2 ± 14.7 pg/ml versus Nrf2-/- 
19.7 ± 12.1, p = 0.009). In contrast to the Th1 findings, there were no significant 
differences LPS-activated DC secretion of IL-2 between Nrf2+/+ and Nrf2-/- mice 
(Figure 3.9C, Nrf2+/+ 18.7 ± 2.4 pg/ml versus Nrf2-/- 21.4 ± 16.6). The Th2 cytokines 
IL-5 and IL-13 were also measured; however, levels were undetected (IL-15) or 
below the limit of detection (IL-13) under basal and LPS-induced conditions for both 
genotypes (data not shown). Taken together, this suggests that under Th1 inducing 
conditions using the TLR4 agonist LPS, Nrf2 deficient DCs exhibit a lowered Th1 
cytokine profile highlighting a potential role of Nrf2 in the regulation of DC-
mediated Th1 polarisation.  
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Figure 3.9 Nrf2 deficient DCs exhibit a lowered Th1 cytokine profile   
Day 6 CD11c+ purified Nrf2+/+ and Nrf2-/- iDCs were stimulated with or without LPS for 48hr. 
Levels of A. TNFα, B. IL-12p70, C. IL-2 in supernatants were measured by ELISA. Data are 
presented as average pg/ml ± S.D. Data is derived from three independent experiments 
(excluding IL-12 which is derived from five experiments). Statistical significance was 
assessed using unpaired Student’s t test. (* p < 0.05; ** p < 0.01). 
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3.3 DISCUSSION 
Dendritic cells are sentinels of the immune system which are not only responsible 
for directing adaptive immune responses to invading pathogens but also critical for 
dampening autoimmune responses to self-antigens through the induction of 
peripheral T cell tolerance (Banchereau et al., 2000; Hawiger et al., 2001; Mellman 
and Steinman, 2001). The DC-mediated immunological outcome of T cell tolerance 
versus T cell immunity is highly dependent on the maturation status of the DC and 
is governed by the expression of co-stimulatory molecules (Steinman and 
Nussenzweig, 2002; Cools et al., 2007). Indeed, low co-stimulatory molecule-
expressing iDCs and high co-stimulatory molecule-expressing mDCs are critical for 
the induction of T cell tolerance and T cell immunity, respectively (Steinman and 
Nussenzweig, 2002; Cools et al., 2007). Therefore, regulation of DC maturation 
status is central to the proper functioning of the immune system, dysregulation of 
which can result in autoimmunity (Steinman and Nussenzweig, 2002; Decker et al., 
2006). It has been identified that DC phenotype and subsequent immune function is 
highly dependent upon its intracellular redox status (Kantengwa et al., 2003; Chan 
et al., 2006; Kim et al., 2007). The antioxidant GSH has also been implicated in the 
regulation of DC immune function (Kim et al., 2007). The main driver of GSH 
biosynthesis is the transcription factor Nrf2 (Copple, 2012). Nrf2 is emerging as a 
key player in the regulation of DC co-stimulatory receptor expression and 
subsequent immune function (Williams et al., 2008; Rangasamy et al., 2010), 
however, its relationship with basal GSH content and DC immune function has not 
been established. The present chapter investigated the role of Nrf2 in DC immune 
function and its relationship with GSH. Previous studies have shown that loss of 
Nrf2 results in lowered GSH levels in a variety of cell types including hepatocytes, 
macrophages and fibroblasts (Chan and Kwong, 2000; Kong et al., 2010; Toyama et 
al., 2011). Although lowered intracellular thiol content has been observed in aged 
Nrf2 deficient splenic-derived DCs (Kim et al., 2008), reduced cellular GSH levels 
have not been directly investigated in BMDCs. Our results revealed that Nrf2-/- iDCs 
exhibited diminished GSH content in relation to their wild type counterpart, a 
finding which has not yet been established (Aw Yeang et al., 2012). It is established 
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that loss of Nrf2 results in increased expression of MHCII and molecules CD80 and 
CD86 in iDCs (Williams et al., 2008; Rangasamy et al., 2010). Our results reaffirm 
that Nrf2 deficient iDCs exhibit an enhanced maturation phenotype (Aw Yeang et 
al., 2012). In contrast to this previous study, we also observed a significant increase 
in the expression of CD40 (Aw Yeang et al., 2012). Reasons for this discrepancy may 
be due to variation in DC culturing methods e.g. the addition of IL-4 into the DC 
culture medium as per Rangasamy et al (Rangasamy et al., 2010). Importantly, 
previous studies looking at the role of Nrf2 in DC immune function were carried out 
using Nrf2 deficient mice with a different genetic background (Williams et al., 2008; 
Rangasamy et al., 2010). In support of this, species differences between inbred 
C57BL/6J and outbred ICR/CD1 mice have been observed within microglial cells 
inflammatory response to LPS (Nikodemova and Watters, 2011). We sought to 
determine whether the increase in co-stimulatory receptor expression observed in 
the Nrf2-/- iDCs was a direct consequence of their lowered GSH levels. By artificially 
lowering iDC GSH using the GCLC inhibitor BSO, we could not recapitulate the 
enhanced maturation phenotype seen in the Nrf2-/- iDCs (Aw Yeang et al., 2012). 
This is in line with previous studies where no differences in co-stimulatory receptor 
expression were observed between BSO-treated and untreated iDCs (Kuppner et 
al., 2003; Kamide et al., 2011). We therefore concluded that the increased levels of 
co-stimulatory molecules displayed in the Nrf2 deficient iDCs was not a 
consequence of lowered GSH content but was rather due to a cell intrinsic defect.  
What other contributing factors could thus be involved in the Nrf2 regulation of co-
stimulatory receptor expression in iDCs? The activation of the NF-κB and p38 MAPK 
intracellular signalling pathways are imperative for the regulation of DC maturation, 
survival, cytokine secretion and subsequent DC-mediated CD4 effector polarisation 
(Ardeshna et al., 2000; Ouaaz et al., 2002; Aiba et al., 2003; Nakahara et al., 2006; 
Neves et al., 2009; Kim et al., 2010; van de Laar et al., 2010). Studies using Nrf2 
deficient mice have illustrated a reciprocal relationship between the Nrf2 and NF-κB 
transcription factors such that loss of Nrf2 results in enhanced NF-κB activity under 
oxidative stress conditions (Thimmulappa et al., 2006a; Jin et al., 2008). This 
transcriptional counter regulation has been observed in other APCs such as 
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macrophages (Thimmulappa et al., 2006a; Yageta et al., 2011). Curcumin (major 
component of turmeric spice), which is known to activate Nrf2 (Yang et al., 2009), 
has been shown to inhibit LPS-induced proinflammatory cytokine secretion in DCs. 
This was associated with a down regulation in nuclear NF-κB levels (Cong et al., 
2009). Importantly, studies have shown that aged DCs exhibit reduced Nrf2 
expression (Kim et al., 2008) and display increased co-stimulatory receptor 
expression associated with augmented NF-κB activation in response to self-antigens 
(Agrawal et al., 2009). Therefore, it would be reasonable to assume that loss of Nrf2 
in iDCs could correspond to enhanced nuclear NF-κB activity, the latter of which 
contributed to the observed enhanced maturation phenotype. In spite of this, our 
group found no differences in basal NF-κB activity between Nrf2+/+ and Nrf2-/- iDCs 
(Aw Yeang et al., 2012). The relationship between Nrf2 and the upstream p38 
MAPK is poorly understood. It has been suggested that p38 MAPK phosphorylates 
Nrf2 which induces an increased association between Nrf2 and Keap-1, ultimately 
suppressing Nrf2 nuclear translocation in human hepatoma HepG2 cell line (Bryan 
et al., 2013). The Nrf2 activator sulforaphane inhibits p38 MAPK kinase activity in 
this model. Furthermore, sulforaphane inhibits p38 MAPK signalling in shear stress 
activated endothelial cells (Zakkar et al., 2009). Therefore, Nrf2 deficiency may 
enhance p38 MAPK signalling causing an increase in co-stimulatory receptor 
expression in iDCs. Recently our group demonstrated that loss of Nrf2 results in 
increased p38 MAPK phosphorylation in DCs (Al-Huseini et al., 2013). Epigenetic 
changes in DC gene expression can also influence the DC maturation status and 
subsequent immune function (Nencioni et al., 2007; Song et al., 2011). Histone 
acetylation induces changes in gene expression through chromatin expansion, 
permitting access of transcription factors to the DNA. This process is facilitated by 
histone acetyltransferase (HAT) enzymes and counter-regulated by histone 
deacetylase (HDAC) enzymes (Tang et al., 2013). Histone deacetylase activity is 
essential for the regulation of DC co-stimulatory receptor expression, cytokine 
secretion, immunostimulatory capacity and maintenance of DC-mediated Th1/Th2 
balance (Brogdon et al., 2007; Nencioni et al., 2007; Song et al., 2011). Importantly, 
it is known that Nrf2 is activated by histone acetylation (Sun et al., 2009). The HAT 
enzyme CBP involved in the transactivation of Nrf2 has been shown to acetylate 
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residues contained within the Nrf2 Neh1 ARE DNA-binding region during oxidative 
stress resulting in the enhancement of the promoter-speciﬁc DNA binding capacity 
of Nrf2 (Sun et al., 2009). Importantly, it has been identified that NF-κB inhibits the 
Nrf2 pathway by recruiting the repressive HDAC3 to the ARE which interacts with 
small Maf K protein and CBP resulting in their deacetylation and functional 
inhibition, both of which are required for Nrf2 activation (Liu et al., 2008). We have 
recently shown that the observed increase in co-stimulatory receptor expression in 
Nrf2-/- iDCs is dependent on HDAC activity as pre-treatment with the HDAC inhibitor 
valproic acid (VPA) downregulates MHCII and CD86 expression (Aw Yeang et al., 
2012). The Nrf2-regulated enzyme HO-1 is involved in the catabolism of cellular 
heme into biliverdin (Poss and Tonegawa, 1997) and has also been implicated in the 
regulation of DC co-stimulatory receptor expression and DC cytokine production 
(Chauveau et al., 2005). Nrf2 deficiency in DCs results in a downregulation of HO-1 
gene expression (Rangasamy et al., 2010). Importantly, it has been shown that HO-1 
is drastically downregulated upon DC maturation (Chauveau et al., 2005). It is 
therefore possible that the enhanced maturation phenotype exhibited in the Nrf2-/- 
iDCs is a result of low HO-1 expression. Heme oxygenase-1 can be marginally 
induced in Nrf2 deficient cells using the cobalt protoporphyrin (CoPP) (Shan et al., 
2006). The effect of pre-treating Nrf2-/- iDCs with CoPP on DC co-stimulatory 
receptor expression seems worthwhile to examine. 
The primary function of iDCs is to continuously acquire antigens from the periphery 
through numerous endocytic and phagocytic mechanisms (Banchereau et al., 2000). 
These events are crucial for the induction of T cell immunity and peripheral T cell 
tolerance. The process of DC maturation is correlated with a down modulation of 
endo- and phagocytic capacity (Banchereau et al., 2000; Garrett et al., 2000), 
therefore we hypothesised that increased co-stimulatory receptor expression 
exhibited in the Nrf2-/- iDCs would be associated with diminished antigen capture 
capacity. Our results revealed that Nrf2-/- iDCs exhibited a reduced capacity to 
endocytose dextran and phagocytose both apoptotic and necrotic cells, 
independently of lowered basal GSH content (Aw Yeang et al., 2012). In contrast, 
Williams et al. concluded that loss of Nrf2 resulted in enhanced endocytosis of 
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dextran in resting DCs (Williams et al., 2008). Reasons for this difference may be 
again due to variation in the mouse strain and DC culturing technique. Loss of 
endocytic function in maturing DCs is associated with diminished Cdc42 activity 
(Garrett et al., 2000), levels of Cdc42 expression in Nrf2+/+ and Nrf2-/- iDCs could be 
examined to further delineate the precise role of Nrf2 in DC antigen capture 
function. Furthermore, it would be noteworthy to see if there are any differences in 
actin polymerisation between Nrf2+/+ and Nrf2-/- iDCs, which is central to DC 
endocytic and phagocytic mechanisms (Niedergang and Chavrier, 2004). This could 
be achieved by staining the iDCs undergoing phagocytosis with fluorescently 
labelled phalloidin (Cougoule et al., 2006). Phalloidin reduces the inorganic 
phosphate release of polymerizing actin and therefore attaches to the polymerised 
F-actin, which can be subsequently visualised using fluorescent microscopy 
(Cougoule et al., 2006). It would also be valuable to compare the migratory capacity 
of the Nrf2+/+ and Nrf2-/-  iDCs in vitro via a chemotaxis assay, using a chamber 
transwell plate filter system and a chemoattactrant such as chemokine (C-C motif) 
ligand 19 (CCL19) (Yen et al., 2008).  
It would be worthwhile to clarify the role of Nrf2 in DC-antigen acquisition and 
migratory capacity within an in vivo system. This could be achieved by injecting 
dextranFITC, CFSE-labelled apoptotic or necrotic cells i.v. into the Nrf2+/+ and Nrf2-/- 
mice and examining their lymphoid organs by flow cytometry.  
Previous studies have shown that iDCs derived from SLE patients also exhibit 
defects in mannose-dependent uptake of dextran and phagocytosis of apoptotic 
cells which correlate with SLE disease activity (Berkun et al., 2008; Monrad et al., 
2008). Moreover, SLE iDCs are associated with increased CD86 (Carreno et al., 2009; 
Gerl et al., 2010), CD40 (Carreno et al., 2009), (Nie et al., 2010) and MHCII (Berkun 
et al., 2008) expression similar to the findings presented in this chapter. Therefore, 
it would be valuable to examine the levels of Nrf2 SLE patient-derived DCs relative 
to healthy controls and to assess whether induction of Nrf2 using CDDO-Me could 
restore the phagocytic function of DCs in SLE. Importantly, sulforaphane has been 
shown to restore phagocytic function and enhance bacterial clearance of 
macrophages from COPD patients (Harvey et al., 2011). Other phenotypic defects 
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have been observed in SLE-derived DCs including enhanced lymphoid homing CCR7 
chemokine levels (Nie et al., 2010), increased ratio of activating (CD32a) to 
inhibitory (CD32b) FcγR expression (Carreno et al., 2009), decreased DC-SIGN and 
mannose receptor expression (Monrad et al., 2008). Thus, a detailed phenotypic 
analysis of Nrf2 deficient DCs in relation to their chemokine, endo- and phagocytic 
receptor expression is essential to further highlight the connection between Nrf2, 
DC phenotype and pathogenesis of SLE.   
In order for naïve CD8 T cells to become fully activated, they must receive both 
antigen-specific DC-mediated TCR signals and strong co-stimulatory signals, 
resulting in the generation of competent effector CTLs and CD8 T cell immunity 
(Gett et al., 2003). Immature DCs fail to induce CD8 T cell immune responses due to 
their low co-stimulatory receptor expression (Banchereau et al., 2000). Under 
resting conditions, iDCs constitutively present self-peptides to CD8 T cells in the 
periphery. This is imperative for the maintenance of naïve T cell homeostasis as 
abrogation of interactions of the TCR with MHC:self-peptide complexes presented 
by iDCs significantly reduces the lifespan of the naive T cell (Surh and Sprent, 2008). 
The presence of low level co-stimulatory receptor expression in iDCs enables them 
to maintain  CD8 T cell homeostasis thus limiting overt T cell activation and 
prevention of detrimental autoimmune responses (Kurts et al., 1997; Steinman and 
Nussenzweig, 2002). As we have established that Nrf2 deficient iDCs possess 
enhanced co-stimulatory receptor expression, we hypothesised that this would be 
associated with an increase in CD8 T cell immunostimulatory capacity in the 
presence of the antigenic peptide NP68 and importantly the surrogate self-peptide 
NP34. Using the F5-TCR transgenic antigen-specific murine model, our findings 
revealed that loss of Nrf2 in iDCs resulted in enhanced iDC-mediated antigen-
specific F5 CD8 T cell proliferation and effector function in response to NP68. 
Examination of other functional readouts of the Nrf2+/+ and Nrf2-/- iDCs stimulated 
F5 CTLs would reaffirm this finding. Cytotoxic T lymphocyte cytolytic capacity could 
be evaluated using the chromium release assay wherein chromium-labelled target 
cells release chromium upon CTL-mediated destruction, levels of radioactivity can 
then be monitored by scintillation counting (Janas et al., 2005). Furthermore, 
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expression of CTL-released cytolytic molecules such as perforin and granzyme B 
could also be measured (Janas et al., 2005) by flow cytometry. We have also shown 
that Nrf2 deficient iDCs induced F5 CD8 T cell proliferation in response to the 
surrogate self-peptide (Aw Yeang et al., 2012). Taken together, these findings 
pinpoint an underlying role for Nrf2 in the regulation of iDC-mediated induction of 
CD8 T cell tolerance. It would be informative to investigate the impact of Nrf2 
deficiency in iDCs, in established murine models of tolerance such as the H-Y TCR-
transgenic male mice. The male mice contain auto-reactive T cells which express 
the H-Y TCR that specifically recognise the H-Y self-antigen in the context of MHC H-
2Db. (Maione et al., 2010; Murakami et al., 2010). The consequences of the 
increased co-stimulatory receptor expression exhibited in the Nrf2-/- iDCs in relation 
to tolerance could thus be assessed by pre-pulsing the  Nrf2+/+ and Nrf2-/- iDCs with 
the H-Y self-antigen ex vivo, and injecting them into male transgenic H-Y mice. Signs 
of enhanced lymphoproliferation within the secondary lymphoid organs could then 
be examined via flow cytometry. 
Dendritic cells can uniquely present exogenous cell-associated antigens derived 
from phagocytosed dying or infected cells in conjunction with MHCI to naïve CD8 T 
cells, in a process termed cross-presentation (Joffre et al., 2012). Depending on the 
context, DC cross-priming mechanisms are essential for the induction of CD8 T cell 
immunity (e.g. presentation of tumour associated antigens) and maintenance of 
peripheral CD8 T cell tolerance (e.g. presentation of self-antigens derived from 
apoptotic cells) (Joffre et al., 2012). We have shown that loss of Nrf2 in iDCs results 
in an impaired capacity to phagocytose dying cells (Aw Yeang et al., 2012). As 
phagocytosis is a prelude to the presentation of cell-associated antigens, it is 
possible that these DCs would be defective in extracting antigen from dying cells 
and cross-presenting them to naïve CD8 T cells. Conversely, our findings have 
illustrated that the LPS-activated Nrf2-/- DCs exhibited an enhanced capacity to 
stimulate F5 CD8 T cells, following extraction of cognate antigen from necrotic cells 
in relation to their wild type counterpart. The phagocytosis of exogenous material 
results in the formation of the phagosome (Trombetta and Mellman, 2005). During 
cross-presentation, this vacuolar compartment is responsible for transporting its 
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cargo to the proteasome for proteolytic degradation into antigenic peptides, 
followed by MHCI peptide loading within the ER and translocation to the surface of 
the DC for presentation to naïve CD8 T cells (Trombetta and Mellman, 2005). The 
efficiency of the cross-presentation is highly dependent on the DC phagosomal pH 
(Kotsias et al., 2013). Unlike other phagocytes which contain acidic, proteolytically 
active phagosomes, DCs possess more alkaline (at around pH 7.5), proteolytically 
inactive, vacuolar compartments ensuring that the exogenous material is not 
completely degraded and can be efficiently loaded onto MHCI molecules (Joffre et 
al., 2012). Alkalisation of the DC phagosome is induced by increased NOX2-
dependent ROS production within the phagosome (Kotsias et al., 2013). Defects in 
ROS levels in the phagosome have resulted in impaired DC-mediated cross-
presentation of cell-associated antigens to CD8 T cells (Joffre et al., 2012). We and 
others have shown that Nrf2 deficient DCs exhibit enhanced intracellular ROS levels 
in comparison to their wild type control (Williams et al., 2008; Aw Yeang et al., 
2012). Therefore, if increased ROS in the phagosome amounts to increased antigen 
cross-presentation, this may explain why Nrf2 deficient DCs exhibited an increased 
cross-priming capacity. However, increased total ROS production in DCs does not 
necessarily correlate with increased DC phagosomal ROS production as 
demonstrated in Savina et al. 2009 (Savina et al., 2009). Evaluation of DC 
phagosomal ROS production could be achieved by examining Nrf2+/+ and Nrf2-/- iDCs 
phagocytosis of latex beads labelled with the ROS indicator dihydrorhodamine 
(Savina et al., 2009). This dye fluoresces green when oxidised and changes in ROS 
can be analysed by flow cytometry (Savina et al., 2009). It has been shown that 
efficient DC cross-presentation, NOX2 assembly and ROS production within the 
phagosome is dependent upon the activity of the small rho GTPase Rac2 (Savina et 
al., 2009). It would be interesting to look at the levels of Rac2 in the phagosomes by 
intracellular staining and flow cytometric analysis (Savina et al., 2009). This 
experiment is not without its limitations; however, as we cannot say for certain that 
the observed increase in naïve F5 CD8 T cell proliferation is exclusively due to 
increased cross-presentation capacity. It could be attributable to differences in co-
stimulatory receptor expression induced by LPS and necrotic cells between both 
genotypes and/or increases in DC cytokine production such as IL-12, which 
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promotes CD8 T cell activation and proliferation. It would be valuable to assess co-
stimulatory receptor expression and IL-12 production in Nrf2+/+ and Nrf2-/- DCs 
treated with both LPS and necrotic cells to clarify the role of Nrf2 in DC cross-
presentation. 
Dendritic cells are not only responsible for the initiation of T cell immune 
responses, they are essential for influencing the nature of the response elicited.  
Functional differentiation of T cells into effector T cells, is highly dependent upon 
their exposure to cytokines within their microenvironment, that are derived from 
the DC itself or other innate immune cells at the site of infection (Curtsinger et al., 
1999). Dendritic cells secrete an array of cytokines depending upon the type of 
pathogen initially encountered by the DC, the corresponding PRR signalling and 
resultant upregulation of cytokine gene expression (Geijtenbeek and Gringhuis, 
2009; Kawai and Akira, 2011). For example, E. coli-derived LPS is known to signal 
through TLR4 on the DC, inducing the production of IFNγ and IL-12 which results in 
CD4 Th1 type immune responses (Agrawal et al., 2003). In contrast, Schistosome 
helminth infection stimulates TLR2 signalling, resulting in the production of IL-4 by 
DCs thus driving a Th2 response (van der Kleij et al., 2002). Dendritic cell-mediated 
regulation of Th1/Th2 differentiation is highly dependent upon its intracellular 
redox status (Ohtani et al., 2005; Traidl-Hoffmann et al., 2005; Vassallo et al., 2005; 
Chan et al., 2006; Csillag et al., 2010). It has been established that loss of Nrf2 in 
DCs perturbs their intracellular redox status (Aw Yeang et al., 2012), which has been 
associated with a dysregulation of CD4 effector Th1/Th2 differentiation toward the 
Th2 phenotype under oxidative stress conditions (Williams et al., 2008). We 
therefore sought to investigate the impact of loss of Nrf2 on basal and LPS-induced 
DC Th1 TNFα, IL-12p70 and Th2 IL-2 cytokine secretion. Results revealed that upon 
LPS activation, Th1 TNFα and IL-12p70 levels were decreased in the Nrf2 deficient 
DCs and in relation to their wild type counterpart. However no differences in IL-2 
production were observed between the genotypes. Moreover Th2 cytokines IL-13 
and IL-5 were undetected within this LPS-stimulated context. This suggests that 
Nrf2 regulates DC Th1 cytokine production in response to a DC-mediated Th1 
polarising stimuli. It has been previously shown that Nrf2 deficient DCs derived 
97 
 
from an ICR/CD1 background exhibited enhanced basal TNFα levels, a trend which 
was accentuated upon activation with the allergen ragweed extract (Rangasamy et 
al., 2010). A previous study has shown that Nrf2 deficient DCs secrete significantly 
enhanced basal IL-12p40 levels in relation to their wild type (Rangasamy et al., 
2010). Moreover, LPS-treated Nrf2+/+ and Nrf2-/- DCs derived from a similar 
C57BL/6J background to the presented work produced similar levels of IL-12p40 
production (Chan et al., 2006). However, as IL-12p70 levels have been examined in 
the present chapter these reports are not comparable. It has been extablished that 
loss of Nrf2 in DCs results in increased Th1 IL-12 and Th2 IL-13 production in 
relation to their wild type control in response to ambient particulate matter 
(Williams et al., 2008). Although both Th1 and Th2 cytokines were induced, the 
level of Th2 IL-13 production in relation to Th1 IL-12 production was increased 
indicating an intense pro-Th2 bias (Williams et al., 2008). From the presented work 
we cannot conclude that loss of Nrf2 results in a skewed Th1/Th2 cytokine profile 
towards a Th2 dominance. However, we can still acertain that Nrf2 plays a pivotal 
role in the regulation of DC Th1 cytokine production, therefore suggesting that Nrf2 
plays a role in maintaining the DC Th1/Th2 cytokine secretion.  It is well recognised 
that LPS induces a strong Th1 response (Agrawal et al., 2003), therefore it would 
not have been a suitable stimulus to examine the effects of loss of Nrf2 on Th2 
cytokine production. Other reports which have demonstrated the loss of Nrf2 in 
DCs results in a skewing towards the Th2 phenotype were based on DCs exposed to 
a Th2 inducing allergen (Williams et al., 2008; Rangasamy et al., 2010). It is 
therefore necessary to stimulate the Nrf2+/+ and Nrf2-/- DCs with TLR2 agonists such 
as Pam3Cys-Ser-Lys4 (pam3cys) or Schistosome egg antigens (SEA) which are 
known to induce a strong DC Th2 cytokine profile (Agrawal et al., 2003) to confirm 
that Nrf2 regulates DC Th1/Th2 cytokine production within a Th2 inducing context. 
It would also be informative to look at the role of Nrf2 in DC secretion of other CD4 
lineage-specific polarising cytokines e.g. TGFβ, IL-6 and IL-23 for Th17 
differentiation (Mangan et al., 2006) to gain a detailed cytokine profile of the Nrf2 
deficient DCs.  
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In conclusion, the present chapter revealed a novel role of Nrf2 in the GSH-
independent regulation of co-stimulatory receptor expression, antigen capture 
function and antigen-specific CD8 T cell stimulatory capacity in bone marrow-
derived iDCs. Importantly, our results implicate a role of Nrf2 in the maintenance 
DC-mediated peripheral CD8 T cell tolerance. Moreover, this study highlighted the 
role of Nrf2 in regulating DC-mediated Th1 cytokine production ultimately 
influencing the nature of the immune response elicited.  
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CHAPTER FOUR 
 
THE ROLE OF NRF2 IN T CELL IMMUNE FUNCTION 
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4.1 INTRODUCTION 
It is evident from the previous chapter that the redox sensitive transcription factor 
Nrf2 is a key player in the regulation of DC immune function (Aw Yeang et al., 
2012). However, the role of Nrf2 in T cell immune function is poorly understood. 
We therefore sought to explore the impact of Nrf2 in T cells. It is recognised that 
Nrf2 maintains Th1/Th2 balance within an oxidative stress environment 
(Rangasamy et al., 2005; Williams et al., 2008). However, its precise role in T cell 
development, T cell activation and CD4 differentiation remains to be fully 
elucidated. The hypothesis of the work described in this chapter is that similarly to 
DCs, Nrf2 regulates T cell immune function. To test this hypothesis, we utilised the 
Nrf2 deficient mouse experimental system, to examine the role of Nrf2 in T cell 
development, its impact on naïve T cell redox homeostasis, T cell activation and 
proliferative capacity, and its influence on CD4 T cell polarisation.  
4.2 RESULTS 
4.2.1 Loss of Nrf2 does not affect T cell development  
Nrf2 is a master regulator of an array of cytoprotective and antioxidant defence 
genes in response to oxidative insult (Copple et al., 2010). Perturbation of the Nrf2 
pathway results in enhanced oxidative stress in a variety of immune cells including 
DCs and macrophages (Thimmulappa et al., 2006b; Williams et al., 2008), 
illustrating the important role of Nrf2 in the maintenance of cellular redox 
homeostasis. It has been established that increased mitochondrial oxidative stress 
induces apoptosis in the thymus, resulting in aberrant thymic CD4 and CD8 T cell 
populations (Case et al., 2011). This suggests that oxidative stress disrupts T cell 
development in the thymus. However, it is not known whether loss of Nrf2 affects 
the composition of CD4:CD8 T cell populations within this region and ultimately T 
cell development. In order to address this, freshly isolated thymocytes derived from 
Nrf2+/+ and Nrf2-/- mice were incubated with fluorescently labelled CD4PE and CD8TC 
cell surface antibodies and analysed by flow cytometry. Flow cytometric analysis 
revealed distinctive subpopulations of T cells at different stages of development 
including CD4-CD8- DN cells, CD4+CD8+ DP cells, and mature CD4+ and CD8+ single 
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positive (SP) T cells (Figure 4.1A, representative dot plot). Percentages of the 
aforementioned T cell populations, as denoted within the quadrant regions in the 
dot plots (Figure 4.1A), were comparatively similar within the thymus of both 
Nrf2+/+ and Nrf2-/- mice, as quantified in Figure 4.1B (Nrf2+/+ versus Nrf2-/-, CD4-CD8-:  
2.9 ± 0.3 % vs. 2.8 ± 0.3 %; CD4+CD8+: 87.3 ± 0.6 % vs. 88.8 ± 0.8 %; CD4+: 7.0 ± 0.3 
% vs. 6.0 ± 0.4 %; CD8+: 2.8 ± 0.5 % vs. 2.4 ± 0.4 %). The 2:1 ratio of CD4 SP cells to 
CD8 SP cells observed in both mice (Figure 4.1B, Nrf2+/+ 7.0% : 2.8% versus Nrf2-/- 
6% : 2.4%) is characteristic of murine C57BL/6J thymocytes (Kontgen et al., 1993). 
Overall, this indicates that Nrf2 is not required for competent T cell development 
within the thymus.  
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Figure 4.1 Nrf2 does not regulate T cell development within the thymus. Isolated 
thymocytes derived from 10-12 week old Nrf2+/+ and Nrf2-/- mice were stained with CD4PE 
and CD8TC antibodies and analysed by flow cytometry. A. Representative flow scatter dot 
plot diagrams of murine Nrf2+/+ (left) and Nrf2-/- (right) thymocytes for expression of CD4 
and CD8. Percentages of T cell populations are indicated within the quadrants. B. 
Quantification of percentage of CD4-CD8-, CD4+, CD8+ and CD4+CD8+ T cells within Nrf2+/+ 
(orange) and Nrf2-/- (purple) thymocytes. Data are presented as average T cell 
percentages ± S.E.M. Data are derived from six independent experiments. 
 
 
 
 
 
A 
B 
103 
 
4.2.2 Loss of Nrf2 does not influence nTreg populations within the thymus 
Within the thymus, a distinctive immunosuppressive CD4 T cell subtype arises from 
mature CD4 SP thymocytes, namely nTregs (Sakaguchi, 2004). Natural occurring T 
regulatory cells are responsible for suppressing the activation and proliferation of 
peripheral self-reactive T cells, which have managed to escape negative selective 
events in the thymus. Therefore, they are critical for the dampening of autoimmune 
responses and subsequent disease (Sakaguchi, 2004). The development and 
immune function of nTregs are highly dependent upon the transcriptional activity 
of FoxP3 and expression of the IL-2 receptor α chain (IL-2Rα) CD25, both of which 
can be used as suitable markers for nTreg identification within the thymus (Yagi et 
al., 2004). It is recognised that Nrf2 deficient mice develop multi-organ 
autoimmune inflammation and lymphoproliferation (Ma et al., 2006). This suggests 
that there may be a potential defect in the nTreg population and subsequent 
immunosuppressive function. Although Nrf2 did not alter mature CD4 T cell 
proportions within the thymus, it does not exclude potential defects in nTreg 
development. In order to decipher whether Nrf2 regulated nTreg development 
within the thymus, Nrf2+/+ and Nrf2-/- thymocytes were incubated with fluorescently 
labelled CD4PE, CD8TC and  CD25Alexafluor®488 cell surface antibodies and analysed by 
flow cytometry. Cells were gated on the CD8-CD4+ T cell subset (upper left quadrant 
section) within the dot plot (Figure 4.1A). The CD25 expression was determined 
within this population and presented as a histogram (Figure 4.2A). These results 
indicate that there were no differences in CD25 expression between Nrf2+/+ and 
Nrf2-/- mature CD4 SP T cells (Figure 4.2B, 11 ± 1.1% versus 9.6 ± 1.4 %). This 
indicates that Nrf2 does not regulate nTreg subpopulations within the thymus.  
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Figure 4.2 Nrf2 does not influence natural occurring T regulatory cell populations within 
the thymus. Isolated thymocytes derived from 10-12 week old Nrf2+/+ and Nrf2-/- mice 
were stained with CD4PE, CD8TC and CD25Alexafluor®488 antibodies and analysed by flow 
cytometry. Cells were gated on CD4+ T cell population for analysis A. Representative 
Histograms of Nrf2+/+ (left) and Nrf2-/- (right) thymocytes for expression of CD25. The 
percentages of CD4 T cells expressing high levels of CD25 are indicated within the marker  
B. Quantification of percentage of CD4+ T cells expressing high levels of CD25 (CD4+CD25+) 
in Nrf2+/+ (orange) and Nrf2-/- (purple) thymocytes. Data are presented as average 
percentage of CD4+CD25+ T cells ± S.E.M. Data are derived from four independent 
experiments.  
A 
B 
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4.2.3 Loss of Nrf2 does not influence CD62L, CD69 and CD44 expression within the 
thymus 
As SP T cells mature within the thymic medulla region of the thymus, their 
chemokine and cell surface molecule expression changes. This reflects their ability 
to migrate through the thymic medulla, ultimately leading to their emigration from 
the thymus, through the blood stream to peripheral lymphoid organs (Nakayama et 
al., 2002). Phenotypic maturation of SP T cells is associated with increased 
expression of the lymphoid homing receptor CD62L (L-selectin) (Rosen et al., 2003) 
and decreased expression of the early T cell activation marker CD69 (Rosen et al., 
2003). Overexpression of CD69 has been shown to result in reduced T cell numbers 
in peripheral lymphoid organs (Nakayama et al., 2002). The cell surface glycoprotein 
CD44 is expressed on progenitor cells enabling their migration to the thymus (Wu et 
al., 1993). It is down regulated during CD4-CD8- DN1-DN4 differentiation, but is 
reacquired at CD4+CD8+ DP development (Rajasagi et al., 2009). Single positive T 
cells regain high expression of CD44 (Rajasagi et al., 2009). However, it is not 
required for egression from the thymus; but rather it operates in a similar way as in 
peripheral T cells, wherein it supports T cell expansion in conjunction with TCR 
activation. Therefore it can be seen as a T cell activation marker (Foger et al., 2000; 
Rajasagi et al., 2009).  
We sought to investigate whether Nrf2 may play a role in the regulation of CD62L, 
CD69 and CD44 in SP CD4 and CD8 T cells within the thymus; therefore, implicating 
a role in thymic lymphoid homing capacity and activation status. To address this 
issue, Nrf2+/+ and Nrf2-/- thymocytes were incubated with combinations of 
fluorescently labelled CD4PE, CD8TC, CD62LFITC, CD69FITC and CD44FITC cell surface 
antibodies and analysed by flow cytometry. Cells were gated on the CD8-CD4+ 
(upper left quadrant section) or CD8+CD4- (lower right quadrant section) T cell 
subsets for CD4+ thymocytes and CD8+ thymocytes, respectively (Figure 4.1A). 
Expression of CD62L (Figure 4.3A), CD69 (Figure 4.3B) and CD44 (Figure 4.3C) were 
determined within these gated populations and presented as overlay histograms. 
Up regulation or down modulation of the cell surface molecules were identified 
through a rightward or leftward shift in the histogram peak, respectively. Results 
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portrayed that there were no differences in CD62L (Figure 4.3A) or CD69 (Figure 
4.3B) expression in either CD4 (left hand panel) or CD8 (right hand panel) SP thymic 
T cells between Nrf2+/+ and Nrf2-/- mice. Collated data for cell surface molecule 
expression is depicted in Figure 4.3D.There was a slight increase in Nrf2-/- CD4+ 
CD44 expression in relation to its wild type counterpart (Figure 4.3C left hand panel 
CD4+ thymocytes, mean fluorescence intensity (MFI) 5466.3 versus 6134.7). 
However, no differences in CD44 expression were observed within the SP CD8 
population (Figure 4.3C right hand panel CD8+ thymocytes). Taken together, this 
suggests that Nrf2 does not play a role in the regulation of CD62L and CD69 
expression in mature thymic T cells, thus excluding Nrf2 from regulating particular 
aspects of mature thymic lymphoid homing capacity. Furthermore, this 
transcription factor plays a negligible role in the regulation of CD44 expression in 
mature thymic T cells.  
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4.2.4 Loss of Nrf2 does not affect T cell populations in peripheral lymphoid 
organs.   
We subsequently investigated whether loss of Nrf2 had any impact on CD4 and CD8 
T cell proportions within secondary lymphoid organs such as the spleen and lymph 
node. To address this, newly isolated Nrf2+/+ and Nrf2-/- splenic T lymphocytes were 
incubated with fluorescently labelled CD4PE and CD8TC  cell surface antibodies and 
analysed by flow cytometry. Results revealed that there were no differences in the 
Figure 4.3 Nrf2 does not regulate single positive CD4 and CD8 T cell expression of CD62L, 
CD69 or CD44 cell surface markers within the thymus. Isolated thymocytes derived from 
10-12 week old Nrf2+/+ and Nrf2-/- mice were stained with CD4PEand CD8TC in conjunction 
with CD62LFITC, CD69FITC or CD44FITC antibodies and analysed by flow cytometry. Cells were 
gated on CD4+ T cell (left) or CD8+ T cell (right) populations for analysis. Representative 
overlay histograms of Nrf2+/+ (grey block) and Nrf2-/- (red line) for thymocytes for A. CD62L, 
B. CD69 and C. CD44 expression. Data are representative of 3 independent experiments.. 
D. Collated CD62L, CD44 and CD69 expression graphs are presented as mean fluorescence 
intensity  (MFI) ± S.D. 
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composition of CD4 and CD8 T cell between Nrf2+/+ and Nrf2-/- T cells within the 
spleen, as illustrated in the representative dot plot (Figure 4.4Ai) and quantified in 
Figure 4.4Aii (Nrf2+/+ - CD4+ 25.7 ± 0.47%, CD8+ 15.2  ± 1.5% versus Nrf2-/- -  CD4+ 
21.7 ± 1.7%, CD8+ 14.1  ± 2.5%). Similar results were attained for Nrf2+/+ and Nrf2-/- 
T cells within the lymph node (Representative dot plot Figure 4.4Bi, collated data 
Figure 4.4Bii Nrf2+/+ - CD4+ 42.2 ± 1.5%, CD8+ 29.3 ± 1.8% versus Nrf2-/- -  CD4+ 40.2 ± 
0.9%, CD8+ 28.2  ± 1.5%). Conclusively, this illustrates that Nrf2 plays a negligible 
role in the homeostasis of T cell subpopulations within secondary lymphoid organs. 
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Figure 4.4 Nrf2 does not regulate the composition of CD4 and CD8 T cells within the 
periphery. Isolated murine Nrf2+/+ and Nrf2-/- splenocytes and lymph node-derived T cells 
were stained with CD4PE and CD8TC antibodies and analysed by flow cytometry. 
Representative flow scatter dot plot diagrams of Nrf2+/+ (left) and Nrf2-/- (right) Ai. 
splenocytes and Bi. lymph node-derived T cells for expression of CD4 and CD8. 
Percentages of T cell populations are indicated within the quadrants. Quantification of 
percentage of CD4-CD8-, CD4+, CD8+ and CD4+CD8+ T cells in Nrf2+/+ (orange) and Nrf2-/- 
(purple) Aii. splenocytes and Bii. lymph node-derived T cells. Data are presented as 
average T cell percentages ± S.E.M. Data are derived from four independent experiments.  
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4.2.5 Loss of Nrf2 results in elevated intracellular ROS levels in peripheral naïve T 
cells 
It is well known that Nrf2 regulates intracellular ROS levels in a variety of cell types 
including DCs and macrophages (Thimmulappa et al., 2006b; Williams et al., 2008); 
however, its role in the regulation of peripheral naïve T cell intracellular redox 
homeostasis has yet to be established. We therefore examined the intracellular 
ROS levels both basally and in response to the oxidative stress inducer H2O2, in 
freshly isolated splenic T cells derived from Nrf2+/+ and Nrf2-/- mice, using the 
fluorescent redox-sensitive probe, Dihydroethidium (DHE). Dihydroethidium is a 
colourless substance that can freely diffuse across the cell membrane. It is oxidised 
by intracellular superoxide radicals, emitting a red fluorescence upon oxidation. 
Therefore, it serves as a suitable ROS detector for flow cytometric analysis 
(Burnaugh et al., 2007). As demonstrated in Figure 4.5, naïve Nrf2-/- T cells displayed 
significantly higher ROS levels in comparison to their wild type control (1595.8 ± 
366.1 versus 2805.5 ± 244.1, p = 0.01). Reactive oxygen species in the Nrf2-/- T cells 
were slightly higher than the H2O2-treated Nrf2
+/+ T cells, although this was not 
significant (2805.5 ± 244.1 versus 2581.2 ± 412.9). Moreover, there was a 
significant increase in ROS levels between basal and H2O2 treated Nrf2
+/+ T cells 
(1595.8 ± 366.1 versus 2581.2 ± 412.9, P = 0.03). Taken together, this suggests that 
Nrf2 plays a role in the regulation of intracellular redox homeostasis in peripheral 
naïve T cells. 
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4.2.6 Loss of Nrf2 does not influence peripheral CD4 T cell activation with respect 
to CD25 expression  
During antigen-specific T cell activation, the high affinity IL-2R subunit CD25 (also 
known as IL-2Rα) is upregulated; combining with the IL-2Rβ (CD122) and γc (CD132) 
chains to complete the multimeric high affinity IL-2R on the T cell surface (Gaffen, 
2001). Activated T cell secretion of IL-2 then works in an autocrine fashion by 
binding to the high affinity IL-2R, driving the clonal expansion and differentiation of 
naive antigen-specific T cells into effector T cells (Boyman and Sprent, 2012). As a 
result, CD25 expression is regarded as one of the early markers of T cell activation 
(Gundelach et al., 2013). We investigated whether increased ROS present in the 
Nrf2 deficient T cells may support T cell activation, thus enhancing CD25 expression 
in naïve CD4 T cells within secondary lymphoid organs. To achieve this, Nrf2+/+ and 
Nrf2-/-splenic T lymphocytes were incubated with fluorescently labelled CD4PE and  
4.5 Nrf2 regulates intracellular ROS levels in naïve T cells. Isolated splenocytes from 10-12 
week old Nrf2+/+ (orange)  and Nrf2-/-  (purple) mice were treated with or without H2O2 
(basal) for 10 min. Cells were subsequently incubated with the ROS indicator 
dihydroethidium and analysed by flow cytometry. Data are presented as average mean 
fluorescence intensity ± S.D. Statistical significance was assessed using unpaired Student’s 
t test. Data are representative of four independent experiments. (*, p < 0.05; **, p < 0.01). 
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CD25Alexafluor®488 cell surface antibodies and analysed by flow cytometry. Results 
revealed that there were no differences in percentages of CD4+CD25+ T cells (upper 
right quadrant section) between Nrf2+/+ and Nrf2-/- T cells within the spleen; as 
illustrated in Figure 4.6Ai and further quantified in Figure 4.6Aii (8.7 ± 0.9% versus 
9.5 ± 0.8%). Similarly, there were no changes in naïve CD4 T cell CD25 expression 
between  Nrf2+/+ and Nrf2-/-  mice within the lymph node (Dot plot Figure 4.6Bi and 
collated data Figure 4.6Bii  9.3 ± 1.0% versus 10.9 ± 0.7%). In summary, these 
results suggest that Nrf2 does not regulate CD25 expression in naïve CD4 T cells in 
secondary lymphoid organs. 
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4.2.7 Naïve Nrf2 deficient T cells manifest low levels of T cell activation within 
lymphoid organs. 
As a consequence of T cell activation, the patterns of chemokines and other 
activation molecules are transformed on the T cell surface. This facilitates further T 
cell proliferation, differentiation and egression from the lymphoid organs to sites of 
Bi 
Bii 
Figure 4.6 Nrf2 does not regulate the CD4 expression of CD25 activation marker within 
the periphery. Isolated  murine Nrf2+/+ and Nrf2-/- splenocytes and lymph node derived T 
cells were stained with CD4PE and CD25Alexafluor®488 antibodies and analysed by flow 
cytometry. Cells were gated on CD4+ T cell population for analysis. Representative flow 
scatter dot plot diagrams of Nrf2+/+ (left) and Nrf2-/- (right) Ai. splenocytes and Bi. lymph 
node-derived T cells for expression of CD4 and CD25. Percentages of T cell populations are 
indicated within the quadrants. Quantification of percentage of CD4+CD25+ T cells in Nrf2+/+ 
(orange) and Nrf2-/- (purple) Aii. splenocytes and Bii. lymph node-derived T cells. Data are 
presented as average percentage of CD4+CD25+ T cells ± S.E.M. Data are derived from four 
independent experiments.  
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infection (Masopust and Schenkel, 2013). In addition to heightened CD25 
expression, T cell activation results in an upregulation of CD69 and CD44 (Foger et 
al., 2000). In contrast to the thymus, CD69 is seen as the earliest T cell activation 
marker, rapidly induced from as early as 1 hour post-T cell activation and is involved 
in the promotion of T cell proliferation (Marzio et al., 1999). Similarly, CD44 
supports signal transduction through the TCR/CD3 complex (Foger et al., 2000). T 
cell activation is also associated with a down regulation in CD62L expression, with 
an increase in levels of non-lymphoid markers such as CXCR3, thus permitting 
departure from the lymphoid organs (Masopust and Schenkel, 2013). Oxidative 
stress can enhance and down regulate CD44 and CD62L expression in peripheral 
naïve T cells, respectively (Case et al., 2011; Foster et al., 2013). However it is 
unknown whether the increased ROS levels exhibited in the Nrf2 deficient T cells 
would promote their T cell activation status through regulation of CD44, CD69 and 
CD62L expression in secondary lymphoid organs. To examine this possibility, Nrf2+/+ 
and Nrf2-/- splenocytes (Figure 4.7A-C) and lymphocytes (Figure 4.7D-E) were 
incubated with combinations of fluorescently labelled CD4PE, CD8TC, CD62LFITC, 
CD69FITC and CD44FITC cell surface antibodies and analysed by flow cytometry. Cells 
were gated on the CD8-CD4+ (upper left quadrant section) or CD8+CD4- (lower right 
quadrant section) T cell subsets shown in Figure 4.5Ai for spleen and Figure 4.5Bi 
for lymph node. Expression of CD62L (Figure 4.7A and D), CD69 (Figure 4.7B and E) 
and CD44 (Figure 4.7C and F) were determined within these gated populations and 
presented as overlay histograms. Up regulation or down modulation of the cell 
surface molecules were identified through a rightward or leftward shift in the 
histogram peak, respectively. Changes in higher expressing cell populations were 
also monitored.  
With reference to the spleen, no differences in CD62L expression were exhibited 
between Nrf2+/+ and Nrf2-/- CD4 or CD8 T cells (Figure 4.7A left hand panel, CD4 T 
cells; right hand panel, CD8 T cells). Similarly, no changes in CD69 expression were 
observed between splenic Nrf2+/+ and Nrf2-/- CD4 T cells (Figure 4.7B left hand 
panel, CD4+ T cells). Although there appears to be a shift in population from the low 
expressing CD69 peak to the higher expressing CD69 peak in Nrf2-/- CD4 T cells 
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(highlighted by marker), there was no major difference in the percentage of high 
expressing CD69 cells between both groups (Figure 4.7B left hand panel, CD4+ T 
cells, Nrf2+/+ 10.8% versus Nrf2-/- 13.3%). In contrast, Nrf2-/- CD8 T cells appeared to 
express higher levels of CD69 in comparison to their wild type counterpart as seen 
in the rightward histogram peak shift in Figure 4.7B (right hand panel, Nrf2+/+ MFI 
1158.9 versus Nrf2-/- MFI 1303.34). As indicated in Figure 4.7C, Nrf2-/- CD4 T cells 
displayed greater levels of CD44 expression in relation to the control group (Nrf2+/+ 
MFI 1998.7 versus Nrf2-/- MFI 2321.5). Although a rightward shift in histogram peak 
was not observed, there was population change in the proportion of Nrf2-/- CD4 T 
cells expressing higher levels CD44 (as indicated by the marker) in comparison to 
the wild type counterpart (20.4% versus 27.3%). Similar expression of CD44 was 
observed between Nrf2+/+ and Nrf2-/- splenic CD8 T cells (Figure 4.7C left hand 
panel). Our results demonstrate that loss of Nrf2 results in marginal low levels of 
CD4 T cell activation in terms of enhanced CD44 expression within the spleen.  
With reference to the lymph node, both naïve Nrf2-/- CD4 and CD8 T cells exhibited 
a down regulation in CD62L expression in comparison to their wild type 
counterparts, as observed as a leftward peak shift illustrated in Figure 4.7D (Left 
hand panel CD4+ T cells, Nrf2+/+ MFI 2423.9 versus Nrf2-/- MFI 2033.5; right hand 
panel CD8+ T cells Nrf2+/+ MFI 3818.37 versus Nrf2-/- MFI 3280.7). In contrast, no 
changes in CD69 expression were observed between Nrf2+/+ and Nrf2-/- lymph node-
derived CD4 and CD8 T cells (Figure 4.7E left and right hand panel, respectively). 
Lymph node-derived naïve Nrf2-/- CD4 T cells displayed enhanced CD44 expression 
in relation to their wild type control group (Figure 4.7F left hand panel CD4+ T cells 
Nrf2+/+ MFI 7783.4, percentage of CD4+CD44hi cells 8.7% versus Nrf2-/- MFI 11231.4, 
13.3%). This proportional increase was also apparent in Nrf2-/- CD8 T cells (Figure 
4.7F left hand panel CD4+ T cells, Nrf2+/+ MFI 7783.4, percentage of CD4+CD44hi cells 
8.7% versus Nrf2-/- MFI 11231.4, 13.3%). Taken together our results demonstrate 
that loss of Nrf2 results in marginally low levels of CD4 and CD8 T cell within the 
lymph node regions of secondary lymphoid organs.  
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Figure 4.7 Loss of Nrf2 results in the induction of low level naïve T cell activation. Isolated 
splenocytes and lymph node derived T cells derived from 10-12 week old Nrf2+/+ and Nrf2-/- 
mice were stained with CD4PEand CD8TC in conjunction with CD62LFITC, CD69FITC or CD44FITC 
antibodies and analysed by flow cytometry. Cells were gated on CD4+ T cell (left) or CD8+ T 
cell (right) populations for analysis. Representative overlay histograms of Nrf2+/+ (grey 
block) and Nrf2-/- (red line) splenocytes for A. CD62L, B. CD69 and C. CD44 expression and 
lymph node derive T cell expression of D. CD62L, E. CD69 and F. CD44. Markers indicated 
above histogram peaks denote high cell surface marker expressing populations. Data are 
representative of 3 independent experiments 
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4.2.8 Loss of Nrf2 results in marginally enhanced effector T cell proliferation. 
We have previously shown that Nrf2 deficient naïve T cells elicit signs of low level T 
cell activation in the secondary lymphoid organs. In light of this finding, we 
investigated whether loss of Nrf2 would influence the proliferative capacity of 
peripheral naïve splenic T cells in response to non-specific TCR/CD3 stimulation, 
using increasing concentrations of immobilised CD3 and CD28 antibodies. 
Utilisation of the CD3 antibody facilitates the cross linkage of the TCR/CD3 complex 
enabling non-specific T cell proliferation in the absence of APC-mediated antigen 
stimulation (Harding et al., 1992). Similarly to APC-mediated T cell activation, 
additional co-stimulatory signalling is necessary for competent T cell proliferation 
(Harding et al., 1992). Therefore, in addition to TCR/CD3 complex signal 
transduction, CD28 antibody is provided, which crosslinks with its co-stimulatory 
molecule, enabling optimal non-specific T cell proliferation (Harding et al., 1992). 
Results revealed that there were no significant differences in T cell proliferation 
between Nrf2+/+ and Nrf2-/- splenic T cells in response to increasing concentrations 
of plate bound anti-CD3 and anti-CD28 (Figure 4.8A).  
Nrf2 plays a pivotal role in the regulation of naïve T cell differentiation in a murine 
asthma model (Rangasamy et al., 2005). However, it is unknown whether Nrf2 
influences the proliferative capabilities of effector T cells in response to increasing 
concentrations of immobilised anti-CD3 and anti-CD28 under normal conditions. To 
address this, naive Nrf2+/+ and Nrf2-/- splenic T cells were stimulated with plate 
bound anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml). Cells were cultured for 6 days to 
enable differentiation into effector T cells which occurs 4-5 days post-naïve T cell 
activation (Murphy et al., 2012). Day 6 splenic effector Nrf2+/+ and Nrf2-/- T cells 
were re-stimulated with increasing concentrations of plate bound anti-CD3 and 
anti-CD28 as above. Results demonstrated that Nrf2-/- T cells exhibited significantly 
enhanced T cell proliferation in relation to the wild type control at all 
concentrations of anti-CD3 and anti-CD28 (Figure 4.8B). At the 0.25 µg/ml 
CD3/CD28 concentration there was an approximate 23% increase in T cell 
proliferation in effector Nrf2-/- T cells in comparison to their wild type counterpart 
(Figure 4.8B, Nrf2+/+ 6.4 x 104 ± 3931 cpm versus Nrf2-/-  7.9 x 104 ± 5811 cpm, p = 
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0.01). An approximate 27% and 56% increase were also observed at the 0.5 µg/ml 
(Nrf2+/+ 6.6 x104 ± 3734 cpm versus Nrf2-/-  8.6 x 104 ± 6122 cpm, p = 0.01) and 1 
µg/ml  (Nrf2+/+ 5.7 x 104 ± 4867 cpm versus Nrf2-/-  8.9 x 104 ± 13744 cpm, p = 0.02) 
concentrations of anti-CD3 and anti-CD28, respectively. This result suggests that 
Nrf2 plays a role in the regulation of effector T cell proliferation.  
 
 
Figure 4.8 Loss of Nrf2 results in the induction enhanced effector T cell proliferation in 
response to TCR stimulation. A. Naïve splenic T cells and B. Day 6 cultured effector T cells  
derived from 10-12 week old Nrf2
+/+
 and Nrf2
-/-  
mice were stimulated with increasing 
concentrations of immobilised anti-CD3 and anti-CD28 antibodies for 72 h. [
3
H]-Thymidine 
(
3
H-Thy) was added for the last 16 h. Proliferation of T cells was determined by scintillation 
counting of incorporated 
3
H-Thy. Data are presented as average 
3
H-Thy scintillation counts 
± S.D. Statistical significance was assessed using unpaired Student’s t test. Data are 
representative of four independent experiments. (* p < 0.05; ** p < 0.01). 
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4.2.9 Loss of Nrf2 results in enhanced effector CD4 T cell IFNγ production. 
Nrf2 regulates CD4 T cell production of Th2 IL-4 and IL-13 in response to antibody 
re-stimulation in a murine model of asthma (Rangasamy et al., 2005). Furthermore, 
Nrf2 regulates CD4 T cell Th1 IFNγ production under hypoxic conditions (Roman et 
al., 2010). Therefore, Nrf2 plays a pivotal role in the maintenance of CD4 T cell 
differentiation within these settings. We thus endeavoured to examine the effects 
of loss of Nrf2 on effector CD4 T cell and CD8 T cell immune function by measuring 
IFNγ production under normal conditions. This was achieved by re-stimulating day 6 
splenic Nrf2+/+ and Nrf2-/- T cells with or without immobilised anti-CD3 and anti-
CD28 for 5 hours. Cell were subsequently incubated with fluorescently labelled 
CD4PE and CD8TC, followed by cell fixation and permeabilisation, and finally 
intracellular cytokine staining with fluorescently labelled IFNγFITC. Effector T cells 
were then analysed using flow cytometry. Initially, we examined whether loss of 
Nrf2 had any impact on the proportion of effector CD4 and CD8 splenic T cells with 
or without antibody re-stimulation. Results portrayed that there were no 
differences in the composition of CD4 and CD8 T cells between effector Nrf2+/+ and 
Nrf2-/- splenic T cells in the presence and absence of antibody stimulation (Figure 
4.9Ai, representative dot plot; Figure 4.9Aii, collated data). It is worthy to note that 
CD3 and CD28 T cell stimulation induces the preferential expansion of CD8 T cells 
over CD4 T cells (Ernst et al., 1989). As a result, the splenic CD4:CD8 T cell ratio 
which was originally approximately 2:1 for naïve T cells (Figure 4.5Ai), has reversed 
in splenic effector T cells in favour of the CD8 subtype at approximately 1:3 ratio 
(Figure 4.9Ai and ii). This was similar for both unstimulated and re-stimulated 
effector T cells (Figure 4.9Ai and ii). Subsequently, cells were gated on the CD8-CD4+ 
T cell subset (Figure 4.9Ai, lower panel, upper left quadrant section) and CD8+CD4- 
T cell subset (Figure 4.9Ai, lower panel, bottom right quadrant section) within the 
dot plot to assess CD4 and CD8 T cell effector IFNγ production as illustrated in 
Figure 4.9B. The IFNγ expression was determined within these populations (Figure 
4.9B). Results demonstrated that loss of Nrf2 gave rise to a significant increase in 
the percentage of CD4+IFNγ+ effector T cells in comparison to their wild type control 
(Figure 4.9Bi, Nrf2+/+ 4.4 ± 0.6% versus Nrf2-/-  8.6 ± 1.2%, p = 0.02) which is 
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indicative of enhanced CD4 Th1 T cells (Hsieh et al., 1993). In contrast, there were 
no significant differences in CD8+IFNγ+ T cell percentages between Nrf2+/+ and Nrf2-
/- mice (Figure 4.9Bii). Taken together, this suggests that loss of Nrf2 results in 
enhanced effector CD4 T cell IFNγ production.  
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4.2.10 Nrf2 regulates CD4 effector subset differentiation in purified splenic CD4 T 
cells 
As we have identified a key role of Nrf2 in the maintenance of CD4 Th1 effector T 
cell immune function, we subsequently investigated whether loss of Nrf2 had an 
impact on the production of other CD4 lineage specific cytokines including TNFα 
(Th1), IL-5 (Th2) and IL-17 (Th17), in an attempt to further explore the role of Nrf2 
in the regulation of CD4 subset differentiation (Zhu et al., 2010). In order to address 
this, purified day 6 Nrf2+/+ and Nrf2-/- splenic  effector CD4 T cells were re-
stimulated with plate bound anti-CD3 and anti-CD28 for 16 hours and cytokine 
production in the effector T cell supernatants were assessed by ELISA method. 
Initially to reaffirm our previous finding that loss of Nrf2 enhances IFNγ production 
in CD4 T cells, we examined the differences in absolute amounts (pg/ml) of IFNγ 
between the two mice. Results confirmed that effector CD4 Nrf2-/- T cells secreted 
B 
Figure 4.9 Loss of Nrf2 enhances the proportion of CD4 effector IFNγ producing T cells 
during re-stimulation. Nrf2
+/+
 and Nrf2
-/-  
day 6 splenic effector T cells were re-stimulated 
with or without immobilised CD3 and CD28 antibodies and assessed for intracellular 
cytokine IFNγ production in CD4 and CD8 T cell populations. Ai. Representative flow 
scatter dot plot diagrams of Nrf2
+/+
 (left) and Nrf2
-/- 
(right) effector splenic effector CD4 
and CD8 T cell populations. Percentages of T cell populations are indicated within the 
quadrants. Aii. Quantification of percentages of CD4
-
CD8
-
, CD4
+
, CD8
+
 and CD4
+
CD8
+ 
T cells 
in Nrf2
+/+
 (orange) and Nrf2
-/- 
(purple) in presence (right) or absence (left) of antibody 
stimulation. B. Quantified percentages of CD4
+
IFNγ
+
 (left) (gated on CD4 high population) 
and CD8
+
IFNγ
+ 
cells (gated on CD8 high population) (right) in Nrf2
+/+
 (orange) and Nrf2
-/- 
(purple) splenic effector T cells. Data are presented as average percentage of T cells ± 
S.E.M. Statistical significance was assessed using unpaired Student’s t test. Data are 
derived from four independent experiments (*, p < 0.05). 
B 
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significantly elevated levels of IFNγ in comparison to the wild type control (Figure 
4.10A, Nrf2+/+ 87704.3 ± 2930.0 pg/ml versus Nrf2-/-  113151.9 ± 7724.7 pg/ml, p = 
0.04). In contrast, Nrf2 deficient T cells produced lower levels of TNFα with respect 
to the wild type effector T cells (Figure 4.10B, Nrf2+/+ 1898.7 ± 113.6 pg/ml versus 
Nrf2-/-  1297.1 ± 7.6 pg/ml, p = 0.04. Studies have shown that loss of Nrf2 does not 
influence naïve CD4 Th2 cytokine secretion in response to antibody stimulation 
(Rangasamy et al., 2005); however, it is unknown whether loss of Nrf2 impacts on 
CD4 effector T cell Th2 cytokine secretion. We therefore assessed the secretion of 
Th2 specific IL-5 production between re-stimulated effector Nrf2+/+ and Nrf2-/- CD4 T 
cells. Results illustrated that Nrf2-/- splenic effector CD4 T cells secreted significantly 
less IL-5 in comparison to the wild type control (Figure 4.10C, Nrf2+/+ 875.5 ± 51.7 
pg/ml versus Nrf2-/-  716.9 ± 31.2 pg/ml, p = 0.04). The recently identified CD4 Th17 
subset plays a pivotal role in the pathogenesis of autoimmune diseases such as MS 
(Zhu and Qian, 2012). Therefore we examined whether Nrf2 had an impact on 
effector Th17 cytokine production of IL-17A under normal conditions. Results 
clearly demonstrated that Nrf2 deficient effector CD4 T cell secreted significantly 
increased levels of IL-17A in comparison to effector Nrf2-/- CD4 T cells (Figure 4.10D, 
Nrf2+/+ 263.3 ± 104.7 pg/ml versus Nrf2-/-  693.8 ± 131.0 pg/ml, p = 0.01). Taken 
together our results reveal a role for Nrf2 in the control of CD4 effector Th1/Th2 
cell differentiation. Importantly, results have indicated a novel underlying role of 
Nrf2 in the regulation of the effector T cell IL-17 production.  
 
 
 
 
 
 
124 
 
 
 
 
 
4.2.11 Loss of Nrf2 results in enhanced differentiation of CD4+IL-17+ splenic 
effector T cells  
In light of our previous finding that Nrf2 deficient effector CD4 T cells produced 
elevated levels of IL-17, we speculated that loss of Nrf2 may predispose CD4 T cells 
to differentiate into effector Th17 cells, under Th17 lineage polarisation conditions 
(Mangan et al., 2006; Veldhoen et al., 2006). In order to explore this, purified naïve 
Nrf2+/+ and Nrf2-/- CD4 T cells were treated with or without a Th17 inducting 
cytokine cocktail consisting of IL-6, TGFβ, IL-23 and IL-1β to promote Th17 
polarisation (Mangan et al., 2006; Veldhoen et al., 2006). Cells were stimulated with 
immobilised anti-CD3 and anti-CD28 as before and cultured for 6 days to enable 
differentiation into effector cells. Day 6 Nrf2+/+ and Nrf2-/- CD4 T cells in the 
A B 
C D 
Figure 4.10 Nrf2 regulates CD4 effector T cell signature cytokine production. CD4 purified 
day 6 cultured Nrf2
+/+ 
and Nrf2
-/- 
effector T cells  were re-stimulated with immobilised anti-
CD3 and anti-CD28 antibodies for 24 h. Levels of A. IFNγ, B. TNFα, C. IL-5 and D. IL-17A in 
supernatants were measured by ELISA. Data are presented as average pg/ml ± S.D. Data is 
representative of three independent experiments. Statistical significance was assessed 
using unpaired Student’s t test. (* p < 0.05; ** p < 0.01). 
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presence or absence of Th17 polarising cytokines were re-stimulated with or 
without PMA, ionomycin and immobilised anti-CD3 for 5 hours. Cells were then 
stained with cell surface CD4PE and subsequently assessed for intracellular cytokine 
production of IL-17APerCp-Cy5.5 and IFNγFITC by flow cytometry. Cells were gated on 
the high CD4 population and simultaneous assessment of the percentage CD4 IL-
17A and or IFNγ producing cells were determined by dot plot as represented in 
Figure 4.11A. Effector CD4+IL-17+ and CD4+IFNγ+ T cells were shown in the upper 
left and lower quadrant sections within the dot plots, respectively (Figure 4.11A). 
Percentages of CD4+IL-17+ and CD4+IFNγ+ T cells present in the stimulated effector T 
cells were subtracted from their respective unstimulated control and quantified in 
Figure 4.11B. Results revealed that basal Nrf2 deficient T cells exhibited significantly 
increased percentages of CD4+IL-17+ T cells in comparison to their wild type 
counterpart (Figure 4.11Bi, Nrf2+/+ 0.3 ± 0.1% versus Nrf2-/-  0.8 ± 0.2%, p = 0.002). 
Under Th17 polarising conditions, both Nrf2+/+ and Nrf2-/- splenic effector CD4 T 
cells showed increased numbers of CD4+IL-17+ T cells in comparison to their 
respective basal controls (Figure 4.11Bi, Nrf2+/+ 0.3 ± 0.1% versus Nrf2+/+ + Th17 
inducing cytokines  1.6 ± 0.3%, p = 0.001; Nrf2-/- 0.8 ± 0.2% versus Nrf2-/- + Th17 
inducing cytokines  2.2 ± 0.5%, p = 0.009). However, there were no significant 
differences in CD4+IL-17+ T cells numbers between the Th17 polarised Nrf2+/+ and 
Nrf2-/- splenic effector CD4 T cells (Figure 4.11Bi). In contrast to our previous 
finding, there was no significant changes in the percentage of CD4+IFNγ+ T cells 
under this type of re-stimulation between the Nrf2+/+ and Nrf2-/- mice. It has been 
established that IFNγ inhibits the development of Th17 cells and thus Th17 cells 
secrete minimal levels of this Th1 specific cytokine (Harrington et al., 2005). Our 
results indicate that under Th17 polarising conditions, a significant decrease in 
CD4+IFNγ+ T cells was observed in both Nrf2+/+ and Nrf2-/- splenic effector CD4 T 
cells in comparison to their respective basal control (Figure 4.11Bii, Nrf2+/+ 17.8 ± 
4.2% versus Nrf2+/+ + Th17 inducing cytokines  4.2 ± 1.5%, p = 0.01; Nrf2-/- 21.3 ± 
5.8% versus Nrf2-/- + Th17 inducing cytokines  5.2 ± 1.4%, p = 0.02). However no 
significant differences were present between the Th17-polarised Nrf2+/+ and Nrf2-/- 
splenic effector CD4 T cells. Taken together, this suggests that loss of Nrf2 enhances 
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the proportion of CD4+IL-17+ T cells under normal conditions Nrf2 appears to play 
under Th17 polarising conditions.  
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Bii 
Figure 4.11 Splenic Nrf2
-/- 
effector T cells exhibit increased levels of CD4 IL-17 producing 
cells. CD4 purified Nrf2
+/+ 
and Nrf2
-/- 
T cells were cultured in the presence or absence of 
Th17 inducing cytokine cocktail (TGFβ, IL-1β, IL-6 and IL-23) for 6 days. Cells were re-
stimulated with plate bound CD3 antibody, PMA and ionomycin for 5 hours and assessed 
for intracellular cytokine production of IFNγ and IL-17A. Cells left unstimulated were used 
as background control. A. Representative dot plot of Nrf2
+/+ 
(left) and Nrf2
-/- 
(right)
 
effector 
T cells expressing IFNγ and IL-17A under basal (upper panel) of Th17 polarising (lower 
panel) conditions. Cells were gated on CD4 high populations. Quantification of the average 
percentage of Bi. CD4
+
IL17A
+
 and Bii CD4
+
IFNy
+ 
cells in basal Nrf2
+/+ 
(orange) and Nrf2
-/- 
(purple), and Th17 polarised Nrf2
+/+ 
(green) and Nrf2
-/- 
(blue) effector T cells. Percentages 
were subtracted from unstimulated control. Data are presented as average percentage of 
T cells ± S.E.M. Statistical significance was assessed using unpaired Student’s t test. Data 
are derived from five independent experiments (**, p < 0.01). 
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4.2.12 Loss of Nrf2 results in enhanced CD4 effector Th17 specific cytokine 
production under basal and Th17 polarising conditions. 
Although loss of Nrf2 does not appear to enhance CD4+IL-17+ or CD4+IFNγ+ T cells 
under Th17 polarising conditions, we cannot rule out that per cell these populations 
could potentially be producing more cytokine in comparison to the wild type 
control. To examine this possibility, day 6 Th17-polarised or basal Nrf2+/+ and Nrf2-/- 
splenic effector CD4 T cells were re-stimulated with plate bound anti-CD3 and anti-
CD28 overnight and cytokine production was assessed by ELISA. In line with our 
previous finding, Nrf2-/- splenic effector CD4 T cells displayed elevated levels of IL-
17A production in comparison to wild type control (Figure 4.12A, Nrf2+/+ not 
detected 0.0 ± 0.0 pg/ml versus Nrf2-/-  1383.9 ± 146.0 pg/ml, p = 0.004). Under 
Th17 polarising conditions, our results clearly demonstrate that polarised Nrf2-/- 
splenic effector CD4 T cells secreted increased levels of IL-17A in comparison to the 
wild type control (Figure 4.12A, Nrf2+/+ + Th17 cytokines 2655.9 ± 212.4 pg/ml 
versus Nrf2-/- + Th17 cytokines 6239.7 ± 490.7 pg/ml, p = 0.0003), thus supporting 
the notion that the Nrf2 deficient effector cells were secreting more cytokine on a 
per cell basis. In line with Figure 4.10, basal Nrf2 deficient effector CD4 T cells 
exhibited increased levels of IFNγ production in comparison to Nrf2+/+ effector T 
cells  (Figure 4.12B, Nrf2+/+ 87704.3 ± 2930.0 pg/ml versus Nrf2-/- 113150.9 ± 7724.7 
pg/ml, p = 0.04). Under Th17 polarising conditions, a significant decrease in IFNγ 
production was observed in both Nrf2+/+ and Nrf2-/- splenic effector CD4 T cells with 
respect to their basal control (Figure 4.12B, Nrf2+/+ 87704.3 ± 2930.0 pg/ml versus 
Nrf2+/+ + Th17 inducing cytokines  9956.6 ± 457.3 pg/ml, p = 0.001; Nrf2-/- 113150.9 
± 7724.7 pg/ml versus Nrf2-/- + Th17 inducing cytokines 20041.3 ± 4027.1 pg/ml, p = 
0.0004). An increase in IFNγ production was observed in the Th17-polarised Nrf2 
deficient CD4 T cells in comparison to their wild type counterpart; however, this 
was not statistically significant (p = 0.07).  We next assessed the level of IL-22 
secretion between re-stimulated basal and Th17-polarised Nrf2+/+ and Nrf2-/- splenic 
effector CD4 T cells. As IL-22 is a key cytokine produced by the distinctive Th17 
effector subset (Zhu and Qian, 2012), it would be reasonable to assume that Nrf2 
deficient T cells would produce enhanced IL-22 levels, as a consequence of their 
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increased IL-17 production. Results revealed that basal Nrf2+/+ and Nrf2-/- splenic 
CD4 T cells secreted very low levels of IL-22. Nonetheless, basal Nrf2 deficient 
effector CD4 T cells still produced significantly more IL-22 than Nrf2+/+ splenic CD4 T 
cells (Figure 4.12C, Nrf2+/+ 1.81 ± 3.1 pg/ml versus Nrf2-/- 23.4 ± 5.3 pg/ml, p = 
0.004). Under Th17 polarising conditions, both Nrf2+/+ and Nrf2-/- splenic CD4 T cells 
exhibited augmented IL-22 levels with respect to their basal control (Figure 4.12C, 
Nrf2+/+ 1.81 ± 3.1 pg/ml versus Nrf2+/+ + Th17 inducing cytokines  47.1 ± 8.5 pg/ml, p 
= 0.001; Nrf2-/- 23.4 ± 5.3 pg/ml versus Nrf2-/- + Th17 inducing cytokines 154.5 ± 6.6 
pg/ml, p < 0.0001). Furthermore, polarised Nrf2 deficient T cells manifested 
enhanced IL-22 production in comparison to their wild type counterpart (Figure 
4.12C, Nrf2+/+ + Th17 inducing cytokines 47.1 ± 8.5 versus Nrf2-/- + Th17 inducing 
cytokines 154.5 ± 6.6 pg/ml, p < 0.0001). We have established that loss of Nrf2 
results in enhanced Th17 specific cytokine production of IL-17A and IL-22 under 
polarising conditions. However, it is unknown whether loss of Nrf2 has an impact on 
effector Th2 IL-5 production under Th17 polarising conditions. Results depicted a 
significant decrease in IL-5 production was observed in both Th17-polarised Nrf2+/+ 
and Nrf2-/- splenic effector CD4 T cells with respect to their basal control (Figure 
4.12D, Nrf2+/+ 869.5 ± 62.0 pg/ml versus Nrf2+/+ + Th17 inducing cytokines  7.3 ± 1.4 
pg/ml, p = 0.002; Nrf2-/- 741.9 ± 22.1 pg/ml versus Nrf2-/- + Th17 inducing cytokines  
38.6 ± 3.0 pg/ml, p = 0.0003). Intriguingly, results revealed that under polarising 
conditions, Nrf2 deficient effector T cells secreted higher levels of IL-5 in 
comparison to their wild type counterpart as shown in Figure 4.12D (Nrf2+/+ + Th17 
inducing cytokines 7.3 ± 1.4 pg/ml versus Nrf2-/- + Th17 inducing cytokines 38.6 ± 3.0 
pg/ml, p < 0.0001). Taken together, these results suggest the loss Nrf2 results in the 
enhanced predisposition of Th17 differentiation in CD4 T cells under basal and Th17 
polarising conditions. 
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Figure 4.12 Nrf2 regulates CD4 effector T cell signature cytokine production. CD4 purified 
Nrf2
+/+ 
and Nrf2
-/- 
T cells were cultured in the presence or absence of Th17 inducing 
cytokine cocktail (TGFβ, IL-1β, IL-6 and IL-23) for 6 days. Cells were re-stimulated with 
immobilised anti-CD3 and anti-CD28 antibodies for 24 h. Levels of A. IL-17A, B. IFNγ, C. IL-
22 and D. IL-5 in supernatants were measured by ELISA. Data are presented as average 
pg/ml ± S.D. Data is representative of three independent experiments. Statistical 
significance was assessed using unpaired Student’s t test. (*, p < 0.05; **, p < 0.01). 
A B 
C D 
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4.3 DISCUSSION 
The transcription factor Nrf2 plays a pivotal role in the regulation of antioxidant and 
cytoprotective genes involved in the counteraction of oxidative insults. Therefore, it 
is indispensable for the maintenance of cellular redox homeostasis (Copple et al., 
2010). Evidence has emerged on the anti-inflammatory effects of Nrf2 in a variety 
of oxidative murine disease models including EAE (MS), sepsis, emphysema, asthma 
and brain neuroinflammation (Rangasamy et al., 2005; Thimmulappa et al., 2006b; 
Innamorato et al., 2008; Sussan et al., 2009; Johnson et al., 2010). Furthermore, 
Nrf2 has been shown to regulate innate immune responses with respect to 
macrophage and DC immune function (Williams et al., 2008; Reddy et al., 2009a; 
Kong et al., 2010; Rangasamy et al., 2010; Kong et al., 2011; Aw Yeang et al., 2012). 
However, little is known about the impact of this transcription factor on the 
maintenance of adaptive immune responses, in particular T cells. The present 
chapter investigated the role of Nrf2 in T cell development and immune function. 
Our results demonstrated that Nrf2 was not a critical driving force of T cell 
development within the thymus and peripheral secondary lymphoid organs. 
However, it did play an important role in the regulation of naïve T cell intracellular 
ROS levels, T cell activation and proliferation. Furthermore, our results established a 
role of Nrf2 in the maintenance of CD4 T cell differentiation, particularly in Th17 
development. This latter finding is of huge relevance given the emerging role of the 
newly identified Th17 cells in the pathogenesis of autoimmune diseases, thus 
merits intense investigations.  
Reflecting on the role of Nrf2 in T cell development within the thymus, although we 
determined that Nrf2 plays a minor role in the overall thymic T cell proportions, we 
have not fully assessed the impact of Nrf2 on the various stages of thymocyte 
differentiation within the DN population. As immature thymocytes transverse 
through the thymic cortex, they proceed through DN1 – DN4 stages of 
differentiation as typified by CD44 and CD25 expression; ensuring the development 
of competent TCR and progression to the DP phase (Germain, 2002). It is feasible 
that Nrf2 may modulate the degree of differentiation from DN1 through to DN4 
maturation stages. Additional staining of CD44 and CD25 on the gated DN cells 
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would resolve this matter. Furthermore, SP CD4 and CD8 T cells undergo various 
stages of maturation within the thymic medulla as characterised by differential 
CD69 and CD62L expression (Rosen et al., 2003). Our results demonstrated that 
there were no changes in the expression of these markers in the Nrf2 deficient 
thymocytes. Retrospectively, it would have been more informative to examine 
CD69 and CD62L simultaneously in the mature SP populations so as to achieve a 
finer resolution of the maturation stages within the thymic medulla. Loss of Nrf2 
had no significant impact on the proportion of nTregs within the thymus with 
respect to CD25 expression. However, it would have been useful to examine the 
levels of FoxP3 expression in this population (Gavin et al., 2007). The expression of 
this transcription factor is necessary not only for their development but for their 
immunosuppressive function (Gavin et al., 2007), the latter of which could also 
have been examined. It has been proposed that another SP CD4- derived T cell 
population which are devoid of FoxP3 expression known as natural Th17 cells 
(nTh17), develop in a somewhat similar fashion to nTregs within the thymus (Kim et 
al., 2011; Zuniga et al., 2013). We observed that Nrf2 modulated Th17 
differentiation in the periphery and although the development pathways between 
adaptive Th17 cells and nTh17 cells are distinct from one another (Kim et al., 2011), 
it would still be interesting to explore the role of Nrf2 in this relatively undiscovered 
thymic-derived T cell population.  
We next deciphered whether loss of Nrf2 impacted on the composition of CD4 and 
CD8 T cell populations within peripheral lymphoid organs. Our results clearly 
demonstrated that no differences in CD4 and CD8 T cells ratios were exhibited 
between Nrf2+/+ and Nrf2-/- mice within the spleen or lymph node. These results are 
in line with recently published data (Rockwell et al., 2012; Wu et al., 2013), wherein 
no overt splenic T cell phenotypic changes were seen in the Nrf2 deficient mouse. 
Loss of Nrf2 results in enhanced basal ROS levels in a variety of cell types including 
hepatocytes (Beyer et al., 2008), macrophages (Thimmulappa et al., 2006b) and DCs 
(Aw Yeang et al., 2012); however, it has yet to be shown in peripheral T cells. Our 
results revealed that Nrf2 deficient naive T cells exhibited enhanced basal ROS 
levels in relation to their wild type control. Nrf2-/- naïve T cells did not display 
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significantly enhanced ROS levels in the presence of H2O2 in comparison to their 
baseline control, as was observed for the wild type mouse. This suggests that naive 
Nrf2 deficient T cells’ heightened basal ROS levels were already saturated hence 
added stress had no real impact on their overall ROS status. A previous study has 
shown that increased ROS levels during T cell development impaired the 
composition of CD4 and CD8 T populations in the spleen (Case et al., 2011). As we 
found no differences in T cell populations within the periphery between both 
genotypes, one would assume that no differences would be observed in basal 
Nrf2+/+ and Nrf2-/- thymocyte ROS levels; nevertheless, this warrants investigation. 
Reactive oxygen species is required for competent T cell activation, proliferation 
and differentiation (Shatynski et al., 2012; Sena et al., 2013). As the naive Nrf2 
deficient T cells exhibited enhanced basal ROS levels, we postulated that this would 
impact on the basal activation status of the mature peripheral T cells, in terms of 
CD25, CD69, CD44 and CD62L expression. No differences in CD25 levels were 
observed between Nrf2+/+ and Nrf2-/- peripheral T cells, which is in line with 
previously published data (Rockwell et al., 2012). Similar results were also observed 
for CD69 expression. In contrast, our results illustrated that Nrf2 deficient naïve T 
cells manifested signs of low level CD4 and CD8 T cell activation, with respect to 
enhanced CD44 and diminished CD62L expression in the lymph node. Augmented 
levels of CD44 were also noted in splenic Nrf2 deficient naïve CD4 T cells. This 
finding conflicts with that of Rockwell et al. where no differences in CD44 
expression between Nrf2+/+ and Nrf2-/- naïve splenic T cells were presented 
(Rockwell et al., 2012). Reasoning for this discrepancy could be attributable to the 
type of flow cytometric analysis performed. Rockwell et al. assessed CD44 
expression within a CD4+CD25- gated population, whereas our cells were gated on 
the CD4+ population only (Rockwell et al., 2012). In support of our finding, 
increased ROS levels in CD4 naïve T cells have been associated with down 
regulation in CD62L expression (Foster et al., 2013). It would be valuable to 
examine the precise impact of the naïve Nrf2 deficient T cell elevated ROS levels on 
subsequent effector T cell function. This could be achieved by pre-treating the 
Nrf2+/+ and Nrf2-/-  T cells with the antioxidants vitamin C and E which are known to 
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reduce ROS levels (Al-Huseini et al., 2013) and assessing effector T cell proliferation 
and effector cytokine production as below. 
We speculated that the increased naïve T cell activation status exhibited in the Nrf2 
deficient mouse would amount to enhanced naïve T cell proliferation upon 
antibody stimulation. However, no differences in splenic naïve T cell proliferative 
capacity were observed between Nrf2+/+ and Nrf2-/- mice. A previous study has 
shown that loss of Nrf2 results in enhanced lymph node-derived naïve T cell 
proliferation in response to CD3 stimulation (Ma et al., 2006). Furthermore, they 
found a decrease in CD8 T cell numbers within the lymph nodes of the Nrf2 
deficient mouse (Ma et al., 2006). The inconsistency between the results presented 
in this chapter and the aforementioned report is undoubtedly due to the age of 
mice used in both studies. Ma et al. utilised 6 month old mice which exhibited gross 
signs of phenotypic abnormalities and illness for their study; whereas 10-12 weeks 
old mice which were devoid of any overt illness were used in the presented study 
(Ma et al., 2006). Reasons for this discrepancy could also be based on the utilisation 
of Nrf2 deficient mice derived from distinctive inbred genetic backgrounds, 129SVJ 
and C57BL/6J in the case of Ma et al. (Ma et al., 2006) and the present study, 
respectively. 
We next explored the role of Nrf2 in effector T cell immune function initially looking 
at their proliferative capacity in response to CD3 and CD28 antibodies. Our results 
demonstrated that loss of Nrf2 significantly enhanced effector T cell proliferation in 
response to increasing concentrations of antibody stimulation, a finding which has 
not been published to date. We reasoned that this increase in T cell proliferation 
would result in an increase in effector T cell immune function. Accordingly, we 
measured the level of effector CD4 and CD8 T cell intracellular IFNγ expression 
upon antibody re-stimulation through flow cytometric analysis. Our results 
indicated that there were no differences in the numbers of splenic effector 
CD8+IFNγ+ T cells between Nrf2+/+ and Nrf2-/- mice, suggesting that Nrf2 does not 
play a role in the regulation of this particular aspect of CD8 T cell immune function. 
It may be the case that both Nrf2+/+ and Nrf2-/- CD8 T cells were secreting such high 
levels of IFNγ, that subtle changes (as was the case for CD4) could not be detected 
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by this method. However, other functional readouts of CD8 T cells should be 
considered to further clarify the role of Nrf2 in CTL immune function. Cytotoxic T 
lymphocyte cytolytic capacity could be evaluated using the chromium release assay 
(Janas et al., 2005). Furthermore, expression of CTL-released cytolytic molecules 
such as perforin and granzyme B could also be measured (Janas et al., 2005) by flow 
cytometry. In contrast to our effector CD8 T cell finding, Nrf2 deficient effector T 
cells displayed enhanced numbers of CD4+IFNγ+ T cells in comparison to their wild 
type counterpart. This has not been shown before through this methodology. 
However, these numbers were approximately 2 fold lower than what was observed 
for the CD8 T cells. As effector IFNγ production is a characteristic Th1 cytokine 
(Hsieh et al., 1993), this suggests that Nrf2 plays a role in the CD4 polarisation 
through the modulation of Th1 differentiation. We sought to confirm this finding by 
evaluating the absolute amounts of IFNγ produced by purified CD4 Nrf2+/+ and Nrf2-
/- re-stimulated effector T cells. Our results demonstrated a clear increase in IFNγ 
levels in the Nrf2 deficient effector T cells. In support of our finding, Rockwell et al 
also presented that loss of Nrf2 in re-stimulated effector T cells induced elevated 
IFNγ secretion (Rockwell et al., 2012). Moreover, a similar increase was observed in 
antibody stimulated Nrf2-/- CD4 naïve T cells (Roman et al., 2010), thus reaffirming 
our previous conclusion that Nrf2 regulates CD4 T cell differentiation, particularly 
Th1 development. Loss of Nrf2 was shown to reduce TNFα secretion by re-
stimulated effector T cells. The converse was previously shown in antibody 
stimulated naïve Nrf2 deficient T cells which exhibited enhanced TNFα production 
(Rockwell et al., 2012). Rockwell et al. concluded that Nrf2 had little effect on naïve 
T cell TNFα production, as no real changes were observed in the wild type or 
knockout mouse, in response to additional increasing concentrations of tert-
butylhydroquinone (tBHQ), a known activator of Nrf2 (Rockwell et al., 2012). 
However, they did not measure its production in re-stimulated effector T cells. As 
this proinflammatory cytokine is produced by both Th1 and Th2 cells (Zhu et al., 
2010), it is not an adequate CD4 effector T cell signature cytokine to measure in 
order to pinpoint the precise role of Nrf2 in CD4 T cell lineage differentiation. It is 
well recognised that cross-regulation exists between Th1 and Th2 cells, in which 
Th1 cells inhibit the differentiation and immune function of Th2 cells, with the 
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converse also true (Szabo et al., 2000; Usui et al., 2003; Usui et al., 2006; Gu et al., 
2012). Therefore, we hypothesised that increased CD4 effector IFNγ production 
would be associated with a down-modulation of Th2 cytokine production such as IL-
5. Our results confirmed that Nrf2 deficient effector T cells manifested reduced 
levels of IL-5 secretion upon re-stimulation. This was reflected in the Rockwell et al. 
study which also examined the nuclear binding activity of CD4 master transcription 
factors T-bet (Th1) and GATA-3 (Th2) in Nrf2 deficient re-stimulated effector T cells. 
Their results revealed an increase and decrease in T-bet and GATA-3 binding, 
respectively, providing a mechanistic basis behind the observed reciprocal Th1/Th2 
cytokine production. This further emphasises a pivotal role for Nrf2 in the 
maintenance of Th1/Th2 differentiation (Rockwell et al., 2012). The importance of 
maintaining a Th1/Th2 balance is highlighted in allergic disease settings such as 
asthma and eczema; pathogenesis which are driven by a dominant Th2 phenotype 
(Holgate, 2012). The pivotal role of Nrf2 in the regulation of the Th1/Th2 
equilibrium has been previously shown in a murine asthma model (Rangasamy et 
al., 2005). In this study, the authors found no significant differences in splenic CD4 
naïve T cell production of IL-4 and IL-13 upon antibody stimulation between Nrf2+/+ 
and Nrf2-/- mice. However, substantial induction of Th2 cytokine secretion was 
observed in OVA-sensitised re-stimulated splenic CD4 T cells in comparison to their 
wild type control, indicating that Nrf2 down-modulates Th2 differentiation within 
this oxidative context (Rangasamy et al., 2005). We next sought to investigate 
whether loss of Nrf2 had any impact on CD4 effector IL-17 production, the 
signature cytokine associated with the more recently identified CD4 Th17 subtype 
(Harrington et al., 2005; Mangan et al., 2006). Although six IL-17 cytokine isoforms 
have been identified from IL-17A-F, the well characterised IL-17A isoform has been 
regarded as critical for the induction of autoimmunity and thus was chosen as an 
ideal candidate for the measurement of IL-17 within this study (Gaffen, 2009). Loss 
of Nrf2 has been shown to exacerbate disease severity in a murine model of MS 
(Johnson et al., 2010). Therefore one would postulate that this may be attributable 
to Nrf2 deficient mediated augmentation of Th17 cell effector function. Results 
revealed that loss of Nrf2 increased IL-17A secretion in effector T cells, implicating a 
role for Nrf2 in Th17 development. This is of great relevance given the emerging 
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role of Th17 in anti-fungal, anti-bacterial immunity and its notorious role in the 
immunopathology of a variety of autoimmune disorders including SLE, MS and RA 
(Zhu and Qian, 2012). We further speculated that loss of Nrf2 results in a 
predisposition of CD4 T cells to develop into the Th17 lineage basally and under 
Th17 polarising conditions. In order to test the latter, Nrf2+/+ and Nrf2-/- effector T 
cells cultured with or without Th17 inducing cytokines (TGFβ, IL-6, IL-23, IL-1β) 
(Mangan et al., 2006; Veldhoen et al., 2006) were assessed for intracellular IL-17A 
and IFNγ. In contrast to our previous finding, no differences in CD4+IFNγ+ T cells 
were observed between basal Nrf2+/+ and Nrf2-/- effector T cells under this type of 
re-stimulation. Similar results were attained for the Th17-polarised Nrf2+/+ and Nrf2-
/- effector T cells. Results reaffirmed that loss of Nrf2 resulted in an increase in basal 
CD4+IL17A+ T cells in comparison to their wild type counterpart. Surprisingly, this 
increase in IL-17 producing cells was not observed within the Th17 induced Nrf2 
deficient effector T cell populations, suggesting that Nrf2 may play a negligible role 
in Th17 development. However, we reasoned that although Th17 polarised Nrf2+/+ 
and Nrf2-/- effector T cells had similar proportions of CD4+IL17A+ T cells, they were 
capable of secreting enhanced absolute amounts of IL-17 per cell basis. Our results 
confirmed by ELISA that Nrf2-/- effector T cells secreted augmented levels of IL-17A 
basally and under Th17 polarising conditions. Furthermore, basal Nrf2-/- effector T 
cells exhibited enhanced IFNγ. It is recognised that a reciprocal relationship exists 
between Th1 and Th17 cells (Nurieva et al., 2007; El-Behi et al., 2011), such that 
IFNγ inhibits Th17 development (Harrington et al., 2005). Therefore it is surprising 
that Nrf2-/- CD4 effector T cells produce enhanced levels of both IL-17A and IFNγ. It 
has been shown that the Nrf2 regulated gene HO-1 controls T cell-mediated IFNγ 
production in response to antibody stimulation (Kapturczak et al., 2004) and 
regulates the percentage of CD4+IL-17+ T cells in murine EAE model (Tzima et al., 
2009). Loss of Nrf2 results in a decrease in HO-1 expression in T cells (Rockwell et 
al., 2012); therefore, the results presented in the Nrf2 deficient mouse may be 
attributable to loss of HO-1 expression rather than Nrf2 deficiency itself. 
Pharmacological inhibition of HO-1 expression using Sn-protoporphyrin (Zhong et 
al., 2010) in the wild type CD4 T cells would allow us to delineate the role of HO-1 in 
CD4 T cell IL-17A and IFNγ production. Nrf2 deficient basal and TH17-induced 
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effector T cells secreted higher levels of IL-22, another Th17 signature cytokine (Zhu 
and Qian, 2012), in relation to their wild type control. These results further 
emphasise the role of Nrf2 in the regulation of Th17 development. However, this 
increase in IL-22 may also point towards an increase in the recently identified Th22 
cells. Effector Th22 cells secrete IL-22 independently of IL-17 and are emerging as a 
key player in the pathogenesis of an array of atopic allergic disorders such as 
eczema and psoriasis (Eyerich et al., 2009). Therefore it would be worthwhile to 
perform an intracellular stain for IL-22 and IL-17A simultaneously, to compare the 
number of CD4+IL17-IL-22+ cells between Nrf2+/+ and Nrf2-/- mice, under basal and 
polarised conditions. A very recent study investigating the role of Nrf2 in heart graft 
rejection, illustrated enhanced mRNA IL-17 levels in the grafts derived from Nrf2 
deficient recipient mice in comparison to wild type control (Wu et al., 2013). 
Oleanoic acid and its triterpenoid derivative CDDO-trifluoroethyl-amide (CDDO-
TFEA) which are known to activate Nrf2 reduce disease severity in murine EAE 
model which is associated with decreased IL-17 levels in the sera and spinal cord of 
CNS affected mice (Pareek et al., 2011; Martin et al., 2012). Pre-treatment with 
another synthetic triterpenoid CDDO-Me limits IL-17, IL-6 and IL-23 production in 
murine plasma upon in vivo challenge with LPS (Auletta et al., 2010). Taken 
together, these further support the role of Nrf2 in the modulation of Th17 
development. Interestingly, Th17-polarised Nrf2-/- CD4 effector T cells secreted 
enhanced IL-5 levels in comparison to their wild type counterpart, which is opposite 
to what we observed in the basal effector T cells. This is surprising given the inverse 
relationship between Th2 and Th17 cells (van Hamburg et al., 2008; Laurence et al., 
2012). Murine STAT6-/- mice (STAT6 is a known Th2 regulator (Zhu et al., 2010)) 
displayed enhanced Th1 and Th17 cells in experimental crescentic 
glomerulonephritis, which was associated with a significant decrease in IL-5 
production (Summers et al., 2011). Furthermore, neutralisation of IL-17 during 
murine corneal graft transplantation was shown to increase IL-5 levels in the spleen 
of recipient mice further implying reciprocal Th17/Th2 cytokine production (Chen et 
al., 2011).  
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A strikingly obvious limitation to the Th17 differentiation protocol utilised in this 
present chapter is the low percentage of effector CD4+IL-17+ T cells yielded in 
comparison to other published data (Mangan et al., 2006; Veldhoen et al., 2006; 
Veldhoen et al., 2009). In fact the literature itself is extremely varied in the numbers 
of effector CD4+IL-17+ T cells produced (ranging from 5-60%), owing to diverse 
range of protocols used to differentiate the Th17 cells (Mangan et al., 2006; 
Veldhoen et al., 2006; Veldhoen et al., 2009; Zhi et al., 2012). These include the 
incorporation of blocking antibodies for IL-2, IFNγ and IL-4 (Mangan et al., 2006; Zhi 
et al., 2012), increasing the concentrations of IL-6 (Zhi et al., 2012) and using of the 
aromatic amino acid-rich Iscove’s Modified Dulbecco’s Medium (IMDM) for culture 
rather than RPMI (Veldhoen et al., 2009). It is therefore imperative to optimise this 
Th17 differentiation method further, to improve yield for subsequent functional 
studies that require large numbers of cells. 
It would have been interesting to evaluate the levels of the master transcription 
factor RORγt (Ivanov et al., 2006; Burgler et al., 2010) between Nrf2+/+ and Nrf2-/- 
mice through flow cytometric analysis, to further reaffirm our findings. Moreover, 
STAT3 is obligatory for Th17 development whilst STAT1 (Th1 inducing STAT) and 
STAT5/STAT6 (Th2 inducing STATs) have been known to inhibit Th17 development, 
thus it would be worth examining their protein expression between the two 
genotypes to uncover a mechanistic basis for our presented findings (Harrington et 
al., 2005; Laurence et al., 2007; Mathur et al., 2007). Transcriptional activity of AHR 
has also been shown to promote Th17 polarisation (Veldhoen et al., 2008; 
Veldhoen et al., 2009). Inhibition of this receptor or supplementation of AHR 
ligands in in vitro cultures results in impaired or optimised Th17 differentiation, 
respectively (Veldhoen et al., 2009). It is recognised that an integral relationship lies 
between Nrf2 and AHR. The nuclear aryl hydrocarbon receptor is activated by 
xenobiotic ligands including 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCCD), resulting 
in its nuclear translocation. Similarly to Nrf2 which binds to the ARE, AHR binds to 
xenobiotic response elements (XRE) present within the promoter regions of its 
regulated genes including phase I metabolising cytochrome p450 enzymes, 
resulting in their upregulation and induction of drug metabolism (Wakabayashi et 
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al., 2010). The dioxin TCCD induces the expression of phase II metabolising enzyme 
NQO1 which was dependent on both Nrf2 and AHR signalling (Ma et al., 2004). 
Moreover, rat exposure to cigarette smoke resulted in the enhancement of both 
Nrf2 and AHR expression within the brain (Khanna et al., 2013). In contrast, green 
tea extract epigallocatechin gallate has been shown to attenuate polychlorinated 
biphenyl (AHR ligand)-mediated inflammation in endothelial cells through the 
inhibition of the AHR pathway. This was associated with a downregulation of AHR-
dependent cytochrome P450 1A1 expression, whilst enhancing the induction of 
Nrf2 related genes e.g. GST and NQO1 (Han et al., 2012). In keeping with the 
suggestion that cross regulation exists between Nrf2 and AHR, it would be 
reasonable to postulate that loss of Nrf2 could possibly result in an increase in AHR 
signalling thus promoting the development of Th17 cells exhibited in the Nrf2 
deficient mice. Addressing the latter could be achieved by comparing differences in 
AHR nuclear protein levels in re-stimulated Nrf2+/+ and Nrf2-/- effector T cells in the 
presence or absence of Th17 inducing cytokines. Furthermore, AHR activation 
results in the upregulation of downstream cytochrome P450 enzymes CYP1A1 and 
CYP1A2 gene expression (Stockinger et al., 2011). The mRNA levels of CYP1A1 and 
CYP1A2 could therefore be examined via RT-PCR within these T cells. The glycolytic 
metabolic activity of Th17 cells is highly dependent on the transcriptional activity of 
Hypoxia-inducible factor-1α (HIF-1α) which further promotes Th17 generation 
(MacIver et al., 2013). Similarly to Nrf2 in its role in the regulating cellular redox, 
HIF-1α is the key player responsible for the maintenance of cellular oxygen 
homeostasis (Semenza, 2003). It upregulates genes involved in cell proliferation, 
cell survival, angiogenesis and glucose metabolism in response to cellular stress 
induced by hypoxia (Semenza, 2003). A study showed that activation of HIF-1α by 
dimethyloxaloylglycine attenuated Nrf2-dependent production of IL-8 in endothelial 
cells, a result that was reversed upon Nrf2 overexpression (Loboda et al., 2009). 
Hypoxia-inducible factor-1α is activated via dimerisation with the AHR nuclear 
translocator (ARNT), which in turn regulates that activity of AHR (Beischlag et al., 
2008). It has been recently demonstrated that ARNT deficiency in CD4 T cells results 
in reduction in Th17 differentiation (Kim et al., 2013). It would be interesting to 
examine the nuclear binding activity of HIF-1 and expression of ARNT between the 
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two Nrf2+/+ and Nrf2-/- mice to delineate a potential mechanism to the enhanced 
Th17 phenotype exhibited in the Nrf2 deficient mouse.  
 Although we have established a role for Nrf2 in Th17 development in vitro, it is 
important to investigate this further in an in vivo murine model. The commonly 
utilised T cell-mediated hepatitis murine model, in which the T cell mitogen Con-A is 
injected intravenously into the mouse, has been shown to induce Th17 
development (Li et al., 2012a). Moreover, Con-A induced T cell hepatitis has been 
previously implemented in the Nrf2 deficient mouse (Osburn et al., 2008). Taken 
together, this provides us with a sound rationale for the exploitation of this model 
in exploring the role of Nrf2 in Th17 development in vivo. Nrf2 deficient 
predisposition to induction of Th17 lineage could be assessed by examining the sera 
levels of IL-6, TGFβ, IL-1β, IL-23 (all of which are important for induction of Th17 
cells) IL-17A, IL-22 (Th17 signature cytokines) IFNγ (Th1) and IL-5 (Th2) in the Con-A 
treated Nrf2+/+ and Nrf2-/- mice. The aforementioned cytokines could also be 
examined in addition to percentages of CD4+IL17+ and CD4+IFNγ+ T cells in antibody-
stimulated splenocytes derived from Con-A treated mice.  
In conclusion, the presented findings reveal a novel role of Nrf2 in the regulation of 
Th17 development. Effector Th17 cells has been implicated in the pathogenesis of a 
variety of autoimmune diseases such as MS, SLE, RA and colitis, therefore targeting 
Nrf2 in these disease settings may potentially reduce the disease severity. Although 
this chapter has pinpointed a relevant immune function of Nrf2 in the modulation 
of Th17 polarisation, the precise role of Nrf2 in Th17 development remains to be 
defined and requires extensive research.  
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CHAPTER FIVE 
 
INTER-INDIVIDUAL VARIATION IN THE CDDO-ME 
INDUCED NRF2 RESPONSE IN HUMAN T CELLS 
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5.1 INTRODUCTION 
Adverse drug reactions (ADRs) are a significant health problem contributing to 6.5% 
of hospital admissions and resulting in post market drug attrition (Pirmohamed et 
al., 2004). Adverse drug reactions fall into 2 main categories, Type A and type B 
reactions. Type A (on-target) reactions are most common, accounting for 
approximately 80% of ADRs. These predictable reactions are concentration-
dependent, related to the pharmacological action of the drug and are associated 
with low mortality; an example of which being digoxin toxicity (Edwards and 
Aronson, 2000). In contrast, the less common Type B (off-target) idiosyncratic ADRs 
are unpredictable, concentration-independent and are associated with high 
mortality (Edwards and Aronson, 2000). Idiosyncratic ADRs are often immune-
mediated, examples of which include methotrexate-induced and penicillin-induced 
anaphylaxis (Uetrecht, 2005; Oulego-Erroz et al., 2010); hydralazine-induced lupus 
erythematous (Antonov et al., 2004), SMX-induced eczema (Castrejon et al., 2010), 
carbamazepine-induced agranulocytosis (Zaccara et al., 2007) and methyl-dopa-
induced hepatitis (Slim et al., 2010). Understanding the mechanisms behind 
idiosyncratic ADRs are extremely complicated due to human individual variation in 
responses to the therapeutic drug concentration, ranging from mild to severe 
reactions (Edwards and Aronson, 2000). Susceptibility to these unpredictable ADRs 
are highly influenced by various individual-specific factors including age, gender, 
lifestyle, disease status, drug-drug interactions and importantly genetic makeup 
(Severino and Del Zompo, 2004). Drug metabolism occurs primarily in the liver 
which entails the biotransformation of non-polar, lipophilic parent drugs into polar, 
water-soluble compounds; ultimately facilitating their safe removal from the body 
(Park et al., 2005a). This is achieved through the activity of phase I (e.g. cytochrome 
P450 enzymes) and phase II (e.g. GST) drug-metabolising enzymes; involved in 
xenobiotic functionalization and detoxification, respectively (Park et al., 2005a). 
However, the process of drug metabolism results in the generation of ROS and 
highly reactive drug metabolites which induce oxidative stress. This  can potentially 
lead to cell death and tissue injury as highlighted in drug-induced liver injury (DILI) 
(Park et al., 2005a). A key component involved in the nullification of xenobiotic-
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mediated oxidative stress is the adaptive Nrf2 pathway. In response to electrophilic 
or oxidative insult, Nrf2 drives the induction of a battery of cytoprotective and anti-
oxidant defence systems resulting in the maintenance of cellular redox homeostasis 
and prevention of cellular damage (Copple et al., 2010). Studies using the Nrf2 
deficient mice have highlighted the crucial role of Nrf2 in protection against 
xenobiotic-induced organ injury including acetaminophen-induced hepatotoxicity 
(Enomoto et al., 2001; Goldring et al., 2004), cisplatin-induced nephrotoxicity 
(Aleksunes et al., 2010) and bleomycin-induced pulmonary fibrosis (Cho et al., 2004; 
Kikuchi et al., 2010). However, Nrf2-mediated protection against xenobiotic-
induced toxicity has yet to be identified in primary human cells. It is established 
that dietary administration of coffee constituent 5-O-caffeoylquinic acid and 
sulforaphane-rich broccoli sprout extract activates the Nrf2 adaptive system in 
human PBMCs, through the induction of Nrf2-regulated gene expression of NQO1 
and HO-1 (Boettler et al., 2011b; Harvey et al., 2011). Moreover, the Nrf2 inducing 
triterpenoids CDDO-Im and CDDO-Me have been shown to enhance nuclear 
accumulation of Nrf2 and downstream gene expression in human PBMCs 
(Thimmulappa et al., 2007). It has been suggested that the adaptive Nrf2 defence 
system itself is varied between individuals (Marzec et al., 2007; Boettler et al., 
2012). Previous reports have indicated that potential variation in human Nrf2 
adaptive response exists, in response to Nrf2 inducers such as CDDO-Im and the 
coffee constituent 5-O-caffeoylquinic acid in human PBMCs. (Thimmulappa et al., 
2007; Boettler et al., 2011b). However, the aforementioned studies did not 
exclusively examine inter-individual variation in the Nrf2 response and thus merits 
investigation. Could susceptibility to idiosyncratic ADRs in humans, therefore, be 
correlated with variation in their Nrf2 adaptive response to xenobiotic stress? To 
begin addressing this complex question, it is important to firstly demonstrate the 
existence of inter-individual variation in the induction of the Nrf2 adaptive system 
in response to a known Nrf2 probe, within a suitable human ex vivo experimental 
model. This should consist of an amenable source of easily obtained cells such as 
blood–derived immune cells, which are also capable of exhibiting Nrf2-mediated 
responses. The hypothesis of the work described in this chapter is that individuals 
vary in their adaptive Nrf2 response to a known Nrf2 inducer. The aim of this 
145 
 
chapter was to optimise a method in which to measure and quantify differences in 
Nrf2 protein and downstream NQO-1 gene expression in homogenous human T 
cells, derived from a small group of healthy subjects, in response to increased 
concentrations of a known Nrf2 probe. As CDDO-Me is known to induce Nrf2 
responses in human immune cells (Thimmulappa et al., 2007), it was chosen as a 
candidate chemical Nrf2 inducer within our human T cell experimental model. 
5.2 RESULTS 
5.2.1 Nrf2 was undetectable in whole cell lysates of human T cells  
To test the hypothesis that individual’s vary in their Nrf2 adaptive response to an 
Nrf2 probe, we first sought to establish an appropriate human ex vivo experimental 
system, which utilised relevant accessible adaptive immune cells for the detection 
of basal and induced Nrf2 protein expression. In order to achieve the latter, human 
PBMCs were isolated from heparinised venous whole blood through density 
gradient centrifugation. The PBMCs were subsequently stimulated with the human 
T-cell mitogen, phytohaemagglutinin (PHA) and co-cultured with IL-2, ensuring the 
expansion of highly purified CD3+ T cell blasts (Figure 5.1A, CD3+ T cells: 98 %); large 
numbers of which were required for the biochemical nature of the presented pilot 
study. It is recognised that CDDO-Me induces Nrf2 expression in a variety of human 
cell types including PBMCs and neutrophils (Thimmulappa et al., 2007). Therefore, 
it was chosen as an appropriate candidate for Nrf2 induction in the human day 5 
PHA-stimulated T cells and whole cell lysates (WCL) were prepared. Human T cells 
were treated with increasing concentrations of CDDO-Me (0-100nM) for 2 hours. It 
has been established that the proteasomal inhibitor MG132 induces Nrf2 
expression in HepG2 human hepatoma cells WCL and thus was used as a positive 
control (Jeong et al., 2005). Whole cell expression of Nrf2 was assessed by western 
blot. Results revealed that under basal or CDDO-Me inducing conditions, Nrf2 was 
not detected in the WCL of human CD3+ T cell blasts (Figure 5.1B). The validity of 
this result was confirmed by substantial induction of Nrf2 expression exhibited in 
the MG132-treated HepG2 positive control. This suggests that Nrf2 protein content 
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Figure 5.1 Nrf2 is not detected in the whole cell lysates of human T cells upon CDDO-Me 
induction. A. Day 5 Phytohaemagglutinin (PHA)-stimulated T cells derived from human 
isolated PBMCs were stained with CD3 APC and analysed by flow cytometry to assess T cell 
purity. Percentage of CD3+ T cells is indicated above the histogram marker. Position of the 
marker is based on the unlabelled control. B. Human PHA-stimulated T cells were treated 
with increasing concentrations of CDDO-Me (0-100nM in 0.1 % DMSO) for 2 h and whole-
cell extracts were prepared. Cell lysates (20μg) were subjected to SDS-PAGE, and levels of 
Nrf2 and the loading control protein  -actin were determined by western blot analysis. 
HepG2 cells treated with or without proteasome inhibitor MG132 (10µM) for 2 h were 
used as a positive and negative control, respectively.   
is extremely low in human T cells; therefore it would be valuable to examine the 
content of Nrf2 in a smaller, more enriched location, namely the nucleus.  
 
 
A 
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5.2.2 CDDO-Me-mediated induction of Nrf2 is detected in the nucleus of human T 
cells 
Under basal conditions, Nrf2 is sequestered in the cytosol by the repressor protein 
Keap-1, which facilitates Nrf2 polyubiquitination and subsequent proteasomal 
degradation. Thus, a minimal cytoplasmic pool of Nrf2 is maintained as a result of 
its rapid degradation (Kobayashi et al., 2004; Katoh et al., 2005). However upon 
xenobiotic stress, Nrf2 is liberated from Keap-1 permitting its translocation into the 
nucleus (Copple, 2012). As Nrf2 accumulates in the nucleus, it would seem more 
appropriate to assess Nrf2 content within this more concentrated organelle rather 
than the whole cell (Thimmulappa et al., 2007). Human T cells (CD3+ T cells: 96 %, 
data not shown) were treated with increasing concentrations of CDDO-Me as 
before, nuclear extracts were prepared and nuclear expression of Nrf2 was 
assessed by western blot. In contrast to the WCL data, results clearly demonstrated 
that Nrf2 expression is detected both basally and upon CDDO-Me treatment (Figure 
5.2). Furthermore, a CDDO-Me concentration-dependent increase in Nrf2 
expression was observed (Figure 5.2). Taken together, these results indicate the 
increased sensitivity of examining of Nrf2 in the nucleus of human T cells, as even 
basal Nrf2 levels can be identified through this optimised method. Moreover, the 
CDDO-Me concentration-dependent increase in Nrf2 expression validated the 
utilisation of homogenous CD3+ human T cells as a suitable ex vivo model for 
examining human variation in iNrf2 expression in response to a known Nrf2 
inducer. 
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5.2.3 Inter-individual variation in Nrf2 adaptive response to CDDO-Me is present 
in human T cells. 
As we have established an optimised protocol for the detection of Nrf2 in human T 
cells, we next sought to determine whether differences could be observed in basal 
and CDDO-Me inducible Nrf2 expression between individuals. Donor T cells were 
subsequently treated with CDDO-Me for 2 h and nuclear fractions were assessed 
for Nrf2 expression via western blot. Nrf2 protein bands were quantified by 
densitometry and Nrf2 was expressed as a percentage relative to β-actin (Figure 
5.3A-B). To calculate the half maximal effective concentration (EC50) of CDDO-Me 
for each donor, the densitometry values (Figure 5.3Ai-xi) were converted into 
percentage of maximal response (highest percentage of Nrf2 expression exhibited 
by each donor was set at 100% maximal response). A concentration-response curve 
(% response versus CDDO-Me concentration) was then plotted for each individual 
and EC50 determined (data not shown). As shown in Figure 5.2Ai-xi, clear trends 
were apparent within the obtained data. Donors could be categorised based on 
their basal expression of Nrf2 (densitometry), the magnitude of the levels of Nrf2 
Figure 5.2 CDDO-Me induces nuclear accumulation of Nrf2 in human T cells. Human PHA-
stimulated T cells were treated with increasing concentrations of CDDO-Me (0-100nM in 
0.1 % DMSO) for 2 h and nuclear fractions were prepared. The nuclear proteins (20μg) 
were subjected to SDS-PAGE, and levels of Nrf2 and the loading control protein  -actin 
were determined by western blot analysis. HepG2 cells treated with the proteasome 
inhibitor MG132 (10µM) for 2 h, was used as a positive control. 
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expressed (densitometry), and how sensitively the donors responded to CDDO-Me 
(EC50). Results revealed that T cells derived from donors 1 (Figure 5.3Ai), 3 (Figure 
5.3Aiii), 4 (Figure 5.3Aiv) and 6 (Figure 5.3Avi) exhibited enhanced basal levels of 
nuclear Nrf2 (D1: 16.4 %, D3: 37.2 %, D4: 19.3 %, D6: 15.5 %). Donor 4-derived T 
cells displayed the highest magnitude of Nrf2 expression as illustrated in Figure 
5.3Aiv (100nM CDDO-Me: 192.9 %). In contrast, D5 T cells exhibited the lowest 
magnitude of Nrf2 expression (Figure 5.3Av, 5nM CDDO-Me: 55.9 %). The EC50 
value was used to determine variation in the sensitivity of the individual’s adaptive 
Nrf2 system to CDDO-Me. The mean EC50 value calculated for all 11 subjects was 
16.8 ± 9.1nM ranging from 6nM (Figure 5.3Aiii, D3) to 30.1nM (Figure 5.2Avi, D6). 
Overall, D4-derived T cells exhibited the highest sensitivity to CDDO-me induction 
of nuclear Nrf2 accumulation; whereas D6 T cells displayed the least sensitivity to 
CDDO-Me Nrf2 induction (Figure5.2Aiv and vi). The order of most sensitive to least 
sensitive donor-derived T-cells was D3 > D4 > D2 > D7 > D8 > D1 > D9 >D5 > D11 > 
D10 > D6 (Figure 5.2A). Evaluation of the collated data revealed that Nrf2 was 
significantly induced from baseline at CDDO-Me concentrations of 10nM and above 
(Figure 5.3B, p < 0.01). Taken together, our results clearly demonstrate that 
variation exists between individuals in their Nrf2 adaptive response to CDDO-Me. In 
light of this, it was necessary to assess a functional output of this Nrf2 inter-
individual variation through examination of Nrf2 downstream gene expression.  
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Figure 5.3 Inter-individual variation in Nrf2 adaptive response to CDDO-Me is present in 
human T cells. Human CD3
+
 PHA-stimulated day 5 T cells derived from donors Ai D1, ii. D2, 
iii. D3, iv. D4, v. D5, vi. D6, vii. D7, viii. D8, ix. D9, x. D10 and xi. D11 were treated with 
increasing concentrations of CDDO-Me (0-100nM in 0.1 % DMSO) for 2 h and nuclear 
fractions were prepared. The nuclear proteins (20μg) were subjected to SDS-PAGE; levels 
of Nrf2 and the loading control protein  -actin were determined by western blot analysis. 
Nrf2 protein bands were quantified by densitometry and Nrf2 was expressed as a 
percentage relative to β-actin. To calculate the half maximal effective concentration (EC
50
)
 
of CDDO-Me for each donor, the densitometry values were converted into percentage of 
maximal response so that the highest percentage of Nrf2 expression exhibited by each 
donor was set to 100% maximal response. A concentration-response curve (% response 
versus CDDO-Me concentration) was then plotted for each individual and EC
50 
determined. 
B. Collated densitometry values for donors 1-11 in response to increasing concentrations 
of CDDO-Me. Treatment groups were compared to the untreated control (0nM CDDO-Me). 
Statistical significance was assessed using the one way analysis of variance (ANOVA) (*, p < 
0.05).  
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5.2.4 Inter-individual variation in Nrf2 downstream NQO1 gene expression is 
present in human T cells 
Once Nrf2 translocates into the nucleus, it upregulates the transcription of an array 
of cytoprotective and antioxidant genes which are involved in the orchestration of 
the Nrf2-mediated cellular defence (Copple, 2012). The Nrf2-regulated gene 
NAD(P)H:quinine oxidoreductase 1 (NQO1) encoding the NQO1 enzyme, plays a 
crucial role in counterbalancing xenobiotic-mediated cellular stress, through the 
detoxification of quinone compounds and their corresponding reactive metabolites 
(Copple et al., 2010). Nrf2-dependent upregulation of NQO1 gene expression, has 
been identified in a variety of human cell types including hepatocytes (Keum et al., 
2006), keratinocytes (van den Bogaard et al., 2013), PBMCs and neutrophils 
(Thimmulappa et al., 2007). Moreover, inter-individual variation in CDDO-Me 
induction of NQO1 gene expression was exhibited in human PBMCs (Thimmulappa 
et al., 2007). It is unknown whether CDDO-Me induces Nrf2-dependent 
upregulation of NQO1 expression in human T cells, and if variation in the induction 
of NQO1 is prevalent. We therefore sought to assess the effect of CDDO-Me on 
Nrf2-dependent downstream NQO1 expression, in day 5 PHA-stimulated CD3+ T 
cells human T cells derived from a small group of 6 donors. In order to investigate 
the latter, an appropriate concentration of CDDO-Me was initially selected that 
would significantly induce Nrf2 and potential downstream NQO1 expression in 
human T cells. This was based on the collated data shown in Figure 5.3B, which 
illustrated that significant induction of Nrf2 was attained at concentrations of 
CDDO-Me from 10nM and above. It would thus seem reasonable to choose 10nM 
as a candidate concentration for gene expression studies. However, CDDO-Me-
mediated Nrf2 induction was not detected in D10-derived T cells at this particular 
concentration (Figure 5.2Ax). For this reason, the higher 50nM CDDO-Me 
concentration was selected to ensure Nrf2 induction in all subsequent donors. 
Donor T cells were treated with CDDO-Me (50nM) and IL-2 (for T-cell survival) over 
a 0-24 h time course. Ribonucleic acid was then isolated and reverse transcribed 
into cDNA. NAD(P)H:quinine oxidoreductase 1 and housekeeping gene GAPDH 
mRNA levels were measured within these samples by RT-PCR. The NQO1 mRNA 
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data was normalised to GAPDH and converted into fold increase in NQO1 
expression compared to untreated cells. Results illustrated that differences were 
observed between donors T cell CDDO-Me-induced NQO1 levels, in terms of the 
magnitude of NQO1 expression and the time at which maximal NQO1 mRNA levels 
were achieved (Figure 5.4Ai-vi). Within the small donor group, D15 exhibited the 
highest levels of NQO1 gene expression after 8 hours of CDDO-Me treatment 
(Figure 5.4Avi, 8h: 75-fold increase in NQO1 mRNA expression). Furthermore, high 
NQO1 induction was observed as early as 1 hour post CDDO-Me treatment in 
comparison to the other donors (Figure 5.4Avi, 1hr: 12-fold NQO1 increase). In 
contrast, minimal induction of NQO1 was observed for D14 and D12-derived T cells 
over the 24 hour time course; maximal NQO1 expression achieved at 24 and 8 
hours post-CDDO-Me treatment for D12 and D14, respectively (Figure  5.4Aiii, 6-
fold NQO1 mRNA increase; Figure  5.4Av, 4-fold NQO1 mRNA increase). Similarly to 
D15, D13-derived T cells attained maximal NQO1 levels after 8 hours of CDDO-Me 
treatment (Figure 5.4Aiv, 22-fold mRNA NQO1 increase); whereas highest levels of 
NQO1 were reached at as early as 3 hours post CDDO-Me treatment for D1 (Figure  
5.4Ai,  30-fold NQO1 mRNA increase). A clear time-dependent increase in CDDO-
Me-induced NQO1 expression was observed for D9-derived T-cells (Figure 5.4Aii). 
Assessment of the collated data, illustrated that significant induction of NQO1 
expression by CDDO-Me was observed after 3 hours of dosing and above, when 
compared to the untreated cells (Figure 5.4B, p < 0.05). Taken together, our 
findings clearly demonstrate that variation is also prevalent in Nrf2-regulated 
downstream NQO1 gene expression in response to CDDO-Me in human T cells. 
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Figure 5.4 Inter-individual variation in Nrf2 regulated downstream NQO1 expression in 
response is present in human T cells. Human PHA-stimulated day 5 T cells derived from 
donors Ai D7, ii. D9, iii. D12, iv. D13, v. D14, vi. D15 were treated with 50nM CDDO-Me for 
the indicated time points. Total RNA was isolated for each sample and reverse transcribed 
into cDNA. NQO1 and housekeeping gene GAPDH mRNA levels were measured within 
these samples by RT-PCR. The NQO1 mRNA data was normalised to GAPDH and converted 
into fold increase in NQO1 expression compared to untreated cells (0nM CDDO-Me). B. 
Collated fold increase in NQO1 expression for D7, 9, 12-15 in response to 50nM CDDO-Me 
time course. Treatment groups were compared to the untreated control (0nM CDDO-Me). 
Statistical significance was assessed using the Mann-Whitney U test (*, p < 0.05).  
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5.3 DISCUSSION 
Extensive inter-individual variability is prevalent in human responses to xenobiotic 
exposure. This can range from drug adaptation and tolerance to severe life 
threatening idiosyncratic ADRs. Evaluation and prediction of these idiosyncratic 
ADRs proves extremely difficult due to this human variability, which is highly 
influenced by a myriad of host-specific factors such as gender, age, underlying 
disease status and genetic makeup (Severino and Del Zompo, 2004). During drug 
metabolism, harmful reactive metabolites and ROS are generated which have the 
potential to induce cellular necrosis and onset of disease (Park et al., 2005a). The 
transcription factor Nrf2 plays a pivotal role in the induction of phase II detoxifying 
and antioxidant enzymes in response to xenobiotic-oxidative insult, thus is 
indispensable for the maintenance of cellular redox homeostasis and prevention of 
drug-induced cellular damage (Copple et al., 2010). A plethora of evidence using 
human cell lines has highlighted the involvement of the Nrf2 pathway in cellular 
protection against xenobiotic stress. Examples include curcumin-mediated 
protection against arsenite-induced cytotoxicity in human keratinocyte HaCaT cells 
(Zhao et al., 2013), and sulforaphane-mediated diminution of microcystin-induced 
cytotoxicity in HepG2 cells (Gan et al., 2010). This has also been further exemplified 
in studies using primary murine hepatocytes (Shinkai et al., 2006) and Nrf2 deficient 
mice, the latter of which are more susceptible to xenobiotic-induced organ toxicity 
(Enomoto et al., 2001; Cho et al., 2004; Goldring et al., 2004; Aleksunes et al., 2010; 
Kikuchi et al., 2010; Kay et al., 2011). Xenobiotic-mediated activation of Nrf2 has 
been detected in a variety of human cell types including hepatocytes, PBMCs, 
neutrophils, alveolar type II cells and keratinocytes (Keum et al., 2006; 
Thimmulappa et al., 2007; Messier et al., 2013; van den Bogaard et al., 2013). 
However, the role of Nrf2 in protection against drug-induced toxicity has not been 
exclusively explored in humans. Furthermore, it has been suggested that the Nrf2 
adaptive cellular defence pathway is also subject to inter-individual variation in 
response to Nrf2 inducers in humans. (Thimmulappa et al., 2007; Boettler et al., 
2011b). However, these findings were not extensive and thus required further 
reaffirmation. In light of this, several questions remain unanswered; does variation 
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in Nrf2 adaptive response to xenobiotic stress exists in humans? And is disparity in 
an individual’s susceptibility to drug toxicity associated with variation in the Nrf2 
adaptive response? To begin answering these complex questions it must first be 
established that inter-individual variation exists in the Nrf2 adaptive system in 
response to a known Nrf2 probe. The present study endeavoured to address the 
latter, by establishing a method to assess variation in Nrf2 adaptive system to a 
chemical inducer of Nrf2 in human T cells, using the oleanolic acid derivative, 
CDDO-Me. This novel synthetic triterpenoid which exhibits anti-inflammatory, anti-
proliferative and anti-oxidant properties in vivo (Auletta et al., 2010; Li et al., 2010a; 
Kulkarni et al., 2013), is recognised as a potent inducer of the Nrf2 pathway (Yates 
et al., 2007). Therefore it posed a likely candidate for manipulating Nrf2 levels 
within our model. Assessment of human variation was achieved by isolating PBMCs 
from the blood derived from a small group of healthy subjects. Blood-derived 
immune cells represent an accessible source of physiologically relevant cells, which 
can be easily utilised for ex vivo human Nrf2 induction studies (Thimmulappa et al., 
2007; Boettler et al., 2011b). Therefore, they are an ideal model for the present 
chapter. The PBMCs were subsequently activated with the human T cell mitogen 
PHA to enable expansion of a homogenous CD3+ T cell population. The use of a 
homogeneous population is advantageous in such studies as additional cell-based 
variability (observed with heterogeneous populations) is avoided. Donor-derived 
CD3+ T cell blasts were subsequently treated with increasing concentrations of 
CDDO-Me for 2 hours to allow for induction of Nrf2 expression. It has been 
previously shown that Nrf2 can be detected within total cell proteins in human 
hepatocytes, both basally and upon butylated hydroxyanisole (BHA) treatment 
(Keum et al., 2006). Therefore, we initially investigated whether CDDO-Me-induced 
Nrf2 protein expression could be identified within the WCL of human T cells, 
through western blot analysis. Results illustrated that Nrf2 could not be detected in 
whole cells. As Nrf2 translocates into the nucleus under conditions of oxidative 
stress, we reasoned that Nrf2 would be easily detected in this smaller and more 
concentrated location. Accordingly, we determined the basal and CDDO-Me 
inducible levels of Nrf2 within the T cell nucleus. Our results illustrated that Nrf2 
protein expression can be identified both basally and upon concentration-
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dependent CDDO-Me induction within the nuclear fraction of human T cells. In 
support of our finding, nuclear Nrf2 expression was detected in the nuclear fraction 
of human PBMCs using a CDDO-Me analogue, CDDO-Im (Thimmulappa et al., 2007). 
This optimised human ex vivo experimental model; therefore, provided an 
appropriate platform by which to subsequently examine variation in Nrf2 adaptive 
response to CDDO-Me in a small group of healthy individuals. Assessment of inter-
individual variability in donor-derived T cells was based upon basal Nrf2 expression, 
the magnitude of the Nrf2 response and the overall sensitivity of the Nrf2 system to 
CDDO-Me-simulated xenobiotic stress. It was apparent that four out of eleven 
donors exhibited enhanced basal Nrf2 levels. Furthermore, the extent of Nrf2 
induction mediated by CDDO-Me differed greatly for each donor. With reference to 
the sensitivity of the Nrf2 system, as evaluated by the donor’s distinctive CDDO-Me 
EC50 value, a trend emerged in the spread of EC50 values. The EC50 value range could 
be subsequently divided into quartiles, so that the lowest (6-12nM) and highest (24-
30nM) quartile corresponded to donors with low and high EC50 values, respectively. 
Therefore, donors could be classified into high (EC50 value < 12 nM), intermediate 
(EC50 value 12-24 nM) and low (EC50 value > 24 nM) responding groups. Donor 2, D3, 
D4, D7 and D8 fell into the high responding group; D1 and D9 in the intermediate 
category; whilst D5, D6, D10 and D11 were found to be low responders 
corresponding to the highest EC50 quartile. Although the numbers of donors were 
limited, it appeared that individuals generally fell within the high and low 
responding groups. What factors could account for this observed disparity in human 
Nrf2 adaptive response to CDDO-Me in this particular model? Marked inter-
individual variability is prevalent in human PBMC responses to PHA stimulation 
(Verheugen et al., 1997), which could ultimately impact on the Nrf2 response  
exhibited in the human T cell blasts. Within humans, it has been established that 
dietary intake of 5-O-caffeoylquinic acid-rich coffee, sulforaphane-containing 
broccoli preparations, resveratrol (the active polyphenol compound present in 
grapes and red wine) and curcumin (active ingredient of turmeric spice) have 
shown to activate Nrf2 signalling in PBMCs (Wu et al., 2010; Boettler et al., 2011b; 
Harvey et al., 2011). Furthermore, cigarette smoke, coal, tar, and diesel exhaust 
particles have also been shown to alter Nrf2 expression in human alveolar cells, 
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keratinocytes and PBMCs, respectively (Messier et al., 2013; van den Bogaard et al., 
2013; Yamamoto et al., 2013). It would therefore seem plausible that additional 
dietary and environmental xenobiotic exposure, would impact on the individual’s 
Nrf2 basal levels and adaptive response to CDDO-Me. Under conditions of oxidative 
stress, Nrf2 accumulates in the nucleus where it binds to the ARE in the promoter 
region of Nrf2-regulated cytoprotective and antioxidant genes including GST, HO-1 
and NQO1, resulting in their transactivation and induction of cellular defence 
(Copple, 2012). NQO1 is responsible for the nullification of quinone compounds and 
their derivatives (Copple et al., 2010). Previous studies using Nrf2 deficient mice 
have highlighted the critical role of Nrf2 in the transcription of NQO1 gene 
expression in response to xenobiotic stress (Kwak et al., 2001; Rangasamy et al., 
2004; Xu et al., 2008).  Furthermore, it has been established that activation of Nrf2 
results in the upregulation of NQO1 gene expression in murine primary hepatocytes 
and activated CD3/CD28 T cells (Keum et al., 2006; Rockwell et al., 2012). Within 
humans, BHA-induced and coal tar-induced activation of Nrf2 results in 
upregulation of NQO1 in hepatocytes and keratinocytes, respectively (Keum et al., 
2006; van den Bogaard et al., 2013). As inter-individual variation was observed in 
Nrf2 protein expression in human T cells, we hypothesised that disparity would also 
be exhibited in downstream gene expression of NQO1 between donors in response 
to CDDO-Me. Generally our results revealed a time-dependent increase in CDDO-
Me-mediated induction of NQO1. This has also been illustrated in BHA-treated 
human hepatocytes (Keum et al., 2006). It was observed that individuals varied in 
their overall magnitude of NQO1 gene expression and time at which peak NQO1 
expression was achieved, in response to CDDO-Me. From the present study we 
cannot correlate the differences in individual’s Nrf2 expression to downstream 
changes in NQO1 expression, as different donors were used per experiment. 
However, we can still ascertain that inter-individual variation is present in CDDO-
Me-mediated NQO1 gene expression in human T cells. A previous study has 
revealed that variation in Nrf2 and NQO1 expression was prevalent in the lungs of 
healthy individuals. However, increased Nrf2 expression did not necessarily amount 
to increased NQO1 expression (Malhotra et al., 2008). It would therefore be 
valuable to simultaneously investigate levels of Nrf2 and NQO1 gene expression in 
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each individual to facilitate correlation between CDDO-Me-mediated Nrf2 induction 
and its subsequent downstream events. An extensive examination of Nrf2-
downstream gene expression profile including HO-1 and GCLC (Keum et al., 2006) in 
response to CDDO-Me per individual, would further support the concept that 
variation is exhibited in Nrf2 adaptive system in response to an Nrf2 inducer. It has 
also recently been suggested that the nrf2-regulated gene expression of aldo-keto 
reductase (AKR) could be used as a marker of xenobiotic-induced Nrf2 activity in 
human monocytes (Jung et al., 2013). Therefore it would be interesting to assess 
levels of AKR in our human T cell model. It would also be worthwhile to evaluate 
the effect of a panel of Nrf2 activators such as curcumin, sulforaphane, BHA and 
tBHQ (Keum et al., 2006; Wu et al., 2010; Rockwell et al., 2012) on this ex vivo 
model, to assess whether the variation in Nrf2 adaptive response is still prevalent, 
and if it is specific to each type of Nrf2 probe.  
It is recognised that genetic variation in phase I drug metabolising CYP450 enzymes 
are associated with increased susceptibility to idiosyncratic ADRs. For example, 
individuals carrying polymorphisms in genes encoding CYP2E1 are more susceptible 
to isoniazid-induced hepatitis. This is a result of enhanced phase I oxidation of 
isoniazid metabolic intermediates into hepatotoxic compounds (Huang et al., 2003). 
Similarly, genetic variations in the human leukocyte antigen (HLA) (also known as 
MHC molecule), which is crucial for the APC presentation of drug-derived antigens 
to T cells, are strongly associated with immune-mediated ADRs e.g. (HLA)-B*57:01 
association with ﬂucloxacillin-induced liver injury (Monshi et al., 2013). Indeed, 
genetic polymorphisms in humans have also been identified in the promoter region 
of the Nrf2 gene. These have been associated with reduced Nrf2 transcriptional 
activity, correlating with an increased risk of acute lung injury in humans (Marzec et 
al., 2007). Other Nrf2 polymorphisms have correlated with Helicobacter pylori-
induced gastritis (Arisawa et al., 2007) and ulcerative colitis (Arisawa et al., 2008). It 
would be interesting to examine the genotype of each donor to observe whether 
differences in their individual Nrf2 adaptive system correlate with polymorphisms 
in the Nrf2 gene itself.  
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The works presented in this chapter has established a means by which to examine 
human variation in Nrf2 adaptive system in an accessible source of physiologically 
relevant cells. We next need to investigate whether this inter-individual variability 
correlates with individual susceptibility to drug toxicity. Thus, could drug-induced 
changes in Nrf2 in blood-derived immune cells be used as a potential biomarker to 
predict drug toxicity in inaccessible organs such as the liver in susceptible 
individuals? In order to address this important issue it is imperative to correlate 
drug-induced Nrf2 expression in primary human hepatocytes with Nrf2 levels in the 
blood derived from the same donor. Our currently established ex vivo model is not 
without its limitations; however, for this more detailed type of correlative 
assessment. The donor-derived T cells have been initially stimulated with PHA and 
grown out for 5 days; therefore, could not be compared to freshly isolated 
hepatocytes from the same donor. In this case, it would be more accurate to 
investigate Nrf2 levels in freshly isolated PBMCs (Thimmulappa et al., 2007). It 
therefore would be valuable to treat donor hepatocytes and their corresponding 
PBMCs with various concentrations of a known hepatotoxic drug such as 
acetaminophen (Goldring et al., 2004), and assess correlation in levels of Nrf2 
expression in both cells. A previous study has highlighted the importance of using 
PBMCs to measure the activity of particular drug metabolising enzymes, for the 
prediction of liver toxicity in patients undergoing chemotherapy (Lu et al., 1993). 
Deficiency in PBMC dihydropyrimidine dehydrogenase enzyme activity, which is 
responsible for the catabolism of 5-fluorouracil, correlated with 5-fluorouracil-
induced liver toxicity in cancer patients (Lu et al., 1993). In spite of this, the 
utilisation of human PBMCs as a suitable model to correlate drug-induced Nrf2 
levels to hepatocytes would also be problematic, due to the heterogeneous nature 
of PBMCs in comparison to the homogenous hepatocytes. Moreover, the 
composition of macrophages, monocytes and lymphocytes within PBMCs differs 
greatly for each individual. Human hepatocytes are generally derived from patients 
with liver cancer and thus would be subject to chemotherapeutic drugs. 
Chemotherapeutics are known to cause leukopenia (Lu et al., 1993); therefore, the 
numbers of PBMCs attained from each patient may be extremely limiting. An 
alternative source of amenable immune cells to the PBMCs would be the 
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neutrophils. These immune cells are extremely abundant in the blood, easily 
isolated and are homogenous in nature. Moreover, nuclear Nrf2 levels can be 
detected in human neutrophils (Thimmulappa et al., 2007) thus pose an attractive 
candidate for the aforementioned predictive liver drug-toxicity model. 
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6.1 DISCUSSION 
The body has evolved a cellular adaptive defence system which counterbalances a 
myriad of oxidative and electrophilic stressors such as environmental diesel exhaust 
fumes and xenobiotics. The functionality of this cellular defence system is 
principally governed by the activity of the redox-sensitive transcription factor Nrf2 
(Copple, 2012). In response to oxidative stress, Nrf2 induces the transcription of a 
battery of cytoprotective and antioxidant genes e.g. GCLC, GST and NQO1, resulting 
in the nullification of oxidative or chemical insult and maintenance of cellular redox 
homeostasis (Copple, 2012). It is recognised that Nrf2 plays a protective role in a 
variety of murine disease models including sepsis, acute lung injury, asthma and 
EAE, all of which are immune-mediated (Rangasamy et al., 2005; Thimmulappa et 
al., 2006a; Reddy et al., 2009a; Johnson et al., 2010). To this end, it emerged that 
Nrf2 plays a prominent role in the regulation of the immune responses. However, 
its precise role in DCs and T cells is poorly understood (Ma et al., 2006; Williams et 
al., 2008; Rangasamy et al., 2010; Rockwell et al., 2012).  
In light of this, the central aim of the present thesis was to further elucidate the 
role of Nrf2 in murine DC and T cell immune function, through the utilisation of the 
Nrf2 deficient mouse experimental model.  
With reference to DCs, this study demonstrated that Nrf2 deficiency in iDCs 
resulted in lowered GSH levels, enhanced iDC co-stimulatory receptor expression, 
impaired endocytic and phagocytic capacity, and increased iDC-mediated antigen-
specific CD8 T cell stimulatory capacity. Furthermore, artificially lowering GSH levels 
in the iDCs did not recapitulate the Nrf2 deficient iDC phenotype. (Aw Yeang et al., 
2012). Immature DCs constitutively present self-peptides to CD8 T cells, and 
instruct the deletion of peripheral autoreactive T-cells that have escaped from 
selection processes in the thymus. Hence, they play a crucial role in the 
maintenance of peripheral CD8 T cell tolerance (Kurts et al., 1997; Kurts et al., 1998; 
Steinman et al., 2000). It has been previously shown that increases in co-
stimulatory receptor expression in iDCs causes a break in peripheral T cell 
tolerance, through the prolongation of T cell activation and enhancement of 
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adaptive immune responses (Hawiger et al., 2001). Therefore, it would be 
reasonable to propose that in the absence of infection, the Nrf2 deficient iDCs 
could present self-antigens to CD8 T cells in such a context that (instead of 
instructing autoreactive T cell deletion or anergy) may result in the induction of 
inappropriate CD8 T cell activation, adaptive immune responses and autoimmunity. 
The observations that aged Nrf2 deficient mice manifest enhanced 
lymphoproliferation and autoimmune-like symptoms, further emphasises the 
underlying role of Nrf2 in the regulation of T cell tolerance and autoimmunity (Ma 
et al., 2006). Nrf2-/- iDCs also exhibited a greater capacity to extract and cross-
present cell-associated antigens derived from dying cells to CD8 T cells. However, 
the increased co-stimulatory receptor expression exhibited by the Nrf2 deficient 
iDCs cannot be ruled out as the driving force behind the increased cross-
presentation observed. We have recently established that Nrf2-/- DCs produced high 
levels of ROS in relation to their wild type counterpart (Aw Yeang et al., 2012). 
Reactive oxygen species production through TLR9 signalling in DCs, promotes 
processing and cross-presentation of intracellular Salmonella bacterial antigens to 
CD8 T cells resulting in increased IFNγ production (Lahiri et al., 2010). Although we 
have concluded that enhanced co-stimulatory receptor expression exhibited in the 
Nrf2 deficient is independent of ROS levels (Al-Huseini et al., 2013), this does not 
rule out the possibility that the DC-mediated ROS production may be a contributing 
factor towards the increased cross-presentation. It would therefore be valuable to 
treat the DCs with vitamin C and E (Al-Huseini et al., 2013) and subsequently assess 
their cross-presentation capacity of necrotic cell-associated antigens to CD8 T cells. 
In general, necrotic cells which release mediators such as High-Mobility Group Box 
1 Protein (HMGB1) can activate TLR4 and TLR2. Toll-like receptor engagement 
initiates DC maturation ultimately resulting in DC-driven CD8 T cell immunity. In 
contrast, apoptotic cells which are immunologically silent and thus do not induce 
DC maturation, facilitate iDC-mediated CD8 T cell tolerance (Kurts et al., 1998; Ip 
and Lau, 2004; Miyake and Yamasaki, 2012; Zelenay et al., 2012). It would therefore 
be valuable to examine the consequence of loss of Nrf2 in DC-mediated cross-
presentation of antigens derived from apoptotic cells to CD8 T cells, to see whether 
enhanced CD8 T cell stimulatory capacity would also be observed within this self-
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antigenic context. Finally in this study, we highlighted that loss of Nrf2 in LPS-
activated DCs resulted in lowered TNFα and IL-12 production. However, we found 
no differences in IL-2 secretion between Nrf2+/+ and Nrf2-/- DCs upon LPS 
stimulation. This suggests that Nrf2 deficiency induces a lowered Th1 cytokine 
profile within a DC-mediated Th1 polarising context (Agrawal et al., 2003). 
Therefore during a bacterial infection, it could be said that Nrf2 deficient DCs may 
secrete less TNFα and IL-12, resulting in a diminished capacity to prime 
neighbouring DCs to induce Th1 responses, leading to a reduction in clearance of 
infection. From a tolerance perspective, it has been previously shown that TNFα-
producing iDCs induce the differentiation of antigen-specific CD4+ IL-10-producing 
regulatory T cells which are known to dampen inappropriate immune responses 
(Hirata et al., 2010). Therefore, as the Nrf2 deficient iDCs secrete less TNFα, it may 
be the case that these DCs fail to induce the differentiation of such regulatory T 
cells, resulting in a diminution of T cell tolerance. Previous studies have 
demonstrated that under an allergic environment known to induce Th2 responses, 
Nrf2 DCs exhibited an altered Th1/Th2 cytokine profile skewed towards the Th2 
phenotype (Williams et al., 2008; Rangasamy et al., 2010). This highlights a pivotal 
role for Nrf2 in the regulation of DC Th1/Th2 cytokine production. To further assess 
the role of Nrf2 in Th1/Th2 differentiation, it would be worthwhile to examine the 
consequences of this altered DC cytokine secretion on antigen-specific CD4 effector 
T cell function through the utilisation of OT-II transgenic mouse (Williams et al., 
2008). Within this model, the CD4 T cells exclusively express TCR specific for 
ovalbumin peptide (OVA323-339) (Williams et al., 2008; Hirata et al., 2010). The 
Nrf2+/+ and Nrf2-/- DCs could be pulsed ex vivo with OVA323-339 and injected into the 
OT-II transgenic mouse. Purified splenic CD4+ OT-II T cells could then be re-
stimulated with OVA-pulsed wild type DCs and effector Th1/Th2 cytokine 
production assessed. Furthermore, expression of the master transcription factors T-
bet and GATA-3 for Th1 and Th2 cells, respectively (Rockwell et al., 2012), could 
also be assessed by flow cytometry. The presented study in chapter 3 is not without 
its limitations. The DCs utilised are BM-derived and thus require 7 days to 
differentiate into DCs in the presence of GMCSF. Therefore, these cells are far 
removed from their normal development in an in vivo setting. However, this 
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method is advantageous in that it allows the assessment of Nrf2 deficiency in 
uninfluenced DCs, in that they have not received any additional signals from other 
surrounding cells in their microenvironment.  
As DCs are the critical drivers of T cell-mediated immunity, DC-based 
immunotherapy pioneered by the late Dr. Ralph Steinman, has emerged at the 
forefront of vaccinology for the potential treatment of chronic infectious diseases 
and cancer; typified by attenuated T cell responses (Banchereau et al., 2005; 
Steinman and Banchereau, 2007; Giannopoulos et al., 2010; Li et al., 2012b; 
Martinet et al., 2012). Generally, DC immunotherapy is based on the utilisation of 
patient PBMCs and separation of CD34+ progenitor cells or monocytes (Banchereau 
et al., 2005; Li et al., 2012b). These autologous cells are differentiated into DCs and 
subsequently loaded with viral-specific peptides (in the case of HCV infection) or 
tumour lysates (in the case for melanoma). The antigen-bearing DCs are then 
reintroduced into the host in an attempt to boost CD4+ and CTL responses 
(Banchereau et al., 2005; Li et al., 2012b). These investigations have led to the 
development of the first FDA-approved DC-based cancer vaccination for the 
treatment of prostate cancer (Hovden and Appel, 2010). Targeting Nrf2 in DCs 
could prove beneficial for the treatment of a disease settings associated with Th2 
dominance such as asthma. Indeed, loss of Nrf2 results in the exasperation of 
disease severity in a murine model of asthma (Rangasamy et al., 2005). Allergic 
mechanisms are initially triggered by low concentration allergen exposure, resulting 
in weak TCR signalling and subsequent DC-mediated Th2 differentiation (Holgate 
2012). Effector Th2 cells trigger B cell allergen-specific IgE production, which is 
secreted throughout the body and binds to high-affinity IgE receptors on the cell 
surface of basophils and mast cells (Voehringer 2013). Cross-linkage of the 
FceR1:IgE complex with multivalent allergens results in mast cell and basophil 
activation, and degranulation of inflammatory mediators e.g. histamine. These 
mediators induce an array of maladaptive effector functions such as local 
inflammation, activation of innate immune cells, mucus overproduction and 
smooth muscle contractility, ultimately resulting in the onset and maintenance of 
allergic disease (Pulendran and Artis 2012). A currently adopted method used to 
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treat allergic disorders including asthma and rhinitis is sublingual immunotherapy 
(SLIT) (Akdis et al., 2006). This involves the administration of the specific allergen 
responsible for the patient’s symptoms to the oral mucosa, in an attempt to 
desensitise the subject to the offending allergen (Akdis et al., 2006). Dendritic cells 
play a pivotal in the mechanisms underlying SLIT. It has been proposed that the 
administered allergen is acquired by oral mucosal DCs, which exhibit a pro-
tolerogenic phenotype upon maturation (Novak et al., 2011). This is typified by 
increased IL-10 production and reduced expression of maturation marker CD83 
(Novak et al., 2011). Therefore, these tolerogenic DCs can induce the differentiation 
of allergen-specific Tregs which dampen the dysregulated Th2 response and 
downstream allergic mechanisms (Novak et al., 2011). Furthermore, targeted 
silencing of co-stimulatory molecule CD40, using siRNA in OVA allergen-bearing 
DCs, resulted in the dampening of OVA-induced allergy in sensitised mice (Suzuki et 
al., 2010). This was a result of increased OVA-specific Tregs and complete 
abolishment of IL-4 producing effector T cells (Suzuki et al., 2010). 
Immunosenescence is also associated with DC-mediated skewed Th2 phenotype 
(Kim et al., 2008). Treatment of aged DCs with sulforaphane has proven to reset the 
DC intracellular redox status and restore Th1/Th2 balance (Kim et al., 2008). 
Therefore it may be possible to prime allergic patient DCs ex vivo with both the 
specific allergen and an Nrf2 activator e.g. sulforaphane, in an attempt to further 
dampen Th2 responses.  
Targeting Nrf2 in DCs to enhance phagocytic function could also be exploited in 
disease settings associated with reduced phagocyte-mediated apoptotic cell 
clearance. These include SLE and advanced atherosclerosis in cardiovascular disease 
(Gaipl et al., 2007; Thorp, 2010). However, failed apoptotic cell clearance exhibited 
in the aforementioned diseases is predominantly due to macrophage phagocytic 
dysfunction (Ren et al., 2003; Thorp, 2010). Nrf2 activation induced via conditional 
knockout of keap-1 in myeloid cells, improved phagocytic and bactericidal capacity 
of peritoneal macrophages, challenged with Pseudomonas aeruginosa in both 
healthy and septic mice (Kong et al., 2011). Moreover, treatment of alveolar 
macrophages derived from COPD patients with sulforaphane, resulted in enhanced 
171 
 
bacterial phagocytosis in response to either nontypeable Haemophilus influenza or 
Pseudomonas aeruginosa infection, which was associated with Nrf2-regulated 
downstream upregulation of the scavenger receptor MARCO (Harvey et al., 2011). 
This further highlights the critical role of Nrf2 in the regulation of innate immune 
cell phagocytic function.  
Previous studies have shown that Nrf2 activity limits proinflammatory cytokine 
production e.g. TNFα and IL-1β in a variety of murine models including sepsis, 
COPD, brain and spinal cord injury, EAE and pulmonary fibrosis (Thimmulappa et al., 
2006a; Jin et al., 2008; Johnson et al., 2010; Kikuchi et al., 2010; Kong et al., 2011; 
Mao et al., 2011; Yageta et al., 2011). One of the main mechanisms by which Nrf2 
exerts its anti-inflammatory activity is through counter-regulation of the NF-κB 
pathway (Thimmulappa et al., 2006a; Jin et al., 2008; Kong et al., 2011; Mao et al., 
2011; Yageta et al., 2011). NF-κB plays a pivotal role in cell proliferation, survival, 
and apoptosis, but importantly it is essential for the regulation of the inflammatory 
response, and orchestration of both the innate and adaptive immune responses 
(Hayden and Ghosh, 2011). Various stimuli have shown to activate NF-κB including 
oxidative, cellular and mechanical stress, bacterial and viral products, inflammatory 
cytokines and environmental factors e.g. cigarette smoke and various xenobiotics 
(Pahl, 1999). Under resting conditions, the NF-κB heterodimer (generally composed 
of p50 and p65 (RelA) subunits) is inactive within the cytoplasm, forming a complex 
with members of the inhibitory IκB proteins such as IκBα (Hayden and Ghosh, 
2011). Upon activation, upstream IκB kinase (IKK) complexes are activated, which in 
turn phosphorylate IκBα, resulting in its ubiquitination and subsequent degradation 
(Hayden and Ghosh, 2011). This enables NF-κB to translocate to the nucleus, where 
it can bind to specific DNA sequences in κB sites present within NF-κB related target 
genes, resulting in their upregulation and initiation of immune responses (Hayden 
and Ghosh, 2011). These include cytokines e.g. TNFα, IL-1β, IFNγ, IL-6, IL-2, IL-12, 
and immunoreceptors such as MHC I, CD80, CD40 (Pahl, 1999; Ahn et al., 2005). It 
has been proposed that the NF-κB subunit p65 can directly repress nrf2 
transcriptional activity. It inhibits Nrf2 by competitively antagonising CBP binding to 
Nrf2 thus preventing Nrf2 transactivation, and also through the recruitment of the 
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co-repressor histone deacetylase 3 (HDAC3) (Liu et al., 2008). Taken together, this 
highlights the critical role of Nrf2 in the modulation of inflammation.  
From a T cell perspective, this study revealed that loss of Nrf2 did not affect the 
development of CD4+CD25+ nTreg, mature CD4 and CD8 T cell populations within 
the thymus. Furthermore, Nrf2 deficiency did not alter the composition of CD4 and 
CD8 T cell populations within secondary lymphoid organs. It was observed that 
splenic Nrf2-/- naïve T cells exhibited enhanced ROS generation; associated with low 
level increases in T cell activation with respect to lowered CD62L and augmented 
CD44 expression. However, the marginal augmentation of Nrf2-/- naïve T cell 
activation status did not mount up to increased T cell proliferation in response to 
antibody stimulation. In contrast, Nrf2 deficient effector T cells exhibited enhanced 
TCR/CD3 triggered proliferation, associated with increases in the proportion CD4+ 
IFNγ-producing effector T cells upon re-stimulation. The findings from this study 
concluded that Nrf2 regulated effector CD4 differentiation. In contrast to Nrf2 
deficient DCs which induce strong Th2 responses (Williams et al., 2008), loss of Nrf2 
in effector T cells resulted in decreased Th2 (IL-5) and increased Th1 (IFNγ) cytokine 
secretion which has previously been correlated with reduced GATA-3 and enhanced 
T-bet DNA binding, respectively (Rockwell et al., 2012). CLTA-4 inhibitory co-
receptor engagement has been shown to be important for promoting Th1 cytokine 
production whilst negatively regulating Th2 effector function (Tao et al., 1997; 
Oosterwegel et al., 1999). Moreover, STAT1 signalling has been shown to be 
essential for the induction of T-bet expression in murine splenocytes in response to 
Toxoplasma gondii (T.gondii) infection, a potent Th1 stimulating antigen (Lighvani 
et al., 2001). On the other hand, STAT5 (a key downstream transducer in IL-2 
signalling) is indispensable for Th2 differentiation (Zhu et al., 2003). Furthermore, 
STAT6 is important in regulating Th2-facilitated B-cell immunoglobulin class 
switching from IgG to IgE, a function of which is vital for humoral immune response 
to parasitic invasion and allergens (Shimoda et al., 1996). In light of this, it would be 
worth examining the levels of CTLA-4, STAT1, STAT5 and STAT6 expression in the 
Nrf2+/+ and Nrf2-/- splenic effector CD4 T cells to reaffirm Nrf2 regulation of Th1/Th2 
differentiation.  
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Importantly this study has demonstrated that re-stimulated Nrf2-/- effector T cells 
secrete increased levels of IL-17A and IL-22, a signature cytokine profile indicative 
of the more recently identified CD4 Th17 cell lineage (Zhu and Qian, 2012). This was 
also observed under Th17 polarising conditions, further suggesting that loss of Nrf2 
predisposes effector Th17 development. The implications of these findings are huge 
given the pivotal role that Th17 cells play in the pathogenesis of a variety of 
autoimmune diseases including SLE, RA, MS and in cancer (Zhu and Qian, 2012; Li et 
al., 2013). Therefore, activating Nrf2 during CD4 T cell differentiation may reduce 
Th17 induction and disease progression in the aforementioned disease settings. In 
support of this, CDDO-TFEA-mediated activation of Nrf2 resulted in reduction in IL-
17 production and disease severity in murine EAE model (Pareek et al., 2011). The 
Th17 subset itself is heterogeneous in nature, which depending upon their initial 
antigen stimulation and contextual microenvironment; they can exhibit differential 
cytokine signatures. This ultimately influences their pathogenic inflammatory 
driving potential in autoimmune murine models such as EAE (McGeachy et al., 
2007; Zielinski et al., 2012). For example, CD4 T cells cultured from immunised mice 
in the presence of TGFβ and IL-6 combination, or IL-23 alone, both induce Th17 
development in vitro. However, TGFβ and IL-6 treatment induces non-pathogenic 
IL-17+IL-10+ immunoregulatory T cells, whilst IL-23 treatment gives rise to 
pathogenic EAE-driving IL-17+IFNγ+ producing T cells in vivo (McGeachy et al., 2007). 
Similarly, Candida albicans and staphlylococcus aureus antigen-specific human T 
cells give rise to Th17 cells that co-produce IFNγ and IL-10, respectively (Zielinski et 
al., 2012). In our findings, loss of Nrf2 did not influence the proportion of IL-
17+IFNγ+ producing T cells. Examination of the proportion of 17+IL-10+ T cells in the 
Nrf2 deficient mouse would allow us to see whether the Th17 cells present are 
immunomodulatory rather than pathogenic.  
Dendritic cells play a crucial role in instructing Th17 differentiation through the 
secretion of TGFβ, IL-6 and IL-23 (Mangan et al., 2006; Veldhoen et al., 2006). 
Dendritic cell secretion of the aforementioned cytokines is highly dependent upon 
engagement of their cell surface CLRs including dectin 1 and DC-SIGN (Geijtenbeek 
and Gringhuis, 2009; Huang et al., 2012). For example, zymosan-mediated 
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activation of dectin-1 in DCs, results in vital PLCγ2 signalling upstream of NF-κB and 
MAPK, resulting in DC IL-6 and IL-23 production (Xu et al., 2009). Deficiency of p38 
MAPK in DCs resulted in a decreased and increased production of IL-6 and IL-27, 
respectively. Interleukin-27 was shown to negatively regulate of Th17 
differentiation, resulting in a significant amelioration of EAE disease severity (Huang 
et al., 2012). Furthermore, knocking out p38 MAPK resulted in a reduction in CD86 
expression in DCs, which is necessary for efficient co-stimulatory signal 
transduction, further impeding Th17 development (Huang et al., 2012). We have 
recently demonstrated that enhanced maturation phenotype in Nrf2 deficient DCs 
is associated with enhanced p38 MAPK phosphorylation (Al-Huseini et al., 2013). In 
this respect, it would be useful to examine the influence of Nrf2 deficiency in DCs 
on Th17 differentiation. The presented work on the impact of loss of Nrf2 in murine 
DC and T cell immune function is summarised in Figure 6.1. 
Although utilisation of the Nrf2 deficient mouse model is extremely informative for 
examining DC and T cell function, it is not without its limitations. The global ablation 
of the nrf2 gene influences several other signalling pathways and transcription 
factors including MAPK and NF-κB (Al-Huseini et al., 2013) Therefore, we cannot say 
for certain that the phenotype exhibited by the deficient mouse in the particular 
cell type examined is solely due to the Nrf2 gene itself, but rather a consequence of 
e.g. increased NF-κB  signalling as observed in the inflammatory models discussed 
above. Furthermore, as the null Nrf2 gene region is introduced into all cells in the 
knockout mouse, the T cell and DC function may be influenced by the dysfunction 
of other cell types which have not been examined. It would therefore be beneficial 
to assess T cell and DC function in an in vivo setting using conditional knockout 
animals, where the Nrf2 gene is genetically removed from specific cell types. This 
could be achieved by initially generating Nrf2flox/flox mice through the introduction of 
LoxP sites into the Nrf2 DNA-binding region (Kong et al., 2011). Targeted ablation of 
Nrf2 in DCs, for example, could then be attained by crossing the Nrf2flox/flox mice 
with Cre transgenic mice where the Cre recombinase is under the control of the 
CD11c promoter (Zhang et al., 2013). Dendritic cell and T cell function were 
examined individually in this thesis. However, it would be more informative to 
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assess the precise role of Nrf2 in both DCs and T-cells function during in vivo T-cell 
DC interactions. Utilisation of adoptive transfer methodologies in which the Nrf2 
deficient DCs and T cells could be injected into a recipient mouse would help 
address such questions. 
 
 
 
 
Extensive research has been carried out on delineating the cytoprotective and drug-
detoxifying role of Nrf2 in the liver, which as the primary drug-metabolising organ, 
is subjected to an array of xenobiotics and their respective metabolites. Individuals 
Figure 6.1 Summary of findings on the impact of loss of Nrf2 on murine dendritic cell 
and T cell immune function.  
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vary in their responses to xenobiotic exposure from adaptation to severe ADRs. 
However, it is unknown whether this human disparity in drug response is a 
consequence of inter-individual variation in the Nrf2 adaptive defence system to 
xenobiotic stress. In light of this, the work presented in the final chapter aimed to 
firstly decipher whether variation in the Nrf2 adaptive system was present within 
individuals in response to a known Nrf2 probe. To address the latter, basal and 
induced Nrf2 protein levels, and downstream NQO1 expression were measured in 
human T cell blasts, in response to increasing concentrations of the Nrf2 inducing 
drug CDDO-Me. Blood-derived immune cells represent an accessible source of 
physiologically relevant cells, thus proved a suitable human ex vivo model to 
examine inter-individual variation in the nrf2 adaptive defence system. It was 
shown that Nrf2 could be detected in the nuclear fractions of human T cells. 
Furthermore, upon examination of various donor-derived T cells, it was concluded 
that humans vary in their Nrf2 response to CDDO-Me, with respect to nuclear Nrf2 
and NQO1 mRNA expression. The next step would be to investigate whether inter-
individual variation in the Nrf2 response exists in humans in response to an 
xenobiotic e.g. acetaminophen, and subsequently correlate Nrf2 inter-individual 
variability with individual susceptibility to drug toxicity. This may attempt to utilise 
Nrf2 expression in the blood as a suitable biomarker for the detection of potential 
drug toxicity in inaccessible organs such as the liver. However, as there are various 
dietary constituents and forms of environmental exposure which are known to 
induce Nrf2 expression in humans (as discussed in chapter 5) (Wu et al., 2010; 
Boettler et al., 2011a; Harvey et al., 2011; Messier et al., 2013), the use of Nrf2 as a 
biomarker for predicting drug toxicity in practice would prove extremely difficult.   
A detailed knowledge of potentially altered function of Nrf2 in disease states will 
open up the possibility of Nrf2 being a viable therapeutic target in such disease 
settings. Nrf2 polymorphisms have been identified in a variety of immune-mediated 
human diseases, which often correlate with increased risk of disease severity as 
seen in acute lung injury (Marzec et al., 2007), nephritis associated in female 
childhood onset in SLE (Cordova et al., 2010), Helicobacter pylori-induced gastritis 
(Arisawa et al., 2007) and ulcerative colitis (Arisawa et al., 2008). Moreover, 
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combined maternal Nrf2 single nucleotide polymorphisms (SNP) and 
acetaminophen exposure throughout pregnancy, has been shown to correlate with 
enhanced risk of childhood asthma (Shaheen et al., 2010). Other polymorphisms 
have been identified in SLE and COPD, but correlation with the disease is yet to be 
determined (Yamamoto et al., 2004). In spite of this, diminished Nrf2 expression 
and subsequent downregulation of Nrf2 governed antioxidant gene expression e.g. 
HO-1 and NQO1 have been observed in alveolar macrophages and lungs of COPD 
patients (Malhotra et al., 2008; Suzuki et al., 2008).  
Senescence is undoubtedly correlated with a decline in the functioning of all major 
organs including the immune system thus increasing susceptibility to an array of 
disorders including viral and bacterial infections, cardiovascular, pulmonary and 
neurodegenerative diseases, diabetes and cancer (Ponnappan and Ponnappan, 
2011). Immunosenescence is highly associated with chronic levels of oxidative 
stress. This results in immune cell dysfunction, decreased immunosurveillance, 
enhanced inflammation and autoimmunity (Ponnappan and Ponnappan, 2011). It 
has also been suggested that there is an age-related decline in nrf2-mediated 
antioxidant and detoxification processes to nullify this increased oxidative 
challenge, ultimately resulting in disease (Kim et al., 2007; Suzuki et al., 2008). In 
support of this, Nrf2 expression is decreased in human alveolar macrophages 
derived from older smokers in comparison to younger smokers (Suzuki et al., 2008). 
Reduced Nrf2 protein expression was also observed between young and aged mice 
exposed to cigarette smoke (Suzuki et al., 2008). Furthermore, increased nrf2 
expression has been observed in PBMCs derived from asthmatic children 
(Fitzpatrick et al., 2011); whereas decreases in Nrf2 expression has been shown in 
adult asthmatic alveolar macrophages (Dworski et al., 2011). Nrf2 activation has 
proven to restore Th1 immunity in aged mice, highlighting a potential role for 
targeting Nrf2 in the treatment of age-related disorders (Kim et al., 2008).  
In reference to the role of Nrf2 in SLE, striking comparisons between the Nrf2 
deficient mouse and the autoimmune disease can be made. Nrf2 deficient mice 
develop complex disease manifestations characteristic of SLE including female 
dominance, multiorgan inflammation, presence of nuclear auto-antigens and 
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immune complex deposition in blood vessels and glomerular nephritis (Ma et al., 
2006). The present thesis has demonstrated that loss of Nrf2 in mice resulted in 
enhanced DC co-stimulatory receptor expression, reduced phagocytosis of 
apoptotic cells, increased DC mediated T cell proliferation in response to self-
antigen and increased predisposition of Th17 development, which have collectively 
been observed in SLE (Berkun et al., 2008; Shah et al., 2010). This highlights a 
critical role for Nrf2 in this autoimmune disease. However, it has yet to be 
established whether Nrf2 expression is altered in the immune cells of SLE patients. 
The human T cell ex vivo model presented in this thesis could be used as an 
appropriate tool to examine basal and inducible levels of Nrf2, and downstream 
gene expression in SLE patients in comparison to healthy individuals. 
Hypothetically, if Nrf2 levels were found to be compromised in SLE patients, it 
would be appropriate to treat SLE patient-derived immune cells with CDDO-Me to 
assess whether Nrf2 activation enhances their function. CDDO-Me had initially 
showed great promise as a potential therapeutic for the treatment of chronic type 
2 diabetic nephropathy (Pergola et al., 2011). However, it was terminated at phase 
III clinical trial stage as a consequence of the induction of adverse side effects (Zoja 
et al., 2013). However, this does not rule out the possibility of CDDO-Me potential 
treatment of SLE. This merits intense investigations in the future.  
The findings from this PhD work could form the basis for several lines of future 
research. In particular, the role of Nrf2 in DC-mediated immune tolerance and its 
potential for pharmacological modulation to achieve tolerance in allergic and 
autoimmune conditions could be investigated. Another strand of future 
investigation can focus on defining the mechanisms by which Nrf2 influences Th17 
development and function. Finally, the hypothesis that Nrf2 function in immune 
cells is dysregulated in human diseases such as SLE requires testing.  
In conclusion, my work has provided a body of scientific evidence that supports the 
case for a pivotal role of Nrf2 in immune cell development and function. It is hoped 
that future studies will be able to build on and exploit my findings in order to devise 
Nrf2-targeted therapies for immune-mediated disease.  
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